NZ724372B2 - Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer - Google Patents
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer Download PDFInfo
- Publication number
- NZ724372B2 NZ724372B2 NZ724372A NZ72437215A NZ724372B2 NZ 724372 B2 NZ724372 B2 NZ 724372B2 NZ 724372 A NZ724372 A NZ 724372A NZ 72437215 A NZ72437215 A NZ 72437215A NZ 724372 B2 NZ724372 B2 NZ 724372B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- certain embodiments
- cancer
- compound
- heterocyclyl
- substituents
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title claims description 159
- 229940058303 antinematodal Benzimidazole derivatives Drugs 0.000 title abstract description 3
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title abstract description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title description 2
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 title description 2
- 102100010782 EGFR Human genes 0.000 claims abstract description 104
- 101700039191 EGFR Proteins 0.000 claims abstract description 104
- 201000010099 disease Diseases 0.000 claims abstract description 92
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 65
- 230000002062 proliferating Effects 0.000 claims abstract description 24
- 230000002730 additional Effects 0.000 claims abstract description 12
- -1 C3-10 lkyl Chemical group 0.000 claims description 242
- 150000001875 compounds Chemical class 0.000 claims description 228
- 239000000203 mixture Substances 0.000 claims description 214
- 125000001424 substituent group Chemical group 0.000 claims description 194
- 125000000623 heterocyclic group Chemical group 0.000 claims description 156
- 125000003118 aryl group Chemical group 0.000 claims description 132
- 125000000217 alkyl group Chemical group 0.000 claims description 121
- 125000001072 heteroaryl group Chemical group 0.000 claims description 117
- 239000011780 sodium chloride Substances 0.000 claims description 114
- 150000003839 salts Chemical class 0.000 claims description 110
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 106
- 239000012453 solvate Substances 0.000 claims description 101
- 230000000155 isotopic Effects 0.000 claims description 97
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 95
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 93
- 239000001257 hydrogen Substances 0.000 claims description 78
- 229910052739 hydrogen Inorganic materials 0.000 claims description 78
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 77
- 239000003814 drug Substances 0.000 claims description 68
- 229940079593 drugs Drugs 0.000 claims description 57
- 125000005843 halogen group Chemical group 0.000 claims description 52
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 49
- 239000002552 dosage form Substances 0.000 claims description 48
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims description 47
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims description 47
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 47
- 102100016662 ERBB2 Human genes 0.000 claims description 43
- 101700025368 ERBB2 Proteins 0.000 claims description 43
- 101710037934 QRSL1 Proteins 0.000 claims description 39
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 37
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 36
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 33
- 229910004664 ORa Inorganic materials 0.000 claims description 28
- 238000003780 insertion Methods 0.000 claims description 27
- 241000658540 Ora Species 0.000 claims description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
- 238000006467 substitution reaction Methods 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 125000005549 heteroarylene group Chemical group 0.000 claims description 23
- 125000000732 arylene group Chemical group 0.000 claims description 21
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 20
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 19
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 19
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 18
- 125000004043 oxo group Chemical group O=* 0.000 claims description 18
- 229910052703 rhodium Inorganic materials 0.000 claims description 18
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 17
- 201000005202 lung cancer Diseases 0.000 claims description 17
- 229910003813 NRa Inorganic materials 0.000 claims description 16
- 125000004429 atoms Chemical group 0.000 claims description 16
- 125000004122 cyclic group Chemical group 0.000 claims description 16
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 12
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 125000002950 monocyclic group Chemical group 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 11
- 229960001686 Afatinib Drugs 0.000 claims description 9
- 229910003667 SRa Inorganic materials 0.000 claims description 9
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 9
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 229960001433 Erlotinib Drugs 0.000 claims description 8
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 8
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 8
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 8
- 125000005605 benzo group Chemical group 0.000 claims description 8
- 229960002584 gefitinib Drugs 0.000 claims description 8
- 210000000214 Mouth Anatomy 0.000 claims description 7
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 239000006186 oral dosage form Substances 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- UWXSAYUXVSFDBQ-CYBMUJFWSA-N 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Chemical compound C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 UWXSAYUXVSFDBQ-CYBMUJFWSA-N 0.000 claims description 5
- 239000005461 Canertinib Substances 0.000 claims description 5
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N Canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 claims description 5
- 229950002826 Canertinib Drugs 0.000 claims description 5
- 229950002205 Dacomitinib Drugs 0.000 claims description 5
- 206010017758 Gastric cancer Diseases 0.000 claims description 5
- QQLKULDARVNMAL-UHFFFAOYSA-N Icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 claims description 5
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 5
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 5
- 229950006299 Pelitinib Drugs 0.000 claims description 5
- 210000003800 Pharynx Anatomy 0.000 claims description 5
- 229950006605 VARLITINIB Drugs 0.000 claims description 5
- 229950007440 icotinib Drugs 0.000 claims description 5
- 229960004891 lapatinib Drugs 0.000 claims description 5
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims description 5
- 229950008835 neratinib Drugs 0.000 claims description 5
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 210000000481 Breast Anatomy 0.000 claims description 4
- 229940121647 EGFR inhibitors Drugs 0.000 claims description 4
- 102100004109 HEY1 Human genes 0.000 claims description 4
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 206010046766 Uterine cancer Diseases 0.000 claims description 4
- 201000011231 colorectal cancer Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 230000000241 respiratory Effects 0.000 claims description 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000006405 methylpyridazinyl group Chemical group 0.000 claims description 3
- 239000006207 intravenous dosage form Substances 0.000 claims description 2
- 230000002685 pulmonary Effects 0.000 claims description 2
- LVXJQMNHJWSHET-AATRIKPKSA-N Dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 claims 2
- 230000000051 modifying Effects 0.000 abstract description 8
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract description 7
- 239000000651 prodrug Substances 0.000 description 85
- 229940002612 prodrugs Drugs 0.000 description 85
- 210000004027 cells Anatomy 0.000 description 45
- 150000002431 hydrogen Chemical class 0.000 description 38
- 239000004215 Carbon black (E152) Substances 0.000 description 36
- 239000004480 active ingredient Substances 0.000 description 32
- 230000002401 inhibitory effect Effects 0.000 description 31
- 102000027777 ERBB4 Human genes 0.000 description 23
- 101700023619 ERBB4 Proteins 0.000 description 23
- 239000003112 inhibitor Substances 0.000 description 21
- 229920002301 Cellulose acetate Polymers 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 16
- 229920001577 copolymer Polymers 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- 239000003981 vehicle Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 230000027455 binding Effects 0.000 description 14
- 239000000969 carrier Substances 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 210000004379 Membranes Anatomy 0.000 description 13
- 239000000460 chlorine Substances 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 150000003254 radicals Chemical class 0.000 description 13
- 208000009956 Adenocarcinoma Diseases 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 12
- 230000002427 irreversible Effects 0.000 description 12
- 230000001404 mediated Effects 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 230000002335 preservative Effects 0.000 description 11
- 239000003755 preservative agent Substances 0.000 description 11
- 230000002441 reversible Effects 0.000 description 11
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 10
- 125000001246 bromo group Chemical group Br* 0.000 description 10
- 201000009030 carcinoma Diseases 0.000 description 10
- 239000003937 drug carrier Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000008101 lactose Substances 0.000 description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 235000010980 cellulose Nutrition 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 9
- 239000007891 compressed tablet Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 229960005150 glycerol Drugs 0.000 description 9
- 150000002430 hydrocarbons Chemical class 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 8
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 8
- 229940015001 Glycerin Drugs 0.000 description 8
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 8
- 108091000081 Phosphotransferases Proteins 0.000 description 8
- 102000001253 Protein Kinases Human genes 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 125000004474 heteroalkylene group Chemical group 0.000 description 8
- 125000005842 heteroatoms Chemical group 0.000 description 8
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000003204 osmotic Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000600 sorbitol Substances 0.000 description 8
- 235000010356 sorbitol Nutrition 0.000 description 8
- 210000001519 tissues Anatomy 0.000 description 8
- 230000000699 topical Effects 0.000 description 8
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 102000009071 ErbB Receptors Human genes 0.000 description 7
- 108010073043 ErbB Receptors Proteins 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- 229940014259 Gelatin Drugs 0.000 description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 7
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 125000004450 alkenylene group Chemical group 0.000 description 7
- 125000002619 bicyclic group Chemical group 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 7
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000008297 liquid dosage form Substances 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 238000007911 parenteral administration Methods 0.000 description 7
- 239000000546 pharmaceutic aid Substances 0.000 description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 239000001993 wax Substances 0.000 description 7
- 239000005977 Ethylene Substances 0.000 description 6
- 102100012247 GRIN2A Human genes 0.000 description 6
- 206010025650 Malignant melanoma Diseases 0.000 description 6
- 239000004698 Polyethylene (PE) Substances 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 229940032147 Starch Drugs 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- 229940035295 Ting Drugs 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- 239000002270 dispersing agent Substances 0.000 description 6
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 108091007956 hepatocyte nuclear factors 4 Proteins 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 235000010981 methylcellulose Nutrition 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 125000006574 non-aromatic ring group Chemical group 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 230000004083 survival Effects 0.000 description 6
- 229910052720 vanadium Inorganic materials 0.000 description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 239000001856 Ethyl cellulose Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 125000004419 alkynylene group Chemical group 0.000 description 5
- 230000000111 anti-oxidant Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 229920000591 gum Polymers 0.000 description 5
- 229920001477 hydrophilic polymer Polymers 0.000 description 5
- 125000002346 iodo group Chemical group I* 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920001888 polyacrylic acid Polymers 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000008299 semisolid dosage form Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- XTXRWKRVRITETP-UHFFFAOYSA-N vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-NJFSPNSNSA-N (18)O Chemical compound [18O] QVGXLLKOCUKJST-NJFSPNSNSA-N 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N Adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 102000027776 ERBB3 Human genes 0.000 description 4
- 101700041204 ERBB3 Proteins 0.000 description 4
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 4
- 229940093915 Gynecological Organic acids Drugs 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 229920001451 Polypropylene glycol Polymers 0.000 description 4
- 208000009527 Refractory Anemia Diseases 0.000 description 4
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N Sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 210000002784 Stomach Anatomy 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 235000010419 agar Nutrition 0.000 description 4
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000003042 antagnostic Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 235000012343 cottonseed oil Nutrition 0.000 description 4
- 239000002385 cottonseed oil Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- ZCYVEMRRCGMTRW-NJFSPNSNSA-N iodine-129 atom Chemical compound [129I] ZCYVEMRRCGMTRW-NJFSPNSNSA-N 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000002357 osmotic agent Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-NJFSPNSNSA-N phosphorus-33 Chemical compound [33P] OAICVXFJPJFONN-NJFSPNSNSA-N 0.000 description 4
- 125000005936 piperidyl group Chemical group 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 4
- 229920000915 polyvinyl chloride Polymers 0.000 description 4
- 239000004800 polyvinyl chloride Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000006215 rectal suppository Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000004434 sulfur atoms Chemical group 0.000 description 4
- NINIDFKCEFEMDL-NJFSPNSNSA-N sulfur-34 Chemical compound [34S] NINIDFKCEFEMDL-NJFSPNSNSA-N 0.000 description 4
- NINIDFKCEFEMDL-RNFDNDRNSA-N sulfur-36 Chemical compound [36S] NINIDFKCEFEMDL-RNFDNDRNSA-N 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 4
- 239000006216 vaginal suppository Substances 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N (+)-tartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- BSPLGGCPNTZPIH-IPZCTEOASA-N (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide;hydrate Chemical compound O.C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 BSPLGGCPNTZPIH-IPZCTEOASA-N 0.000 description 3
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 3
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Natural products CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 3
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 3
- 208000006673 Asthma Diseases 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 101700063338 CR13 Proteins 0.000 description 3
- WZNRVWBKYDHTKI-UHFFFAOYSA-N Cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- VEXZGXHMUGYJMC-IGMARMGPSA-N Chlorine-35 Chemical compound [35ClH] VEXZGXHMUGYJMC-IGMARMGPSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229960000367 Inositol Drugs 0.000 description 3
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- 229960005015 Local anesthetics Drugs 0.000 description 3
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 210000002307 Prostate Anatomy 0.000 description 3
- 229940075582 Sorbic Acid Drugs 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 229940033134 Talc Drugs 0.000 description 3
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 3
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 108010010691 Trastuzumab Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- WKBOTKDWSSQWDR-BJUDXGSMSA-N bromine-79 atom Chemical compound [79Br] WKBOTKDWSSQWDR-BJUDXGSMSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 229960005188 collagen Drugs 0.000 description 3
- 239000008139 complexing agent Substances 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 230000002209 hydrophobic Effects 0.000 description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 200000000018 inflammatory disease Diseases 0.000 description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 229940064003 local anesthetic throat preparations Drugs 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 239000002687 nonaqueous vehicle Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920002689 polyvinyl acetate Polymers 0.000 description 3
- 239000011118 polyvinyl acetate Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000001603 reducing Effects 0.000 description 3
- 239000003352 sequestering agent Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- NINIDFKCEFEMDL-IGMARMGPSA-N sulfur-32 Chemical compound [32S] NINIDFKCEFEMDL-IGMARMGPSA-N 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- ILJSQTXMGCGYMG-UHFFFAOYSA-M triacetate(1-) Chemical compound CC(=O)CC(=O)CC([O-])=O ILJSQTXMGCGYMG-UHFFFAOYSA-M 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-(1R,3R,4S)-menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2S,3R,4S,5S,6R)-2-[(2R,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- LGXVIGDEPROXKC-UHFFFAOYSA-N 1,1-Dichloroethene Chemical compound ClC(Cl)=C LGXVIGDEPROXKC-UHFFFAOYSA-N 0.000 description 2
- RGUQWGXAYZNLMI-UHFFFAOYSA-N 1,1-dioxo-6-(trifluoromethyl)-4H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- QOWAMIUFBNBINS-UHFFFAOYSA-N 2-[6-[4,5-diethoxy-2-(ethoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(OC)C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)O1 QOWAMIUFBNBINS-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- ASQUQUOEFDHYGP-UHFFFAOYSA-N 2-methoxyethanolate Chemical group COCC[O-] ASQUQUOEFDHYGP-UHFFFAOYSA-N 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- XRZWVSXEDRYQGC-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-1-ium-2-carboxylate Chemical compound C1NC(C(=O)O)CC1C1CCCCC1 XRZWVSXEDRYQGC-UHFFFAOYSA-N 0.000 description 2
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 2
- 229940024606 Amino Acids Drugs 0.000 description 2
- 241001550224 Apha Species 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- CPELXLSAUQHCOX-OUBTZVSYSA-N Bromine-81 Chemical compound [81BrH] CPELXLSAUQHCOX-OUBTZVSYSA-N 0.000 description 2
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- SXVBHNXTPNLOKR-FCLWLKJISA-L Calcium alginate Chemical compound [Ca+2].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O SXVBHNXTPNLOKR-FCLWLKJISA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000004709 Chlorinated polyethylene Substances 0.000 description 2
- 241000272194 Ciconiiformes Species 0.000 description 2
- 210000001072 Colon Anatomy 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960000913 Crospovidone Drugs 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 229960004397 Cyclophosphamide Drugs 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010025223 Endothelin-Converting Enzymes Proteins 0.000 description 2
- 102000015375 Endothelin-Converting Enzymes Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 229920000896 Ethulose Polymers 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229960003028 Flumethiazide Drugs 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- 229960002989 Glutamic Acid Drugs 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- 210000003128 Head Anatomy 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 240000008528 Hevea brasiliensis Species 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N Hippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 206010020243 Hodgkin's disease Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- ZCYVEMRRCGMTRW-RNFDNDRNSA-N I-131 Chemical compound [131I] ZCYVEMRRCGMTRW-RNFDNDRNSA-N 0.000 description 2
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 229960004873 LEVOMENTHOL Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N Lauric acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- 206010024190 Leiomyosarcomas Diseases 0.000 description 2
- 208000000214 Leukemia, Myelomonocytic, Chronic Diseases 0.000 description 2
- 206010024627 Liposarcoma Diseases 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 206010025135 Lupus erythematosus Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229940072082 Magnesium Salicylate Drugs 0.000 description 2
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 2
- 208000003393 Mammary Paget's Disease Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 206010027476 Metastasis Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- 102100015381 PTGS2 Human genes 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229940066842 Petrolatum Drugs 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N Pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229940081974 Saccharin Drugs 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 229940005550 Sodium alginate Drugs 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N Spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 229960005202 Streptokinase Drugs 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010042863 Synovial sarcoma Diseases 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical class [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 2
- 206010046736 Urticarias Diseases 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- UGZICOVULPINFH-UHFFFAOYSA-N acetic acid;butanoic acid Chemical compound CC(O)=O.CCCC(O)=O UGZICOVULPINFH-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 229960000250 adipic acid Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- QGZKDVFQNNGYKY-OUBTZVSYSA-N ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 201000003076 angiosarcoma Diseases 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 201000000274 carcinosarcoma Diseases 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001082 cryoprotectant Effects 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 201000004624 dermatitis Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008355 dextrose injection Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 229920005558 epichlorohydrin rubber Polymers 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 235000019314 gum ghatti Nutrition 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000001965 increased Effects 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- ZCYVEMRRCGMTRW-AHCXROLUSA-N iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-IGMARMGPSA-N iodine-127 atom Chemical compound [127I] ZCYVEMRRCGMTRW-IGMARMGPSA-N 0.000 description 2
- 229920000554 ionomer Polymers 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Chemical compound [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 230000003003 lyoprotectant Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 229920003087 methylethyl cellulose Polymers 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000005565 oxadiazolylene group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- OAICVXFJPJFONN-OUBTZVSYSA-N phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 2
- 229920002492 poly(sulfones) Polymers 0.000 description 2
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920001195 polyisoprene Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920001290 polyvinyl ester Polymers 0.000 description 2
- 229920001289 polyvinyl ether Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 125000005551 pyridylene group Chemical group 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 229940116353 sebacic acid Drugs 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 230000003248 secreting Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008137 solubility enhancer Substances 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 239000003558 transferase inhibitor Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 150000003668 tyrosines Chemical class 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000008136 water-miscible vehicle Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N β-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- OKTJSMMVPCPJKN-IGMARMGPSA-N (12)6C Chemical compound [12C] OKTJSMMVPCPJKN-IGMARMGPSA-N 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N (1S,3R,4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,25R,27R,29R,32R,33R,35S,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14, Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- NJGIRBISCGPRPF-KXQOOQHDSA-N (2-aminoethoxy)[(2R)-2-(icosanoyloxy)-3-(pentadecanoyloxy)propoxy]phosphinic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP(O)(=O)OCCN)COC(=O)CCCCCCCCCCCCCC NJGIRBISCGPRPF-KXQOOQHDSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-AIECOIEWSA-N (2R,3R,4R,5S,6R)-2,3,4,5,6,7-hexahydroxyheptanoic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-AIECOIEWSA-N 0.000 description 1
- XUFXOAAUWZOOIT-WVJZLWNXSA-N (2S,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-WVJZLWNXSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 1
- NINIDFKCEFEMDL-AKLPVKDBSA-N (35)S Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
- DEQANNDTNATYII-MEUDYGGUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)NC(CO)C(O)C)C1=CC=CC=C1 DEQANNDTNATYII-MEUDYGGUSA-N 0.000 description 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (±)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2R)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- POTBKLVBOJZRNG-UHFFFAOYSA-N 1-hydroxy-2H-naphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)(O)CC=CC2=C1 POTBKLVBOJZRNG-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- VHVPQPYKVGDNFY-TUJWMRSMSA-N 2-[(2S)-butan-2-yl]-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-TUJWMRSMSA-N 0.000 description 1
- CZKPOZZJODAYPZ-WSGIOKLISA-N 2-[(3S,6R,12R,20S,23R)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid Chemical compound N1C(=O)[C@@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](CCCCN=C(N)N)NC(=O)CCSSC[C@H](C(N)=O)NC(=O)[C@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-WSGIOKLISA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- JRMAQQQTXDJDNC-UHFFFAOYSA-M 2-ethoxy-2-oxoacetate Chemical compound CCOC(=O)C([O-])=O JRMAQQQTXDJDNC-UHFFFAOYSA-M 0.000 description 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N 2-hydroxyethyl 2-methylacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-hydroxypropyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- VHOQXEIFYTTXJU-UHFFFAOYSA-N 2-methylbuta-1,3-diene;2-methylprop-1-ene Chemical compound CC(C)=C.CC(=C)C=C VHOQXEIFYTTXJU-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- KUDUQBURMYMBIJ-UHFFFAOYSA-N 2-prop-2-enoyloxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC(=O)C=C KUDUQBURMYMBIJ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3 Hydroxycoumarin Chemical class C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 1
- BUJCVBRLTBAYCW-UHFFFAOYSA-N 3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxyphenoxy)propan-1-one Chemical compound COC1=CC=CC=C1OC(CO)C(=O)C1=CC=C(O)C(OC)=C1 BUJCVBRLTBAYCW-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-Aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-Aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 229940046932 4-aminosalicylic acid Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N 6-chloro-2-methyl-1,1-dioxo-3-{[(2,2,2-trifluoroethyl)sulfanyl]methyl}-3,4-dihydro-2H-1lambda^{6},2,4-benzothiadiazine-7-sulfonamide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 108060005293 AGA Proteins 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229940030486 ANDROGENS Drugs 0.000 description 1
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
- 102100004323 ASPG Human genes 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N AZAPROPAZONE Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 108010004463 Abciximab Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QCXJEYYXVJIFCE-UHFFFAOYSA-N Acedoben Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 1
- 229960004892 Acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N Acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960002054 Acenocoumarol Drugs 0.000 description 1
- VABCILAOYCMVPS-UHFFFAOYSA-N Acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 1
- 208000004064 Acoustic Neuroma Diseases 0.000 description 1
- 206010000583 Acral lentiginous melanoma Diseases 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000002517 Adenoid Cystic Carcinoma Diseases 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 208000007128 Adrenocortical Carcinoma Diseases 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 1
- 208000002205 Allergic Conjunctivitis Diseases 0.000 description 1
- 208000002029 Allergic Contact Dermatitis Diseases 0.000 description 1
- 206010058284 Allergy to arthropod sting Diseases 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N Amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N Ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- MQHLMHIZUIDKOO-AYHJJNSGSA-N Amorolfine Chemical compound C1=CC(C(C)(C)CC)=CC=C1CC(C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-AYHJJNSGSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 229940031955 Anhydrous lanolin Drugs 0.000 description 1
- 229960003348 Anidulafungin Drugs 0.000 description 1
- 108010064760 Anidulafungin Proteins 0.000 description 1
- 229960000983 Anistreplase Drugs 0.000 description 1
- 108010058207 Anistreplase Proteins 0.000 description 1
- 240000005415 Anogeissus latifolia Species 0.000 description 1
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 1
- 229940046836 Anti-estrogens Drugs 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N Argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 Aspartame Drugs 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 206010003557 Asthma exercise induced Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 229960002170 Azathioprine Drugs 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N BAY 38-9456 Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 208000003373 Basosquamous Carcinoma Diseases 0.000 description 1
- 208000009137 Behcet Syndrome Diseases 0.000 description 1
- 201000008335 Behcet's disease Diseases 0.000 description 1
- FEJKLNWAOXSSNR-UHFFFAOYSA-N Benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N Benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 206010058956 Bicytopenia Diseases 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N Bifonazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- 229940096699 Bile acid sequestrants Drugs 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- OYVAGSVQBOHSSS-WXFSZRTFSA-O Bleomycin Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-WXFSZRTFSA-O 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- 206010048396 Bone marrow transplant rejection Diseases 0.000 description 1
- 206010006007 Bone sarcoma Diseases 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 208000003362 Bronchogenic Carcinoma Diseases 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N Bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N Butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N Butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 101710027095 C14orf180 Proteins 0.000 description 1
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 description 1
- 229940084030 CARBOXYMETHYLCELLULOSE CALCIUM Drugs 0.000 description 1
- 102100016444 CCDC50 Human genes 0.000 description 1
- 101710023985 CCDC50 Proteins 0.000 description 1
- 241000220450 Cajanus cajan Species 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 208000002458 Carcinoid Tumor Diseases 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 208000010027 Carcinoma, Intraductal, Noninfiltrating Diseases 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N Carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N Carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229940089960 Chloroacetate Drugs 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- 229960002155 Chlorothiazide Drugs 0.000 description 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N Chlortalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
- 229940107084 Chlorthalidone Drugs 0.000 description 1
- 208000006990 Cholangiocarcinoma Diseases 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010008943 Chronic leukaemia Diseases 0.000 description 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N Ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N Cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229920002839 Cis-regulatory element Polymers 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 229960003009 Clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N Clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 206010009839 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010055114 Colon cancer metastatic Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 206010070976 Craniocerebral injury Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 229960005168 Croscarmellose Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- 208000002445 Cystadenocarcinoma Diseases 0.000 description 1
- 229940030606 DIURETICS Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N DL-tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960002887 Deanol Drugs 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229960004486 Desoxycorticosterone acetate Drugs 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940096516 Dextrates Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N Dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Dichlothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N Diethylethanolamine Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N Diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N Dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 229960002768 Dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N Dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 229940034984 ENDOCRINE THERAPY ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Drugs 0.000 description 1
- 210000002304 ESC Anatomy 0.000 description 1
- 229960003913 Econazole Drugs 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N Econazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 229960001484 Edetic Acid Drugs 0.000 description 1
- 241001669679 Eleotris Species 0.000 description 1
- 208000001991 Endodermal Sinus Tumor Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 210000004696 Endometrium Anatomy 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N Eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- 229960004468 Eptifibatide Drugs 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- 229940011871 Estrogens Drugs 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N Etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 229950000152 FILIPIN Drugs 0.000 description 1
- 229940012414 Factor VIIa Drugs 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N Fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N Fenticonazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- IMQSIXYSKPIGPD-NKYUYKLDSA-N Filipin Chemical compound CCCCC[C@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O IMQSIXYSKPIGPD-NKYUYKLDSA-N 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229940014144 Folate Drugs 0.000 description 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 229960004580 GLIBENCLAMIDE Drugs 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- YRSVDSQRGBYVIY-GJZGRUSLSA-N Gemopatrilat Chemical compound O=C1N(CC(O)=O)C(C)(C)CCC[C@@H]1NC(=O)[C@@H](S)CC1=CC=CC=C1 YRSVDSQRGBYVIY-GJZGRUSLSA-N 0.000 description 1
- 229950006480 Gemopatrilat Drugs 0.000 description 1
- 210000004392 Genitalia Anatomy 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N Glibenclamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N Glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229960001381 Glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N Glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229940014653 Glyburide Drugs 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N Glyceryl behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- 229940076085 Gold Drugs 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N Gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000001922 Gum ghatti Substances 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 101700042506 HIRUD Proteins 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N HMG-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 208000006359 Hepatoblastoma Diseases 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 229940006607 Hirudin Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 1
- 101710044247 ITGA2B Proteins 0.000 description 1
- 102100019332 ITGA2B Human genes 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Ilacox Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 208000009326 Ileitis Diseases 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 206010027665 Immune disorder Diseases 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 206010022437 Insomnia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022498 Insulinoma Diseases 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 229940044173 Iodine-125 Drugs 0.000 description 1
- 206010073086 Iris melanoma Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N Isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N Ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 210000000244 Kidney Pelvis Anatomy 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- WQXXXVRAFAKQJM-WHFBIAKZSA-N L-γ-glutamyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CC[C@H](N)C(O)=O WQXXXVRAFAKQJM-WHFBIAKZSA-N 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- 208000003849 Large Cell Carcinoma Diseases 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 210000000867 Larynx Anatomy 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010024217 Lentigo Diseases 0.000 description 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N Levofloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 208000009856 Lung Disease Diseases 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- 206010025224 Lymphangiosarcomas Diseases 0.000 description 1
- 210000004324 Lymphatic System Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 208000008585 Mastocytosis Diseases 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 229940057917 Medium chain triglycerides Drugs 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 206010027191 Meningioma Diseases 0.000 description 1
- 240000006217 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 206010063569 Metastatic squamous cell carcinoma Diseases 0.000 description 1
- 229960003105 Metformin Drugs 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N Metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 Metoprolol Drugs 0.000 description 1
- 229960002159 Micafungin Drugs 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N Mucic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010073101 Mucinous breast carcinoma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- RLWRMIYXDPXIEX-UHFFFAOYSA-N Muzolimine Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C)N1N=C(N)CC1=O RLWRMIYXDPXIEX-UHFFFAOYSA-N 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 208000001611 Myxosarcoma Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940100662 Nasal Drops Drugs 0.000 description 1
- 229960003255 Natamycin Drugs 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N Natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 210000003739 Neck Anatomy 0.000 description 1
- 208000009025 Nervous System Disease Diseases 0.000 description 1
- 208000007538 Neurilemmoma Diseases 0.000 description 1
- 208000004235 Neutropenia Diseases 0.000 description 1
- 229940053207 Niacin Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N Nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 229960001494 Octreotide Acetate Drugs 0.000 description 1
- 206010030032 Ocular disorder Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N Omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
- 229950000973 Omapatrilat Drugs 0.000 description 1
- 229960005010 Orotic Acid Drugs 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N Orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N Oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- CNDQSXOVEQXJOE-UHFFFAOYSA-N Oxyphenbutazone Chemical compound O.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 CNDQSXOVEQXJOE-UHFFFAOYSA-N 0.000 description 1
- 102100010469 P2RY12 Human genes 0.000 description 1
- 101710037784 P2RY12 Proteins 0.000 description 1
- 229960000540 POLACRILIN POTASSIUM Drugs 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102100000077 PPARG Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 108010061219 Panitumumab Proteins 0.000 description 1
- 208000004019 Papillary Adenocarcinoma Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 229960000280 Phenindione Drugs 0.000 description 1
- NFBAXHOPROOJAW-UHFFFAOYSA-N Phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N Phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 229960004838 Phosphoric acid Drugs 0.000 description 1
- 229940097886 Phosphorus 32 Drugs 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 206010035059 Pineocytoma Diseases 0.000 description 1
- 229960005095 Pioglitazone Drugs 0.000 description 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 206010035109 Pituitary-dependent Cushing's syndrome Diseases 0.000 description 1
- 208000003359 Plasma Cell Leukemia Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229960003171 Plicamycin Drugs 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 229950005134 Polycarbophil Drugs 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 208000008696 Polycythemia Vera Diseases 0.000 description 1
- 229940068918 Polyethylene Glycol 400 Drugs 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229960002965 Pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 208000007541 Preleukemia Diseases 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 229960001309 Procaine hydrochloride Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229940097325 Prolactin Drugs 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 229940075579 Propyl Gallate Drugs 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N Propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N Propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N Propyne Chemical group CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- VIAFLMPQBHAMLI-UHFFFAOYSA-N PyBOP Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 VIAFLMPQBHAMLI-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N Pyroglutamic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 229940073095 Questran Drugs 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N Quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 101710005157 RPLP0 Proteins 0.000 description 1
- 101710005414 RPLP1 Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N Raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940100618 Rectal Suppository Drugs 0.000 description 1
- 206010038038 Rectal cancer Diseases 0.000 description 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 1
- 206010038428 Renal disease Diseases 0.000 description 1
- 229940086526 Renin-inhibitors Drugs 0.000 description 1
- 229960002917 Reteplase Drugs 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229940030484 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Drugs 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N Saccharic acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- 229940085605 Saccharin Sodium Drugs 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 206010039667 Schwannoma Diseases 0.000 description 1
- FEBUJFMRSBAMES-UHFFFAOYSA-N Scleroglucan Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- 210000001732 Sebaceous Glands Anatomy 0.000 description 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N Sertaconazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- 206010058141 Skin graft rejection Diseases 0.000 description 1
- 208000000927 Sleep Apnea Syndrome Diseases 0.000 description 1
- 206010040979 Sleep apnoea syndrome Diseases 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108009000491 Small cell lung cancer Proteins 0.000 description 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000003823 Soleirolia soleirolii Species 0.000 description 1
- 229960000553 Somatostatin Drugs 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 229960000391 Sorbitan trioleate Drugs 0.000 description 1
- 229960004274 Stearic acid Drugs 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 229960005137 Succinic Acid Drugs 0.000 description 1
- 229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 description 1
- 229940032330 Sulfuric acid Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 229960004492 Suprofen Drugs 0.000 description 1
- MDKGKXOCJGEUJW-UHFFFAOYSA-N Suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229960001967 Tacrolimus Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N Tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 210000000538 Tail Anatomy 0.000 description 1
- 229940033123 Tannic Acid Drugs 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N Tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229960000216 Tenecteplase Drugs 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N Terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N Terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 235000002423 Theobroma angustifolium Nutrition 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 235000002425 Theobroma bicolor Nutrition 0.000 description 1
- 235000002424 Theobroma grandiflorum Nutrition 0.000 description 1
- 235000002323 Theobroma simiarum Nutrition 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N Thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N Thiodipropionic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 206010043554 Thrombocytopenia Diseases 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- GUHPRPJDBZHYCJ-UHFFFAOYSA-N Tiaprofenic acid Chemical compound S1C(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-UHFFFAOYSA-N 0.000 description 1
- 229960005001 Ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N Ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- AGHANLSBXUWXTB-UHFFFAOYSA-N Tienilic acid Chemical compound ClC1=C(Cl)C(OCC(=O)O)=CC=C1C(=O)C1=CC=CS1 AGHANLSBXUWXTB-UHFFFAOYSA-N 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 208000005765 Traumatic Brain Injury Diseases 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960001288 Triamterene Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N Trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 229940117013 Triethanolamine oleate Drugs 0.000 description 1
- YFNKIDBQEZZDLK-UHFFFAOYSA-N Triethylene glycol dimethyl ether Chemical compound COCCOCCOCCOC YFNKIDBQEZZDLK-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triurene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N Troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- 206010073104 Tubular breast carcinoma Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N Undecylenic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 229940120293 Vaginal Suppository Drugs 0.000 description 1
- 206010046885 Vaginal cancer Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000008662 Verrucous Carcinoma Diseases 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 208000009311 Vipoma Diseases 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 1
- 229960005080 Warfarin Drugs 0.000 description 1
- 208000008383 Wilms Tumor Diseases 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6S)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2R,3R,4S,5R,6S)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- MIOPJNTWMNEORI-OMNKOJBGSA-N [(4S)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-OMNKOJBGSA-N 0.000 description 1
- PRXRUNOAOLTIEF-XDTJCZEISA-N [2-[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-XDTJCZEISA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- UQYZFNUUOSSNKT-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 UQYZFNUUOSSNKT-UHFFFAOYSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000005571 adamantylene group Chemical group 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 230000002152 alkylating Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229960003204 amorolfine Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229960003942 amphotericin B Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 125000004653 anthracenylene group Chemical group 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000002424 anti-apoptotic Effects 0.000 description 1
- 230000000879 anti-atherosclerotic Effects 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 230000003474 anti-emetic Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites Pyrimidine analogues Drugs 0.000 description 1
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 201000002936 artery disease Diseases 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 230000003385 bacteriostatic Effects 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960004277 benorilate Drugs 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- QDHFHIQKOVNCNC-UHFFFAOYSA-M butane-1-sulfonate Chemical compound CCCCS([O-])(=O)=O QDHFHIQKOVNCNC-UHFFFAOYSA-M 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SOGAXMICEFXMKE-UHFFFAOYSA-N butyl 2-methylprop-2-enoate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZTHQBROSBNNGPU-UHFFFAOYSA-N butyl hydrogen sulfate Chemical compound CCCCOS(O)(=O)=O ZTHQBROSBNNGPU-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005622 butynylene group Chemical group 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000005566 carbazolylene group Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 229940082638 cardiac stimulant Phosphodiesterase inhibitors Drugs 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 201000001084 cerebrovascular disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 230000001055 chewing Effects 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 201000009047 chordoma Diseases 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000005747 chromanylene group Chemical group 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 201000006233 congestive heart failure Diseases 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical class CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004977 cycloheptylene group Chemical group 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 125000005754 decalinylene group Chemical group 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- 231100000080 dermatitis contact Toxicity 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000005992 dihydrobenzisothiazinyl group Chemical group 0.000 description 1
- 125000005993 dihydrobenzisoxazinyl group Chemical group 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- PSHRANCNVXNITH-UHFFFAOYSA-N dimethylamino acetate Chemical compound CN(C)OC(C)=O PSHRANCNVXNITH-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 description 1
- 150000004659 dithiocarbamates Chemical class 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940046080 endocrine therapy drugs Estrogens Drugs 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 229930013356 epothilones Natural products 0.000 description 1
- 230000003628 erosive Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-M ethyl carbonate Chemical compound CCOC([O-])=O CQDGTJPVBWZJAZ-UHFFFAOYSA-M 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 201000008808 fibrosarcoma Diseases 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000005567 fluorenylene group Chemical group 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000008064 heavy chain disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 238000009217 hyperthermia therapy Methods 0.000 description 1
- 239000007946 hypodermic tablet Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000005835 indanylene group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229960005085 indometacin Drugs 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000005994 isobenzotetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005990 isobenzothienyl group Chemical group 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 125000003151 isocoumarinyl group Chemical group C1(=O)OC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 229940087748 lithium sulfate Drugs 0.000 description 1
- HCQWRNRRURULEY-UHFFFAOYSA-L lithium;potassium;dichloride Chemical compound [Li+].[Cl-].[Cl-].[K+] HCQWRNRRURULEY-UHFFFAOYSA-L 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 208000009018 medullary Thyroid cancer Diseases 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 229950000257 metamizole Drugs 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 200000000023 metastatic cancer Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000002297 mitogenic Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229960001788 muzolimine Drugs 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N nabumeton Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- QJGQUHMNIGDVPM-OUBTZVSYSA-N nitrogen-15 Chemical compound [15N] QJGQUHMNIGDVPM-OUBTZVSYSA-N 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000000269 nucleophilic Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- KREXGRSOTUKPLX-UHFFFAOYSA-N octadecanoic acid;zinc Chemical compound [Zn].CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O KREXGRSOTUKPLX-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 201000010133 oligodendroglioma Diseases 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000009234 osteosclerotic myeloma Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000005564 oxazolylene group Chemical group 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 235000006678 peppermint Nutrition 0.000 description 1
- 235000015132 peppermint Nutrition 0.000 description 1
- 235000007735 peppermint Nutrition 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000005562 phenanthrylene group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- ZPHBZEQOLSRPAK-XLCYBJAPSA-N phosphoramidon Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)P(O)(=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O ZPHBZEQOLSRPAK-XLCYBJAPSA-N 0.000 description 1
- 108010072906 phosphoramidon Proteins 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 229940096700 plain lipid modifying drugs Fibrates Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920002496 poly(ether sulfone) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920001291 polyvinyl halide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- 102000004257 potassium channel family Human genes 0.000 description 1
- 108020001213 potassium channel family Proteins 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- UOVHNSMBKKMHHP-UHFFFAOYSA-L potassium;sodium;sulfate Chemical compound [Na+].[K+].[O-]S([O-])(=O)=O UOVHNSMBKKMHHP-UHFFFAOYSA-L 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- HETCEOQFVDFGSY-UHFFFAOYSA-N prop-1-en-2-yl acetate Chemical compound CC(=C)OC(C)=O HETCEOQFVDFGSY-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 230000001185 psoriatic Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000005550 pyrazinylene group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000005548 pyrenylene group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000005576 pyrimidinylene group Chemical group 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000008175 ready-to-use sterile solution Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000001850 reproductive Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 108010051412 reteplase Proteins 0.000 description 1
- 201000000582 retinoblastoma Diseases 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- CKNPWBAXEKSCRG-UHFFFAOYSA-J satraplatin Chemical compound CC(=O)O[Pt-2]([NH3+])(Cl)(Cl)(OC(C)=O)[NH2+]C1CCCCC1 CKNPWBAXEKSCRG-UHFFFAOYSA-J 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000580 secretagogue Effects 0.000 description 1
- 201000010208 seminoma Diseases 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000003351 stiffener Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- NWJQLQGQZSIBAF-MLAUYUEBSA-N tacrolimus hydrate Chemical compound O.C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 NWJQLQGQZSIBAF-MLAUYUEBSA-N 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 101700082413 tant Proteins 0.000 description 1
- 230000035917 taste Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000035923 taste sensation Effects 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 125000006836 terphenylene group Chemical group 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005756 tetralinylene group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005557 thiazolylene group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960000103 thrombolytic agents Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 229960000356 tienilic acid Drugs 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005558 triazinylene group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000005559 triazolylene group Chemical group 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 239000006217 urethral suppository Substances 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229960001522 ximelagatran Drugs 0.000 description 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
Provided herein are benzimidazole derivatives, for example, of Formula I, and pharmaceutical compositions thereof capable of modulating ERBB tyrosine kinases. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
Description
WO 43148
IDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE
INHIBITORS FOR THE TREATMENT OF CANCER
CROSS REFERENCE TO RELATED APPLICATION
This application claims the benefit of the priority ofUS. Provisional
Application No. 61/968,225, filed March 20, 2014; the disclosure of which is incorporated
herein by reference in its entirety.
FIELD
Provided herein are benzimidazole derivatives and ceutical
compositions thereof. Also provided herein are methods of their use for treating, preventing,
or ameliorating one or more symptoms of a erative disease.
BACKGROUND
In the human receptor tyrosine kinase superfamily, the ERBB family
comprises four members: ERBBl (epidermal growth factor receptor or EGFR), ERBB2
(HER2), ERBB3 (HER3), and ERBB4 (HER4). The ERBB receptors share an overall similar
structure with a ligand-binding ectodomain, a single transmembrane domain, and an
ellular kinase domain, which is active in ERBBl, HER2 and ERBB4, but defective in
ERBB3. A diverse array of ligands has been identified for the ectodomains of ERBBl,
ERBB3, and ERBB4, but not HER2. Ligand binding induces conformational change in
receptors to form homo- and hetero-dimerization. Without ligand binding, the extracellular
domain of HER2 is already fixed in a mation that resembles the other -activated
ERBB members, making it a preferred dimerization partner for other ligand-bound ERBBs.
The dimerized receptors activate the intrinsic kinase activity, leading to phosphorylation of
tyrosines at cytoplasmic tails. The ERBB receptors differ in kinase potency, phosphorylation
sites, and substrate specificity. The phosphorylated tyrosines serve as the docking sites to
recruit downstream effectors and activate multiple es of intracellular signaling
pathways, including the anti-apoptotic/survival PI3K/AKT and the mitogenic
RAS/RAF/MEK/ERK pathways. In normal cells, the ty of ERBB receptors is under
tight control to regulate various cellular processes, such as growth, proliferation, pment
and differentiation, al and apoptosis, cell shape and on, migration, and
angiogenesis. Yarden et al., Nat. Rev. Mol. Cell. Biol. 2001, 2, 127-137; Hynes et al., Nat.
Rev. Cancer 2005, 5, 341—354.
As a major proliferation and survival engine for cells, constitutive activation
ofERBB receptors, particularly ERBBl and HER2, is nic and can be a strong driver
for genesis in cultured cells and animal models. In addition, the activated receptors
accelerate cancer development by promoting tumor angiogenesis and metastasis. Persistent
activation can result from overexpression of the receptors, production of excessive ligands, or
generation of activating ons in the ectodomains and kinase domains of the receptors.
Yarden et al., Nat. Rev. Mol. Cell. Biol. 2001, 2, 127-137. In , genetic alterations in
ERBB genes and other genes that lead to similar deregulation of ERBB receptors are
frequently identified in majority of carcinomas, such as lung, breast, colon, prostate, brain,
head and neck, agus, ovary, cervix, bladder, stomach, and endometrium cancer. The
aberrant activation of ERBB receptors is in general an adverse prognostic indicator for higher
recurrence rate and shorter survival time. Nicholson et al., Eur. J. Cancer 2001, 3 7, 9-15;
Slamon et al., Science 1997, 235, 177-182.
Given the compelling association of activation of ERBB receptors with human
cancers, ERBBl and HER2 are among the kinase targets for drug development, aiming to
tame signaling uction pathways for cancer treatment. To reverse the abnormal activity
ofERBB receptors in , monoclonal antibodies targeting the extracellular domains of
ERBBl and HER2 and small molecule chemicals ting the intracellular kinase domains
have been developed.
The monoclonal dy drugs attack the ERBB receptors with high
specificity and attenuate ediated signaling by prevention of ligand binding and
receptor dimerization, ation receptors from cell surface through endocytosis, inhibition
of shedding of extracellular domain, and activation of immune system. Hudis, N. Engl. J.
Med. 2007, 35 7, 39-51. mab and panitumumab, two anti-ERBBl antibodies, have
shown improvement in response rate and the rate of ssion-free survival in the treatment
of metastatic colon cancer either as monotherapy or in combination with chemotherapies. In
addition, cetuximab has also been approved for the treatment of locally advanced,
unresectable or metastatic squamous cell carcinoma of the head and neck. ello et al.,
N. Engl. J. Med. 2008, 358, 1160-1174. Anti-HER2 antibody trastuzumab binds to the
domain IV of the HER2 receptor at the juxtamembrane position. In clinical development,
trastuzumab has demonstrated increased overall survival rate in early- and metastatic-stage
breast cancer patients with tumors showing IHC 3+ HER2 overexpression or FISH gene
amplification ratio of at least 2.0. Using the same criteria for patient selection, umab,
which binds to a distinct epitope at the domain II of the HER2 receptor, has been found to
filrther increase the complete response rate by addition to trastuzumab and docetaxel regimen
as a neoadjuvant ent for patients with locally advanced, early-stage breast cancer.
Gradishar, N. Engl. J. Med. 2012, 366, 176-178.
Development of small-molecule ERBBl kinase inhibitors (ERBBlIs) has
become an evolving paradigm for using cancer genomics to guide targeted drug development
and treatment. Gefinitib and erlotinib, the first two ERBBlI drugs, are reversible ATP
mimetic inhibitors that bind to the wild-type ERBBl catalytic domain to inhibit tyrosine
kinase activity. In unselected patients of non-small cell lung cancer (NSCLC) or pancreatic
cancer, only erlotinib has demonstrated clinical benefit by modestly increasing overall
survival. Ciardiello et al., N. Engl. J. Med. 2008, 358, 1160-1174. In a subset C
patients that harbor ting ons within ERBBl tyrosine kinase domain, both
gefitinib and erlotinib ents are highly ive and can achieve lasting efficacy as
monotherapy. These drug-responding mutations are mostly in-frame deletions nested around
g-Glu-Ala from position 747 to 750 in ERBBl exon 19, or a leucine to arginine
substitution at position 858 (L85 8R) in exon 21.
However, the initial response to nib or gefitinib relapses in 10-14 months
by developing resistant mutations in tumors. Among them, a T790M gate-keeper point
mutation in the exon 20 of ERBBl, which poses a steric interference to drug binding, is
found in over 50% of acquired resistant tumors. To overcome the resistance from T790M
mutation and confer sustained ERBBl inhibition, the second-generation ERBBlIs have been
developed, some of them are irreversible ERBBl and HER2 dual inhibitors. The rsible
compounds overcome the kinase binding hindrance from T790M on by better fitting
into the mutated binding pocket and g covalent bond with the protein amino acid
residues. Additionally, irreversible ERBBlIs appear to cause slower acquired resistance to
the treatment than reversible inhibitors. Sharma et al. Nat. Rev. Cancer 2007, 7. 169-18 1.
In preclinical testing, afatinib, a second-generation , inhibited the
growth ofNSCLC HCC827 cells, which harbor the sensitive exon 19 on, and is d
more potent than erlotinib in inhibition of growth ofNSCLC H1975 cells, which has a
T790M mutation in-cis with the L858R mutation. However, afatinib also inhibits A431 cells,
whose growth is driven by a wild-type ERBB1, 100-fold more potent than H1975. The
difference in ies portends that, in cancer patients, the compound could inhibit wild-type
ERBB1 completely before it reaches sufficient blood level for pharmacological effect on
T790M mutant ERBB1. Since wild-type ERBB1 inhibition has been reported to cause doselimiting
toxicity in virtually all previously ERBB1I drugs, the preferential inhibition of pe
ERBB1 over resistant mutant pose a ial challenge for afatinib to achieve high enough
dose for T790M mutant inhibition. Consistent with the preclinical discovery, clinical
development has found afatinib only showed equivalent efficacy to nib or gefitinib in
patients with sensitive mutations, but failed to demonstrate statistically meaningful superiority
to erlotinib and gefitinib in ng patients with acquired T790M resistant mutation even at
the maximum tolerated dose. Langer, J. Clin. Oncol. 2013, 31, 3303-3330. Thus, there is a
clear and unmet need to develop effective therapeutics for treating a proliferative disease,
ally drug-resistant cancer.
SUMMARY OF THE DISCLOSURE
[009a] The t invention particular relates to aspects and ments set out in
the clauses below and as described further herein. However, other aspects and embodiments
are also described herein for completeness.
1. A compound of Formula XIa or XIX:
(XIa) (XIX)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt or solvate f; wherein each R1 is
independently ed from the group consisting of:
(followed by page 4A)
, , ,
, , ,
, , ,
, , ,
, , ,
O N
, ,
and ;
R2 is C6-14 aryl, or heteroaryl;
each R4, R5, and R7 is independently (a) en, cyano, halo, or nitro; (b) C1-6 alkyl, C2-6
alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, aryl, or heterocyclyl; or
(c) –C(O)R1a, –C(O)OR1a, –C(O)NR1bR1c, –C(NR1a)NR1bR1c, –OR1a, –OC(O)R1a,
–OC(O)OR1a, –OC(O)NR1bR1c, R1a)NR1bR1c, R1a, –OS(O)2R1a,
–OS(O)NR1bR1c, –OS(O)2NR1bR1c, –NR1bR1c, –NR1aC(O)R1d, –NR1aC(O)OR1d,
–NR1aC(O)NR1bR1c, –NR1aC(=NR1d)NR1bR1c, –NR1aS(O)R1d, –NR1aS(O)2R1d,
–NR1aS(O)NR1bR1c, –NR1aS(O)2NR1bR1c, –SR1a, –S(O)R1a, –S(O)2R1a, –S(O)NR1bR1c, or
–S(O)2NR1bR1c;
R6a is C3-7 cycloalkyl, C6-14 aryl, heteroaryl, or heterocyclyl;
R7a is C3-7 cycloalkyl, C6-14 aryl, heteroaryl, or heterocyclyl;
(followed by page 4B)
R2n is C1-6 alkyl or –OR1a;
each R1a, R1b, R1c, and R1d is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl,
C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or R1a and R1c together
with the C and N atoms to which they are attached form heterocyclyl; or R1b and R1c together
with the N atom to which they are attached form heterocyclyl; and
wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl,
aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally
tuted with one or more substituents Q, where each Q is independently selected from (a)
oxo, cyano, halo, and nitro; (b) C1-6 alkyl, C2-6 l, C2-6 alkynyl, C3-7 cycloalkyl, C6-14
aryl, C7-15 aralkyl, aryl, and heterocyclyl, each of which is r optionally substituted
with one or more substituents Qa; and (c) –C(O)Ra, –C(O)ORa, –C(O)NRbRc, –
C(NRa)NRbRc, –ORa, –OC(O)Ra, –OC(O)ORa, –OC(O)NRbRc, –OC(=NRa)NRbRc, –
ORa)2, –OS(O)Ra, –OS(O)2Ra, –OS(O)NRbRc, –OS(O)2NRbRc, –NRbRc, –
NRaC(O)Rd, –NRaC(O)ORd, –NRaC(O)NRbRc, –NRaC(=NRd)NRbRc, –NRaS(O)Rd, –
)2Rd, –NRaS(O)NRbRc, –NRaS(O)2NRbRc, –SRa, –S(O)Ra, –S(O)2Ra, –S(O)NRbRc,
and –S(O)2NRbRc, wherein each Ra, Rb, Rc, and Rd is independently (i) hydrogen; (ii) C1-6
alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or
heterocyclyl, each of which is ally tuted with one or more substituents Qa; or (iii)
Rb and Rc together with the N atom to which they are attached form heterocyclyl, optionally
substituted with one or more substituents Qa;
wherein each Qa is independently selected from the group ting of (a) oxo, cyano, halo,
and nitro; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl,
heteroaryl, and heterocyclyl; and (c) –C(O)Rf, –C(O)ORf, –C(O)NRgRh,
–C(NRf)NRgRh, –ORf, –OC(O)Rf, –OC(O)ORf, –OC(O)NRgRh, –OC(=NRf)NRgRh,
(ORf)2, –OS(O)Rf, –OS(O)2Rf, –OS(O)NRgRh, –OS(O)2NRgRh, –NRgRh,
–NRfC(O)Rk, –NRfC(O)ORk, –NRfC(O)NRgRh, –NRfC(=NRk)NRgRh, –NRfS(O)Rk,
–NRfS(O)2Rk, –NRfS(O)NRgRh, –NRfS(O)2NRgRh, –SRf, –S(O)Rf, –S(O)2Rf, –S(O)NRgRh,
and –S(O)2NRgRh; wherein each Rf, Rg, Rh, and Rk is independently (i) hydrogen; (ii) C1-6
alkyl, C2-6 alkenyl, C2-6 l, C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or
heterocyclyl; or (iii) Rg and Rh together with the N atom to which they are attached form
heterocyclyl.
(followed by page 4C)
2. The compound of 1, having the structure of Formula XIa:
(XIa)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an ic variant
thereof; or a ceutically acceptable salt or solvate thereof.
3. The compound of 2, wherein R2n is methyl, uoromethyl, difluoromethyl,
trifluoromethyl, –OH, or –OCH3.
4. The compound of any one of 1 to 3, wherein R7a is C3-10 cycloalkyl or heterocyclyl,
each of which is optionally substituted with one or more substituents Q.
. The compound of 4, wherein R7a is heterocyclyl, optionally substituted with one or
more substituents Q.
6. The compound of 4, wherein R7a is
N O O N
R1a , R1a , , ,
O N O N O N
, R1a , R1a , , R1a ,
O N N
O N O N R1b O N R1b O
R1a , , R1a , R1a , ,
(followed by page 4D)
O O N
O O O O N
O , O
, , O
R1a ,
R1a ,
, ,
, , ,
, , , ,
, , or ;
wherein:
p and q are each independently an integer of 0, 1, or 3, with the proviso that the total of p and
q is no less than 1; and
each r is ndently an integer of 0, 1, 2, 3, 4, 5, or 6.
7. The compound of 4, wherein R7a is
, , , , ,
, or .
(followed by page 4E)
8. The nd of 2, wherein the compound is selected from the group consisting of:
O O
N N N N
NH NH
N N
O O O O
N N
N O N
, ,
A1 A2
N N
O O
N ,
O , D2
, ,
D3 D4
N CF3
N N
O O
, ,
D5 D6
(followed by page 4F)
N N
O O
F3C N
N N
NH NH
N N N N
O O O
O O O
N N
O O S
, and O ;
D10 D11
or a single enantiomer, a racemic e, a mixture of diastereomers, or an isotopic variant
thereof; or a ceutically acceptable salt or solvate thereof.
9. The compound of 1, having the structure of Formula XIX:
R4 O
R5 N R2
O N
N R1
(XIX)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt or solvate thereof.
. The compound of 9, having the structure of a XXa:
N R2n
O N N
N R1
(XXa)
(followed by page 4G)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
f; or a pharmaceutically acceptable salt or solvate thereof.
11. The nd of 9, wherein R2n is methyl, monofluoromethyl, difluoromethyl,
oromethyl, –OH, or –OCH3.
12. The compound of any one of 9 to 11, wherein R7 is chloro, methyl,
monofluoromethyl, difluoromethyl, trifluoromethyl, or –OR1a.
13. The compound of 12, wherein R7 is chloro.
14. The compound of any one of 9 to 13, wherein R6a is:
N O O N
R1a , R1a , , ,
O N O N O N
, R1a , R1a , , R1a ,
O N N
O N O N R1b O N R1b O
R1a , , R1a , R1a , ,
O O N
O O O O N
O , O
, , O
R1a ,
, R1a
, ,
, , ,
(followed by page 4H)
, , , , ,
, , , , ,
or ;
wherein:
p and q are each independently an integer of 0, 1, or 3, with the proviso that the total of p and
q is no less than 1; and
each r is independently an integer of 0, 1, 2, 3, 4, 5, or 6.
. The nd of any one of claims 9 to 13, wherein R6a is:
, , , ,
, , or .
16. The compound of any one of 1, 9, and 12 to 15, wherein R2 is 6- to 10-membered
monocyclic or bicyclic aryl, optionally substituted with one or more substituents Q.
(followed by page 4I)
17. The compound of any one of 1, 9, and 12 to 15, wherein R2 is 5- to 10-membered
monocyclic or bicyclic heteroaryl comprising 1 to 4 heteroatoms selected from N, O, and S,
optionally substituted with one or more substituents Q.
18. The compound of any one of 1, 9, and 12 to 15, wherein R2 is phenyl, pyridinyl,
pyridazinyl, benzo[c][1,2,5]oxodiazolyl, or benzo[c][1,2,5]thiodiazolyl, each of which is
optionally substituted with one or more substituents Q.
19. The nd of any one of 1, 9, and 12 to 15, wherein R2 is hydroxy-pyridinyl,
methoxy-pyridinyl, methyl-pyridinyl, difluoromethyl-pyridinyl, trifluoromethyl-pyridinyl,
methylaminocarbonyl-pyridinyl, or methyl-pyridazinyl.
. The nd of any one of 1, 9, and 12 to 19, wherein R4 is hydrogen.
21. The compound of any one of 1, 9, and 12 to 20 wherein R5 is hydrogen.
22. The compound of any one of 1, 9, and 12 to 21, wherein R6 is hydrogen.
23. The nd of 9, wherein the compound is selected from the group ting of:
, ,
C1 C2
(followed by page 4J)
, ,
C3 C4
, ,
C7 C8
, ,
C9 C10
wed by page 4K)
N OCH3 N OCH3
NH NH
O N N O N N
Cl O O
Cl O
N N
O O
, ,
C11 C12
N OH N OH
NH NH
O N N O N N
O O O
Cl Cl O
N N
O O
, ,
C13 C14
N CHF2 N CHF2
NH NH
O N N O N N
O O O
Cl Cl O
N N
O O
, , and
C15 C16
N OCH3
O N N
Cl O
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt or e thereof.
24. A compound selected from:
(followed by page 4L
and ,
D1 D8
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt or solvate thereof.
. A pharmaceutical composition comprising the nd of any one of 1 to 24, or a
pharmaceutically acceptable salt or solvate thereof; and a pharmaceutically acceptable
excipient.
26. The pharmaceutical composition of 25, wherein the ition is formulated as a
single dosage form.
27. The pharmaceutical composition of 25 or 26, n the composition is formulated
as oral, parenteral, nasal, respiratory, pulmonary, or intravenous dosage form.
28. The pharmaceutical composition of 27, wherein the pharmaceutical ition is in
an oral dosage form.
29. The pharmaceutical ition of 28, wherein the oral dosage form is a tablet or
. Use of the compound of any one of 1 to 24, or the pharmaceutical composition of any
one of 25 to 29, in the preparation of a medicament for treating, preventing, or ameliorating a
proliferative disease in a human subject.
31. The use of 30, wherein the erative disease is cancer.
32. The use of 31, wherein the cancer is drug-resistant.
33. The use of 31 or 32, wherein the cancer contains an ERBB variant.
34. The use of 33, wherein the ERBB variant is an EGFR variant.
(followed by page 4M
. The use of 34, wherein the EGFR variant contains one or more deletions, insertions,
or substitutions at the amino acid positions of 689, 700, 709, 715, 719, 720, 9, 761-
765, 767-775, 783, 784, 790, 796, 826, 839, 846, 858, 861, and 863.
36. The use of 34, n the EGFR variant contains one or more deletions, insertions,
or substitutions at the amino acid positions of 719, 746-751, 790, and 858.
37. The use of 34, wherein the EGFR variant ns one, two, or more deletions,
insertions, and/or substitutions, each independently selected from G719C, G719S. G719A,
ΔE746-A750, ΔE746-T751, ΔE746-A750 (ins RP), ΔD761-E762 (ins EAFQ), D770
(dup SVD), ΔV769-D770 (ins ASV), ΔD770-N771 (ins SVQ), ΔP772-H773 (ins PR),
ΔH773-V774 (ins NPH), ΔH773-V774 (ins H), ΔH773-V774 (ins PH), and ΔH773-V774
(ins GNPH), T790M, and L858R.
38. The use of 34, wherein the EGFR variant contains T790M, L858R, or a combination
thereof.
39. The use of 33, wherein the ERBB variant is a HER2 variant.
40. The use of 39, n the HER2 is overexpressed in the cancer.
41. The use of any one of 31 to 40, wherein the cancer is resistant to an EGFR inhibitor.
42. The use of 41, wherein the cancer is resistant to afatinib, canertinib, dacomitinib,
erlotinib, gefitinib, icotinib, lapatinib, neratinib, pelitinib, varlitinib, or a combination thereof.
43. The use of any one of 31 to 42, wherein the cancer is bladder cancer, brain tumor,
breast cancer, cancer of the mouth and throat, ctal cancer, lung cancer, or pancreatic
cancer, prostate cancer, stomach cancer, or uterine .
44. The use of 43, wherein the cancer is lung cancer.
45. The use of 43, n the cancer is non-small cell lung cancer.
(followed by page 4N
46. The use of any one of 31 to 45, wherein the cancer is relapsed or refractory.
47. A method of treating, preventing, or ameliorating a proliferative disease in a nonhuman
subject, the method comprising administering a compound of any one of 1-24, or the
composition according to any one of 25-29.
48. The method of 47, wherein the proliferative disease is cancer.
49. The method of 48, wherein the cancer is drug-resistant.
50. The method of 48 or 49, wherein the cancer ns an ERBB variant.
51. The method of 50, wherein the ERBB variant is an EGFR variant.
52. The method of 51, wherein the EGFR variant contains one or more ons,
insertions, or tutions at the amino acid positions of 689, 700, 709, 715, 719, 720, 746-
759, 761-765, 767-775, 783, 784, 790, 796, 826, 839, 846, 858, 861, and 863.
53. The method of 51, n the EGFR variant contains one or more ons,
insertions, or substitutions at the amino acid positions of 719, 746-751, 790, and 858.
54. The method of 51, n the EGFR variant contains one, two, or more deletions,
insertions, and/or substitutions, each independently selected from G719C, G719S. G719A,
ΔE746-A750, ΔE746-T751, ΔE746-A750 (ins RP), ΔD761-E762 (ins EAFQ), ΔS768-D770
(dup SVD), ΔV769-D770 (ins ASV), ΔD770-N771 (ins SVQ), ΔP772-H773 (ins PR),
ΔH773-V774 (ins NPH), ΔH773-V774 (ins H), ΔH773-V774 (ins PH), and ΔH773-V774
(ins GNPH), T790M, and L858R.
55. The method of 51, wherein the EGFR variant contains T790M, L858R, or a
combination thereof.
56. The method of 50, wherein the ERBB variant is a HER2 variant.
57. The method of 56, wherein the HER2 is overexpressed in the cancer.
(followed by page 4O)
58. The method of any one of 48 to 57, wherein the cancer is resistant to an EGFR
inhibitor.
59. The method of 58, wherein the cancer is resistant to afatinib, canertinib, dacomitinib,
nib, nib, icotinib, lapatinib, neratinib, pelitinib, varlitinib, or a combination thereof.
60. The method of any one of 48 to 59, wherein the cancer is bladder cancer, brain tumor,
breast cancer, cancer of the mouth and throat, colorectal cancer, lung cancer, or pancreatic
cancer, prostate , stomach cancer, or uterine cancer.
61. The method of 60, wherein the cancer is lung cancer.
62. The method of 60, wherein the cancer is non-small cell lung cancer.
63. The method of any one of 48 to 62, wherein the cancer is ed or refractory.
More broadly, provided herein is a compound of Formula I:
or a single enantiomer, a racemic mixture, a e of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof;
R1 is –C(O)CR1e=CR1fCR1g, , –N1aC(O)CR1e=CR1fCR1g, , –
1e=CR1fCR1g, , –S(O2)CR1e=CR1fCR1g, , –
NR1aS(O)CR1e=CR1fCR1g, , –NR1aS(O2)CR1e=CR1fCR1g, or
(followed by page 5)
| O R g1
/N‘§’ l :le
R16
R2 is C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C340 cycloalkyl, C644 aryl, C745
l, heteroaryl, or heterocyclyl;
L1 is a bond, —O—, —S—, )—, or —C(R1AR1B)—, wherein each R1A and R113
is independently hydrogen, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, or heterocyclyl;
L2 is C340 cycloalkylene, C644 arylene, C7_1 5 aralkylene, heteroarylene, or
cyclylene;
T is a bond, 0 s
, , N—, N(R4) , C(R4)—, or C(R“)2 ;
U is a bond, 0 s
, , N—, N(R5) , C(R5)—, or C(R5)2 ;
V is a bond, 0 s
, , N—, N(R6) , C(R6)—, or C(R6)2 ;
W is a bond, 0 s
, , N—, N(R7) , C(R7)—, or C(R7)2 ;
X and Y are each independently C or N;
Z is NR2A or CRZARZB, wherein each R2A and R213 is independently hydrogen,
halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl,
or heterocyclyl;
each R4, R5, R6, and R7 is independently (a) hydrogen, cyano, halo, or nitro;
(b) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C340 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl,
or heterocyclyl; or (c) 1a, —C(O)OR1a, —C(O)NR1bR1°, —C(NR1a)NR1bR1°, —0R1a,
—OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1°, —OC(=NR1a)NR1bR1°, —OS(O)R1a, —OS(O)2R1a,
—OS(O)NR1bR1°, 2NR1bR1°, —NR1bR1°, —NR1aC(O)R1d, —NR1aC(O)OR1d,
—NR1aC(O)NR1bR1°, —NR1aC(=NR1d)NR1bR1°, —NR1aS(O)R1d, —NR1aS(O)2R1d,
—NR1aS(O)NR1bR1°, —NR1aS(O)2NR1bR1°, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1°, or
—S(O)2NR1bR1°;
each R”, Rlb, R”, and R1d is independently hydrogen, C1_6 alkyl, C2_6 alkenyl,
C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, or cyclyl; or R1&1 and
R10 together with the C and N atoms to which they are attached form heterocyclyl; or R1b and
R10 together with the N atom to which they are attached form heterocyclyl; and
each R13, R”, and ng is independently hydrogen, halo, C1_6 alkyl, C2_6 alkenyl,
C2_6 alkynyl, C3_7 lkyl, C644 aryl, C745 aralkyl, heteroaryl, or heterocyclyl;
with the proviso that no more than one of T, U, V, and W is a bond; and
with the proviso that, when L1 is a bond, at least one of R4, R5, R6, and R7 is
bromo, —OR7a, or —NR1bR1°, wherein R7&1 is C4_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7
cycloalkyl, C644 aryl, C7_1 5 l, heteroaryl, or heterocyclyl;
wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, aryl, arylene,
aralkyl, aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is ally
substituted with one or more, in one embodiment, one, two, three, or four, substituents Q,
where each Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) C1_6 alkyl,
C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, and
heterocyclyl, each of which is filrther optionally substituted with one or more, in one
embodiment, one, two, three, or four, substituents Qa; and (c) —C(O)Ra, Ra,
—C(O)NRbR°, —C(NRa)NRbR°, —0Ra, Ra, —OC(O)ORa, NRbR°,
—OC(=NRa)NRbR°, —OP(O)(ORa)2, —OS(O)Ra, —OS(O)2Ra, —OS(O)NRbR°, —OS(O)2NRbR°,
—NRbR°, —NRaC(O)Rd, —NRaC(O)ORd, —NRaC(O)NRbR°, =NRd)NRbR°,
—NRaS(O)Rd, O)2Rd, —NRaS(O)NRbR°, —NRaS(O)2NRbR°, —SRa, —S(O)Ra, —S(O)2Ra,
—S(O)NRbR°, and —S(O)2NRbR°, wherein each Ra, Rb, RC, and Rd is independently (i)
hydrogen; (ii) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl,
heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one
embodiment, one, two, three, or four, tuents Qa; or (iii) Rb and Rc together with the N
atom to which they are attached form heterocyclyl, optionally substituted with one or more,
in one embodiment, one, two, three, or four, substituents Qa;
wherein each Qa is independently selected from the group consisting of (a)
oxo, cyano, halo, and nitro; (b) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, and heterocyclyl; and (c) —C(O)Rf, —C(O)ORf, —C(O)NRth,
—C(NRf)NRth, —ORf, —OC(O)Rf, —OC(O)ORf, —OC(O)NRth, —OC(=NRf)NRth,
—OP(O)(ORf)2, —OS(O)Rf, —OS(O)2Rf, —OS(O)NRth, —OS(O)2NRth, —NRth,
—NRfC(O)Rk, —NRfC(O)ORk, O)NRth, —NRfC(=NRk)NRth, O)Rk,
—NRfS(O)2Rk, —NRfS(O)NRth, —NRfS(O)2NRth, —SRf, f, —S(O)2Rf, —S(O)NRth,
and —S(O)2NRth; n each Rf, Rg, Rh, and Rk is independently (i) hydrogen; (ii) C1_6
alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, or
heterocyclyl; or (iii) Rg and Rh er with the N atom to which they are attached form
heterocyclyl.
Also provided herein is a compound of Formula I:
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof;
R1 is (a) hydrogen, cyano, halo, or nitro; (b) C1_6 alkyl, C2_6 alkenyl, C2_6
alkynyl, C340 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, or heterocyclyl; or (c) 1a,
—C(O)OR1a, —C(O)NR1bR1°, —C(NR1a)NR1bR1°, —0R1a, —OC(O)R1a, —OC(O)OR1a,
—OC(O)NR1bR1°, —OC(=NR1a)NR1bR1°, —OS(O)R1a, —OS(O)2R1a, NR1bR1°,
—OS(O)2NRle1°, —NR1bR1°, —NR1aC(O)R1d, —NR1aC(O)ORld, (O)NR1bR1°,
—NR1aC(=NR1d)NR1bR1°, —NR1aS(O)R1d, —NR1aS(O)2Rld, —NR1aS(O)NR1bR1°,
—NR1aS(O)2NR1bR1°, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1°, or —S(O)2NR1bR1°;
R2 is C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C340 cycloalkyl, C644 aryl, C745
aralkyl, heteroaryl, or heterocyclyl;
L2 is C340 cycloalkylene, C644 arylene, C7_1 5 aralkylene, heteroarylene, or
heterocyclylene;
T is a bond, 0 s
, , N—, N(R4) , C(R4)—, or C(R“)2 ;
U is a bond, 0 s
, , N—, N(R5) , C(R5)—, or C(R5)2 ;
V is a bond, 0 s
, , N—, N(R6) , C(R6)—, or C(R6)2 ;
W is a bond, 0 s
, , N—, N(R7) , C(R7)—, or C(R7)2 ;
X and Y are each independently C or N;
Z is NR2A or CRZARZB, wherein each R2A and R213 is ndently hydrogen,
halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 lkyl, C644 aryl, C7_1 5 aralkyl, aryl,
or heterocyclyl;
R4, R5, R6, R7, and L1 are:
(i) each R4, R5, and R6 is independently (a) en, cyano, halo, or
nitro; (b) C1_6 alkyl, C2_6 l, C2_6 alkynyl, C340 cycloalkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a,
—C(O)OR1a, —C(O)NR1bR1°, —C(NR1a)NR1bR1°, —0R1a, —OC(O)R1a,
—OC(O)OR1a, —OC(O)NR1bR1°, R1a)NR1bR1°, —OS(O)R1a,
—OS(O)2R1a, —OS(O)NR1bR1°, —OS(O)2NR1bR1°, —NR1bR1°,
—NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1°,
—NR1aC(=NR1d)NR1bR1°, —NR1aS(O)R1d, —NR1aS(O)2Rld,
—NR1aS(O)NR1bR1°, —NR1aS(O)2NR1bR1°, —SR1a, —S(O)R1a, —S(O)2R1a,
—S(O)NR1bR1°, or —S(O)2NR1bR1°;
each R7 is independently bromo, —OR7a, or 7°;
R7&1 is C4_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl,
C7_1 5 aralkyl, heteroaryl, or heterocyclyl;
R7b and R70 is independently hydrogen, C1_6 alkyl, C2_6 alkenyl, C2_6
alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, or
heterocyclyl; or R7b and R70 together with the N atom to which they are
attached form heterocyclyl; and
L1 is a bond; or
(ii) each R4, R5, R6, and R7 is independently (a) hydrogen, cyano, halo, or
nitro; (b) C1_6 alkyl, C2_6 l, C2_6 l, C340 cycloalkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a,
—C(O)OR1a, —C(O)NR1bR1°, —C(NR1a)NR1bR1°, —0R1a, R1a,
—OC(O)OR1a, —OC(O)NR1bR1°, —OC(=NR1a)NR1bR1°, —OS(O)R1a,
—OS(O)2R1a, —OS(O)NR1bR1°, —OS(O)2NR1bR1°, —NR1bR1°,
—NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1°,
—NR1aC(=NR1d)NR1bR1°, —NR1aS(O)R1d, —NR1aS(O)2Rld,
—NR1aS(O)NR1bR1°, —NR1aS(O)2NR1bR1°, —SR1a, —S(O)R1a, —S(O)2R1a,
—S(O)NRle1°, or —S(O)2NR1bR1°; with the proviso that at least one of
R4, R5, R6, and R7 is not en; and
L1 is —O—, —S—, —N(R1A)—, or —C(R1AR1B)—, wherein each R1A and R113
is independently hydrogen, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl,
C3_7 cycloalkyl, C644 aryl, C7_1 5 l, heteroaryl, or heterocyclyl;
each R”, Rlb, R”, and R1d is independently hydrogen, C1_6 alkyl, C2_6 alkenyl,
C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, or heterocyclyl; or R1&1 and
R10 together with the C and N atoms to which they are attached form heterocyclyl; or R1b and
R10 together with the N atom to which they are ed form cyclyl;
with the proviso that no more than one of T, U, V, and W is a bond;
wherein each alkyl, l, l, cycloalkyl, cycloalkylene, aryl, arylene,
WO 43148
aralkyl, aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally
substituted with one or more, in one embodiment, one, two, three, or four, substituents Q,
where each Q is ndently selected from (a) oxo, cyano, halo, and nitro; (b) C1_6 alkyl,
C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, and
heterocyclyl, each of which is filrther optionally substituted with one or more, in one
ment, one, two, three, or four, substituents Qa; and (c) —C(O)Ra, —C(O)ORa,
—C(O)NRbR°, —C(NRa)NRbR°, —0Ra, —OC(O)Ra, —OC(O)ORa, NRbR°,
—OC(=NRa)NRbR°, (ORa)2, —OS(O)Ra, —OS(O)2Ra, —OS(O)NRbR°, —OS(O)2NRbR°,
—NRbR°, —NRaC(O)Rd, —NRaC(O)ORd, —NRaC(O)NRbR°, —NRaC(=NRd)NRbR°,
—NRaS(O)Rd, —NRaS(O)2Rd, —NRaS(O)NRbR°, —NRaS(O)2NRbR°, —SRa, —S(O)Ra, —S(O)2Ra,
—S(O)NRbR°, and —S(O)2NRbR°, wherein each Ra, Rb, RC, and Rd is independently (i)
hydrogen; (ii) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl,
heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one
embodiment, one, two, three, or four, substituents Qa; or (iii) Rb and Rc together with the N
atom to which they are attached form heterocyclyl, optionally substituted with one or more,
in one embodiment, one, two, three, or four, substituents Qa;
wherein each Qa is independently selected from the group consisting of (a)
oxo, cyano, halo, and nitro; (b) C1_6 alkyl, C2_6 alkenyl, C2_6 l, C3_7 cycloalkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, and heterocyclyl; and (c) —C(O)Rf, Rf, —C(O)NRth,
—C(NRf)NRth, —ORf, —OC(O)Rf, —OC(O)ORf, NRth, —OC(=NRf)NRth,
—OP(O)(ORf)2, —OS(O)Rf, —OS(O)2Rf, —OS(O)NRth, —OS(O)2NRth, —NRth,
O)Rk, —NRfC(O)ORk, —NRfC(O)NRth, —NRfC(=NRk)NRth, —NRfS(O)Rk,
—NRfS(O)2Rk, —NRfS(O)NRth, —NRfS(O)2NRth, —SRf, f, —S(O)2Rf, —S(O)NRth,
and —S(O)2NRth; wherein each Rf, Rg, Rh, and Rk is independently (i) hydrogen; (ii) C1_6
alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, or
heterocyclyl; or (iii) Rg and Rh together with the N atom to which they are ed form
heterocyclyl.
onally, provided herein is a compound of Formula XXI:
0 N R2
R5a/ \>—z>\—
R6 1‘!
Cl LLLZ
(XXI)
or a single enantionier, a racemic mixture, a mixture of reoniers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or g thereof;
0 NE
1- C(O)CR1:32 If
R CR CRlg O CR1:32 If
is _ _N CR CRlg
, , ,
Illla O ng O
N O Q
/ W18f
_§ :Rg1
0 CR e=CR CR1 1f 1 g, R61 ,—S(02)CR e=CR CR1 1f 1 g,
O“ARg1 1 a
| O Q
—'Si R1f /N\g :ng
Rle R”
0 1 1 1f 1 1 1 1f 1 ,—NR aS(O)CR e=CR CR g, Re1 ,—NR aS(Oz)CR e=CR CR g, or
Rla O
I o W
/N\§/l <R1f
(1)1 R
R2 is C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C340 cycloalkyl, C644 aryl, C745
aralkyl, heteroaryl, or heterocyclyl;
L1 is a bond, —O—, —S—, —N(R1A)—, or —C(R1AR1B)—, wherein each R1A and R113
is independently hydrogen, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, or heterocyclyl;
L2 is C340 cycloalkylene, C644 arylene, C7_1 5 aralkylene, arylene, or
heterocyclylene;
Z is NR2A or CRZARZB, wherein each R2A and R213 is independently hydrogen,
halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 l, aryl,
or heterocyclyl;
R4 and R6 are each independently (a) hydrogen, cyano, halo, or nitro; (b) C1_6
alkyl, C2_6 alkenyl, C2_6 l, C340 lkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, or
heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(0)NR1bR1°, —C(NR1a)NR1bR1°, —0R1a,
—OC(O)R1a, —OC(O)OR1a, —0C(0)NR1bR1°, —OC(=NR1a)NR1bR1°, —OS(O)R1a, —OS(O)2R1a,
—OS(0)NR1bR1°, —OS(O)2NR1bR1°, —NR1bR1°, —NR1aC(O)R1d, —NR1aC(O)OR1d,
—NR1aC(O)NR1bR1°, —NR1aC(=NR1d)NR1bR1°, —NR1aS(O)R1d, —NR1aS(O)2R1d,
—NR1aS(O)NR1bR1°, —NR1aS(O)2NR1bR1°, —SR1a, —S(O)R1a, —S(O)2R1a, —S(0)NR1bR1°, or
—S(O)2NR1bR1°;
R5&1 is C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745
aralkyl, heteroaryl, or heterocyclyl;
each R”, Rlb, R”, and R1d is independently hydrogen, C1_6 alkyl, C2_6 alkenyl,
C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, or heterocyclyl; or R1&1 and
R10 er with the C and N atoms to which they are attached form heterocyclyl; or R1b and
R10 together with the N atom to which they are attached form heterocyclyl; and
each R13, R”, and ng is independently hydrogen, halo, C1_6 alkyl, C2_6 alkenyl,
C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, or heterocyclyl;
wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, aryl, arylene,
aralkyl, lene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally
substituted with one or more, in one embodiment, one, two, three, or four, tuents Q,
where each Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) C1_6 alkyl,
C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, and
heterocyclyl, each of which is r optionally substituted with one or more, in one
embodiment, one, two, three, or four, substituents Qa; and (c) —C(O)Ra, —C(O)ORa,
—C(O)NRbR°, —C(NRa)NRbR°, —0Ra, —OC(O)Ra, ORa, —OC(O)NRbR°,
—OC(=NRa)NRbR°, —OP(O)(ORa)2, Ra, —OS(O)2Ra, —OS(O)NRbR°, —OS(O)2NRbR°,
—NRbR°, —NRaC(O)Rd, —NRaC(O)ORd, —NRaC(O)NRbR°, —NRaC(=NRd)NRbR°,
—NRaS(O)Rd, —NRaS(O)2Rd, O)NRbR°, —NRaS(O)2NRbR°, —SRa, —S(O)Ra, —S(O)2Ra,
—S(O)NRbR°, and —S(O)2NRbR°, wherein each Ra, Rb, RC, and Rd is independently (i)
en; (ii) C1_6 alkyl, C2_6 alkenyl, C2_6 l, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl,
heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one
embodiment, one, two, three, or four, substituents Qa; or (iii) Rb and Rc together with the N
atom to which they are attached form heterocyclyl, optionally tuted with one or more,
in one embodiment, one, two, three, or four, substituents Qa;
wherein each Qa is independently selected from the group consisting of (a)
oxo, cyano, halo, and nitro; (b) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, and heterocyclyl; and (c) —C(O)Rf, —C(O)ORf, —C(O)NRth,
)NRth, —ORf, —OC(O)Rf, ORf, NRth, —OC(=NRf)NRth,
—OP(O)(ORf)2, —OS(O)Rf, —OS(O)2Rf, —OS(O)NRth, 2NRth, —NRth,
—NRfC(O)Rk, —NRfC(O)ORk, —NRfC(O)NRth, —NRfC(=NRk)NRth, —NRfS(O)Rk,
—NRfS(O)2Rk, —NRfS(O)NRth, —NRfS(O)2NRth, —SRf, —S(O)Rf, —S(O)2Rf, —S(O)NRth,
and —S(O)2NRth; wherein each Rf, Rg, Rh, and Rk is independently (i) hydrogen; (ii) C1_6
alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, or
heterocyclyl; or (iii) Rg and Rh together with the N atom to which they are attached form
heterocyclyl.
ed herein are pharmaceutical compositions comprising a compound
disclosed herein, e.g., a compound of Formula I or XXI, or a single omer, a racemic
mixture, a mixture of diastereomers, or an isotopic t thereof; or a pharmaceutically
acceptable salt, solvate, or prodrug thereof; and optionally a pharmaceutically acceptable
ent or carrier.
Provided herein is a method for treating, preventing, or ameliorating one or
more symptoms of a proliferative disease in a t, comprising administering to the
subject a compound disclosed , e.g., a compound of Formula I or XXI, or a single
enantiomer, a racemic mixture, a mixture of reomers, or an isotopic variant thereof; or a
pharmaceutically acceptable salt, solvate, or prodrug thereof.
Provided herein is a method for treating, preventing, or ameliorating one or
more symptoms of an ERBB-mediated condition, disorder, or disease in a subject,
comprising administering to the subject a compound disclosed herein, e.g., a nd of
Formula I or XXI, or a single omer, a racemic mixture, a mixture of diastereomers, or
an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug f.
Provided herein is a method for treating, preventing, or ameliorating one or
more symptoms of cancer in a subject, comprising administering to the subject a compound
disclosed herein, e.g., a nd of Formula I or XXI, or a single enantiomer, a racemic
mixture, a mixture of diastereomers, or an isotopic variant thereof; or a pharmaceutically
acceptable salt, solvate, or prodrug thereof In one embodiment, the cancer is drug-resistant.
Provided herein is a method of inhibiting the growth of a cell, comprising
contacting the cell with a compound provided herein, 6.g. , a nd of Formula I or XXI,
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an ic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof
Provided herein is a method of inhibiting the growth of a cell in a t,
comprising administering to the subject a compound disclosed herein, e.g., a compound of
Formula I or XXI, or a single enantiomer, a c mixture, a mixture of diastereomers, or
an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
ed herein is a method for modulating the activity of a tyrosine kinase, in
one embodiment, an ERBB kinase, comprising contacting the ERBB kinase with a compound
disclosed , e.g., a compound of Formula I or XXI, or a single enantiomer, a racemic
mixture, a mixture of diastereomers, or an ic variant thereof; or a pharmaceutically
acceptable salt, solvate, or prodrug thereof.
Provided herein is a method for modulating the activity of a ne kinase, in
one embodiment, an ERBB , in a subject, comprising administering to the subject a
compound disclosed herein, e.g., a compound of Formula I or XXI, or a single enantiomer, a
racemic e, a e of diastereomers, or an isotopic variant thereof; or a
pharmaceutically acceptable salt, solvate, or prodrug thereof.
DETAILED DESCRIPTION
To facilitate understanding of the disclosure set forth , a number of
terms are defined below.
Generally, the nomenclature used herein and the laboratory procedures in
biology, biochemistry, medicinal chemistry, organic chemistry, and pharmacology described
herein are those well known and commonly employed in the art. Unless defined otherwise,
all technical and scientific terms used herein generally have the same g as commonly
understood by one of ry skill in the art to which this disclosure s.
The term “tumor,” “neoplasm,” and “neoplastic disorder or disease” are used
interchangeably herein and are meant to refer to unwanted cell proliferation of one or more
subset of cells in a multicellular organism resulting in harm (z'.e. discomfort or decreased life
expectancy) to the multicellular organisms. In certain embodiments, a tumor can be benign
(non-invasive) or malignant (invasive).
The term “cancer” is meant to refer to a malignant neoplasm, which is
characterized by uncontrolled cell proliferation where cells have lost their normal regulatory
controls that would otherwise govern the rate of cell growth. These unregulated, dividing
cells can spread throughout the body and invade normal tissues in a process ed to as
“metastasis.”
The term ct” refers to an animal, including, but not limited to, a primate
(e.g., human), cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, and mouse. The terms
“subject” and “patient” are used interchangeably herein in reference, for example, to a
WO 43148
mammalian subject, such as a human subject, in one embodiment, a human.
The terms “treat,” “treating,” and “treatment” are meant to include alleviating
or abrogating a condition, disorder, or disease, or one or more of the symptoms associated
with the ion, disorder, or disease; or alleviating or eradicating the cause(s) of the
condition, disorder, or disease itself.
The terms “prevent,” nting,” and “prevention” are meant to e a
method of delaying and/or precluding the onset of a condition, disorder, or disease, and/or its
attendant symptoms; barring a subject from acquiring a condition, disorder, or disease; or
reducing a subject’s risk of acquiring a condition, er, or disease.
The term “contacting” or “contact” is meant to refer to bringing together of a
therapeutic agent and cell or tissue such that a physiological and/or chemical effect takes
place as a result of such contact. Contacting can take place in vitro, ex vivo, or in vivo. In
one embodiment, a therapeutic agent is contacted with a cell in cell culture (in vitro) to
determine the effect of the therapeutic agent on the cell. In another embodiment, the
ting of a therapeutic agent with a cell or tissue includes the administration of a
therapeutic agent to a subject having the cell or tissue to be contacted.
The term “therapeutically effective amount” are meant to include the amount
of a compound that, when administered, is sufficient to prevent pment of, or alleviate
to some extent, one or more of the ms of the condition, disorder, or disease being
treated. The term “therapeutically effective ” also refers to the amount of a compound
that is sufficient to elicit the biological or medical se of a biological molecule (e.g., a
protein, enzyme, RNA, or DNA), cell, tissue, system, animal, or human, which is being
sought by a researcher, veterinarian, l doctor, or clinician.
The term “IC50” or “EC50” refers an amount, concentration, or dosage of a
compound that is required for 50% inhibition of a maximal se in an assay that
measures SUCh a response.
The term “GC50” refers an amount, concentration, or dosage of a compound
that is required to reduce the viability of cells treated with the compound by 50%, in
comparison with cells untreated with the compound.
2015/021455
The term “CC50” refers an amount, concentration, or dosage of a compound
that results in 50% reduction of the viability of a host. In certain embodiments, the CC50 of a
compound is the amount, concentration, or dosage of the compound that is required to reduce
the viability of cells treated with the compound by 50%, in comparison with cells untreated
with the compound.
The term “relapsed” refers to a ion where a subject, who has had a
remission of cancer after therapy has a return of cancer cells.
The term “refractory or resistant” refers to a circumstance where a subject,
even after ive treatment, has residual cancer cells in his body.
The term “drug ance” refers to the condition when a disease does not
respond to the treatment of a drug or drugs. Drug resistance can be either intrinsic, which
means the disease has never been sive to the drug or drugs, or it can be acquired,
which means the disease ceases responding to a drug or drugs that the disease had previously
responded to. In certain embodiments, drug resistance is intrinsic. In certain embodiments,
the drug resistance is acquired.
[003 6] The term “pharmaceutically acceptable carrier, 33 CCpharmaceutically acceptable
excipient,3, “physiologically acceptable r,” or “physiologically acceptable excipient”
refers to a pharmaceutically-acceptable material, ition, or vehicle, such as a liquid or
solid filler, diluent, solvent, or encapsulating material. In one embodiment, each component
is aceutically acceptable” in the sense of being compatible with the other ingredients
of a ceutical formulation, and suitable for use in contact with the tissue or organ of
humans and s without excessive toxicity, irritation, allergic response, genicity,
or other problems or complications, commensurate with a reasonable benefit/risk ratio. See,
Remington: The Science and Practice ofPharmacy, 2lst ed.; Lippincott Williams & Wilkins:
Philadelphia, PA, 2005; Handbook ofPharmaceutical Excipients, 6th ed.; Rowe et al., Eds.;
The Pharmaceutical Press and the American Pharmaceutical Association: 2012; Handbook of
Pharmaceutical ves, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company: 2007;
Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson Ed.; CRC Press LLC:
Boca Raton, FL, 2009.
[003 7] The term “about” or “approximately” means an acceptable error for a
particular value as determined by one of ry skill in the art, which depends in part on
how the value is measured or determined. In certain embodiments, the term “about” or
ximately” means within 1, 2, 3, or 4 standard deviations. In certain embodiments, the
term “about” or “approximately” means within 50%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%,
4%, 3%, 2%, 1%, 0.5%, or 0.05% ofa given value or range.
The terms “active ingredient” and “active substance” refer to a compound,
which is administered, alone or in combination with one or more ceutically acceptable
excipients, to a subject for treating, preventing, or ameliorating one or more symptoms of a
condition, disorder, or disease. As used herein, “active ingredient” and “active substance”
may be an optically active isomer or an isotopic variant of a compound described herein.
The terms “drug,” “therapeutic agent,” and “chemotherapeutic agent” refer to
a compound, or a pharmaceutical composition thereof, which is administered to a subject for
treating, preventing, or rating one or more symptoms of a condition, disorder, or
disease.
The term “naturally occurring” or “native” when used in connection with
biological materials such as nucleic acid molecules, polypeptides, host cells, and the like,
refers to materials which are found in nature and are not lated by man. Similarly,
“non-naturally occurring” or “non-native” refers to a material that is not found in nature or
that has been structurally modified or sized by man.
The term “ERBB” or “ERBB ” refers to a tyrosine kinase of the ERBB
family or a variant thereof, including, but not limited to, ERBBl (EGFR or HERl), ERBB2
(HER2/c-neu), ERBB3 (HER3), and ERBB4 (HER4). ERBB variants include proteins
ntially homologous to a native ERBB , z'.e. one or more
, proteins having
naturally or non-naturally occurring amino acid deletions, insertions or substitutions (e.g.,
ERBB derivatives, homologs, and fragments), as compared to the amino acid sequence of a
native ERBB. The amino acid sequence of an ERBB variant is at least about 80% identical,
at least about 90% identical, or at least about 95% identical to a native ERBB.
The terms “ERBB-mediated condition, disorder or disease” and “a condition,
disorder, or disease mediated by ERBB” refer to a condition, er, or disease
characterized by abnormal or dysregulated, e.g., greater than , ERBB activity.
Abnormal ERBB kinase fimctional activity might arise as the result of ERBB kinase
overexpression in cells, expression of the ERBB kinase in cells which normally do not
express ERBB, or dysregulation due to constitutive activation, caused, for example, by a
mutation in ERBB. An ediated condition, disorder, or disease may be completely or
partially mediated by inappropriate ERBB activity. In particular, an ERBB-mediated
condition, er, or e is one in which modulation of an ERBB activity results in
some effect on the underlying condition, disorder, or disease, e.g., an ERBB inhibitor results
in some improvement in at least some of patients being treated.
The term “alkyl” refers to a linear or ed saturated monovalent
hydrocarbon radical, n the alkyl may optionally be substituted with one or more
substituents Q as described herein. For example, C1_6 alkyl refers to a linear saturated
monovalent hydrocarbon radical of l to 6 carbon atoms or a branched saturated monovalent
hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the alkyl is a linear
saturated lent hydrocarbon radical that has 1 to 20 (C1_20), l to 15 (C145), 1 to 10 (C1-
), or 1 to 6 (C1_6) carbon atoms, or branched saturated monovalent hydrocarbon radical of 3
to 20 (C340), 3 to 15 (C345), 3 to 10 (C340), or 3 to 6 (C3_6) carbon atoms. As used herein,
linear C1_6 and ed C3_6 alkyl groups are also referred as “lower alkyl.” Examples of
alkyl groups include, but are not limited to, methyl, ethyl, propyl (including all isomeric
forms), n-propyl, isopropyl, butyl (including all isomeric forms), n-butyl, isobutyl, sec-butyl,
t—butyl, pentyl (including all isomeric forms), and hexyl (including all isomeric forms).
The term “alkylene” refers to a linear or branched saturated divalent
arbon radical, wherein the alkylene may optionally be substituted with one or more
tuents Q as described herein. For example, C1_6 alkylene refers to a linear saturated
divalent hydrocarbon radical of l to 6 carbon atoms or a ed saturated divalent
hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the alkylene is a linear
saturated divalent hydrocarbon l that has 1 to 20 (C1_20), l to 15 (C145), 1 to 10 (C140),
or 1 to 6 (C1_6) carbon atoms, or ed saturated divalent arbon radical of 3 to 20
(C340), 3 to 15 (C345), 3 to 10 (€3-10), or 3 to 6 (C3_6) carbon atoms. As used herein, linear C1-
6 and branched C3_6 alkylene groups are also referred as “lower alkylene.” Examples of
alkylene groups include, but are not limited to, methylene, ethylene, propylene ding all
isomeric forms), n-propylene, isopropylene, butylene (including all isomeric forms), n-
butylene, isobutylene, t—butylene, ene (including all isomeric forms), and hexylene
(including all isomeric forms).
The term “heteroalkylene” refers to a linear or branched ted divalent
WO 43148
hydrocarbon radical that contains one or more atoms in the hydrocarbon chain, each of
which is independently selected from O, S, and N,. For example, C1_6 heteroalkylene refers
to a linear ted divalent hydrocarbon radical of 1 to 6 carbon atoms or a branched
saturated divalent arbon radical of 3 to 6 carbon atoms. In n embodiments, the
alkylene is a linear saturated divalent arbon radical that has 1 to 20 (C1_20), 1 to
(C145), 1 to 10 , or 1 to 6 (C1_6) carbon atoms, or branched saturated divalent
hydrocarbon radical of 3 to 20 (€3-20), 3 to 15 (C345), 3 to 10 (€3-10), or 3 to 6 (C3_6) carbon
atoms. As used herein, linear C1_6 and ed C3_6 heteroalkylene groups are also referred
as “lower heteroalkylene.” Examples of heteroalkylene groups include, but are not limited to,
—CHzO—, —CH20CH2—, —CH2CHzO—, —CH2NH—, CH2—, —CH2CH2NH—, —CHZS—,
—CHZSCH2—, and —CH2CHZS—. In certain embodiments, heteroalkylene may also be
optionally substituted with one or more substituents Q as described .
The term “alkenyl” refers to a linear or branched monovalent arbon
radical, which contains one or more, in one embodiment, one, two, three, four, or five, in
another embodiment, one or two, carbon-carbon double bond(s). The alkenyl may be
optionally substituted with one or more substituents Q as described herein. The term
“alkenyl” embraces ls having a “cis” or “trans” configuration or a mixture thereof, or
alternatively, a “Z” or “E” configuration or a mixture thereof, as appreciated by those of
ordinary skill in the art. For example, C2_6 alkenyl refers to a linear unsaturated monovalent
hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated monovalent
hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the alkenyl is a linear
monovalent hydrocarbon radical of 2 to 20 (C2_20), 2 to 15 (C245), 2 to 10 (C240), or 2 to 6
(C2_6) carbon atoms, or a branched monovalent hydrocarbon radical of 3 to 20 (C3_20), 3 to 15
(C345), 3 to 10 (C340), or 3 to 6 (C3_6) carbon atoms. es of alkenyl groups include, but
are not limited to, ethenyl, propenyl, propenyl, allyl, butenyl, and 4-methylbutenyl.
The term “alkenylene” refers to a linear or branched divalent hydrocarbon
radical, which contains one or more, in one embodiment, one, two, three, four, or five, in
another embodiment, one or two, carbon-carbon double bond(s). The alkenylene may be
optionally substituted with one or more substituents Q as described herein. The term
“alkenylene” embraces ls having a “cis” or ” configuration or a mixture thereof,
or alternatively, a “Z” or “E” configuration or a mixture thereof, as appreciated by those of
ordinary skill in the art. For example, C2_6 alkenylene refers to a linear unsaturated divalent
hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated divalent hydrocarbon
radical of 3 to 6 carbon atoms. In certain embodiments, the alkenylene is a linear divalent
hydrocarbon radical of 2 to 20 (€2-20), 2 to 15 (€2-15), 2 to 10 (€2-10), or 2 to 6 (C2_6) carbon
atoms, or a ed divalent hydrocarbon radical of 3 to 20 (C3_20), 3 to 15 (C345), 3 to 10
(C340), or 3 to 6 (C3_6) carbon atoms. Examples of alkenylene groups include, but are not
limited to, ethenylene, allylene, propenylene, lene, and 4-methylbutenylene.
The term oalkenylene” refers to a linear or branched divalent
hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, four,
or five, in another embodiment, one or two, carbon-carbon double bond(s), and which
contains one or more atoms in the hydrocarbon chain, each of which is independently
selected from O, S, and N. The heteroalkenylene may be optionally substituted with one or
more substituents Q as bed . The term “heteroalkenylene” embraces radicals
having a “02's” or “trans” configuration or a mixture thereof, or alternatively, a “Z” or “E”
configuration or a mixture thereof, as iated by those of ordinary skill in the art. For
example, C2_6 heteroalkenylene refers to a linear unsaturated divalent hydrocarbon radical of
2 to 6 carbon atoms or a branched unsaturated divalent arbon radical of 3 to 6 carbon
atoms. In certain embodiments, the heteroalkenylene is a linear divalent hydrocarbon radical
of 2 to 20 (C2_20), 2 to 15 (C245), 2 to 10 , or 2 to 6 (CM) carbon atoms, or a branched
divalent hydrocarbon radical of 3 to 20 (C3_20), 3 to 15 (C345), 3 to 10 (C340), or 3 to 6 (C3_6)
carbon atoms. Examples of heteroalkenylene groups include, but are not limited to,
O—, —CH=CHOCH2—, —CH=CHCHzO—, —CH=CHS—, —CH=CHSCH2—,
—CH=CHCHZS—, or —CH=CHCH2NH—.
The term “alkynyl” refers to a linear or branched monovalent hydrocarbon
l, which contains one or more, in one embodiment, one, two, three, four, or five, in
another embodiment, one or two, carbon-carbon triple bond(s). The alkynyl may be
optionally substituted with one or more substituents Q as described herein. For example, C2_6
alkynyl refers to a linear unsaturated monovalent hydrocarbon radical of 2 to 6 carbon atoms
or a branched unsaturated monovalent hydrocarbon radical of 3 to 6 carbon atoms. In certain
embodiments, the alkynyl is a linear lent arbon radical of 2 to 20 ), 2 to
(C245), 2 to 10 (C240), or 2 to 6 (C2_6) carbon atoms, or a branched monovalent
hydrocarbon radical of 3 to 20 (€3-20), 3 to 15 (C345), 3 to 10 (€3-10), or 3 to 6 (C3_6) carbon
atoms. Examples of alkynyl groups include, but are not d to, ethynyl (—CECH),
propynyl (including all isomeric forms, e.g., l-propynyl (—CECCHg) and propargyl
(—CHZCECH», butynyl (including all isomeric forms, e.g., l-butyn-l-yl and 2-butyn-l-yl),
pentynyl (including all isomeric forms, 6.g. l -yl and l-methylbutyn- l -yl), and
, l-pentyn-
hexynyl (including all isomeric forms, e.g., l-hexyn-l-yl).
The term “alkynylene” refers to a linear or branched divalent hydrocarbon
l, which contains one or more, in one embodiment, one, two, three, four, or five, in
another embodiment, one or two, carbon-carbon triple ). The alkynylene may be
optionally substituted with one or more substituents Q as described herein. For example, C2_6
alkynylene refers to a linear unsaturated divalent hydrocarbon radical of 2 to 6 carbon atoms
or a branched rated divalent hydrocarbon radical of 3 to 6 carbon atoms. In certain
embodiments, the alkynylene is a linear divalent hydrocarbon radical of 2 to 20 (C2_20), 2 to
, 2 to 10 (C240), or 2 to 6 (C2_6) carbon atoms, or a branched divalent hydrocarbon
radical of 3 to 20 (C340), 3 to 15 (C345), 3 to 10 (C340), or 3 to 6 (C3_6) carbon atoms.
es of alkynylene groups include, but are not limited to, ethynylene, propynylene
(including all ic forms, e.g., l-propynylene and propargylene), butynylene (including
all ic forms, 6.g. and 2-butyn-l-ylene), pentynylene (including all
, l-butyn-l-ylene
isomeric forms, e.g., l-pentyn-l-ylene and l-methylbutyn-l-ylene), and lene
(including all isomeric forms, e.g., l-hexyn-l-ylene).
[005 l] The term “cycloalkyl” refers to a cyclic monovalent hydrocarbon radical,
which may be optionally substituted with one or more substituents Q as described herein. In
one embodiment, lkyl groups may be saturated or unsaturated but non-aromatic, and/or
bridged, and/or non-bridged, and/or fused bicyclic groups. In certain embodiments, the
cycloalkyl has from 3 to 20 (€3-20), from 3 to 15 (C345), from 3 to 10 (C340), or from 3 to 7
(Cs—7) carbon atoms. Examples of cycloalkyl groups include, but are not limited to,
cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, exyl, cyclohexenyl,
cyclohexadienyl, cycloheptyl, cycloheptenyl, bicyclo [2. l . l ]hexyl, bicyclo[2.2. l]heptyl,
decalinyl, and adamantyl.
The term “cycloalkylene” refers to a cyclic divalent hydrocarbon radical,
which may be optionally substituted with one or more tuents Q as described . In
one embodiment, cycloalkyl groups may be saturated or unsaturated but non-aromatic, and/or
bridged, and/or non-bridged, and/or fused bicyclic groups. In certain embodiments, the
lkylene has from 3 to 20 (C3_20), from 3 to 15 (C345), from 3 to 10 (C340), or from 3 to
WO 43148
7 (C34) carbon atoms. es of cycloalkylene groups include, but are not limited to,
ropylene (e.g., l,l-cyclopropylene and l,2-cyclopropylene), cyclobutylene (e.g., l,l-
cyclobutylene, l,2-cyclobutylene, or l,3-cyclobutylene), cyclopentylene (e.g., l,l-
cyclopentylene, l,2-cyclopentylene, or l,3-cyclopentylene), cyclohexylene (e.g., l,lcyclohexylene
, l,2-cyclohexylene, l,3-cyclohexylene, or clohexylene), cycloheptylene
(e.g., l,l-cycloheptylene, l,2-cycloheptylene, l,3-cycloheptylene, or 1,4-cycloheptylene),
decalinylene, and adamantylene.
The term “aryl” refers to a monovalent monocyclic aromatic hydrocarbon
radical or monovalent polycyclic aromatic hydrocarbon l that contains at least one
aromatic hydrocarbon ring. In certain embodiments, the aryl has from 6 to 20 (C6_20), from 6
to 15 (C645), or from 6 to 10 (C640) ring atoms. Examples of aryl groups e, but are not
d to, phenyl, naphthyl, fluorenyl, azulenyl, anthryl, thryl, pyrenyl, biphenyl, and
terphenyl. Aryl also refers to bicyclic or tricyclic carbon rings, Where one of the rings is
aromatic and the others of which may be saturated, partially unsaturated, or aromatic, for
example, dihydronaphthyl, l, indanyl, or tetrahydronaphthyl (tetralinyl). In certain
embodiments, aryl may be optionally substituted with one or more tuents Q as
described herein.
The term ne” refers to a divalent monocyclic aromatic hydrocarbon
radical or divalent polycyclic aromatic hydrocarbon l that contains at least one aromatic
hydrocarbon ring. In certain embodiments, the arylene has from 6 to 20 (C6_20), from 6 to 15
(C645), or from 6 to 10 (C640) ring atoms. Examples of arylene groups include, but are not
limited to, phenylene, naphthylene, fluorenylene, azulenylene, anthrylene, phenanthrylene,
pyrenylene, biphenylene, and terphenylene. Arylene also refers to bicyclic or tricyclic carbon
rings, Where one of the rings is aromatic and the others of which may be saturated, partially
unsaturated, or aromatic, for example, dihydronaphthylene, indenylene, indanylene, or
tetrahydronaphthylene (tetralinylene). In certain embodiments, arylene may be optionally
substituted with one or more substituents Q as described herein.
The term “aralkyl” or “arylalkyl” refers to a lent alkyl group
substituted With one or more aryl groups. In certain embodiments, the aralkyl has from 7 to
(€7-30), from 7 to 20 (C740), or from 7 to 16 (€7-16) carbon atoms. Examples of aralkyl
groups include, but are not limited to, benzyl, 2-phenylethyl, and 3-phenylpropyl. In certain
embodiments, aralkyl are ally substituted with one or more substituents Q as described
herein.
The term “heteroaryl” refers to a monovalent monocyclic aromatic group or
monovalent polycyclic aromatic group that contains at least one aromatic ring, wherein at
least one aromatic ring contains one or more atoms in the ring, each of which is
independently selected from O, S, and N. Heteroaryl groups are bonded to the rest of a
molecule h the aromatic ring. Each ring of a heteroaryl group can contain one or two
0 atoms, one or two S atoms, and/or one to four N atoms, provided that the total number of
heteroatoms in each ring is four or less and each ring ns at least one carbon atom. In
certain embodiments, the heteroaryl has from 5 to 20, from 5 to 15, or from 5 to 10 ring
atoms. es of monocyclic heteroaryl groups include, but are not limited to, furanyl,
imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl,
pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, triazinyl,
and triazolyl. Examples of bicyclic heteroaryl groups include, but are not limited to,
benzofuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl,
benzothiazolyl, benzothienyl, riazolyl, benzoxazolyl, furopyridyl, imidazopyridinyl,
othiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl,
isoquinolinyl, isothiazolyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl,
pyridyl, pyrrolopyridyl, inyl, quinoxalinyl, quinazolinyl, thiadiazolopyrimidyl,
and thienopyridyl. Examples of tricyclic heteroaryl groups include, but are not limited to,
acridinyl, benzindolyl, olyl, dibenzofuranyl, perimidinyl, phenanthrolinyl,
phenanthridinyl, sazinyl, phenazinyl, hiazinyl, phenoxazinyl, and xanthenyl. In
certain embodiments, heteroaryl may also be optionally substituted with one or more
substituents Q as described herein.
The term “heteroarylene” refers to a divalent monocyclic aromatic group or
divalent clic aromatic group that contains at least one aromatic ring, wherein at least
one aromatic ring contains one or more heteroatoms in the ring, each of which is
independently selected from O, S, and N. A heteroarylene group has at least one linkage to
the rest of a molecule via its aromatic ring(s). Each ring of a heteroarylene group can contain
one or two 0 atoms, one or two S atoms, and/or one to four N atoms, ed that the total
number of atoms in each ring is four or less and each ring contains at least one carbon
atom. In certain embodiments, the heteroarylene has from 5 to 20, from 5 to 15, or from 5 to
ring atoms. Examples of monocyclic heteroarylene groups include, but are not limited to,
furanylene, imidazolylene, isothiazolylene, isoxazolylene, oxadiazolylene, oxadiazolylene,
oxazolylene, pyrazinylene, pyrazolylene, pyridazinylene, pyridylene, pyrimidinylene,
pyrrolylene, thiadiazolylene, thiazolylene, thienylene, tetrazolylene, triazinylene, and
triazolylene. Examples of bicyclic heteroarylene groups include, but are not limited to,
benzofuranylene, benzimidazolylene, benzoisoxazolylene, benzopyranylene,
benzothiadiazolylene, benzothiazolylene, benzothienylene, benzotriazolylene,
benzoxazolylene, furopyridylene, opyridinylene, imidazothiazolylene, indolizinylene,
indolylene, indazolylene, isobenzofuranylene, isobenzothienylene, isoindolylene,
isoquinolinylene, azolylene, naphthyridinylene, oxazolopyridinylene, phthalazinylene,
pteridinylene, purinylene, pyridylene, pyrrolopyridylene, quinolinylene,
quinoxalinylene, quinazolinylene, thiadiazolopyrimidylene, and thienopyridylene. Examples
of tricyclic heteroarylene groups include, but are not d to, acridinylene, dolylene,
carbazolylene, dibenzofuranylene, perimidinylene, phenanthrolinylene, phenanthridinylene,
phenarsazinylene, phenazinylene, phenothiazinylene, phenoxazinylene, and xanthenylene. In
certain embodiments, heteroarylene may also be optionally substituted with one or more
substituents Q as described herein.
The term “heterocyclyl” or “heterocyclic” refers to a monovalent monocyclic
non-aromatic ring system or monovalent polycyclic ring system that contains at least one
non-aromatic ring, wherein one or more of the non-aromatic ring atoms are heteroatoms
independently selected from O, S, and N; and the remaining ring atoms are carbon atoms. In
certain embodiments, the heterocyclyl or heterocyclic group has from 3 to 20, from 3 to 15,
from 3 to 10, from 3 to 8, from 4 to 7, or from 5 to 6 ring atoms. Heterocyclyl groups are
bonded to the rest of a molecule through the non-aromatic ring. In certain embodiments, the
heterocyclyl is a monocyclic, ic, lic, or yclic ring system, which may be
fused or bridged, and in which nitrogen or sulfur atoms may be ally oxidized, nitrogen
atoms may be optionally quatemized, and some rings may be partially or fillly saturated, or
aromatic. The heterocyclyl may be attached to the main structure at any heteroatom or
carbon atom which s in the on of a stable compound. Examples of such
heterocyclic groups include, but are not limited to, azepinyl, benzodioxanyl, benzodioxolyl,
benzofuranonyl, benzopyranonyl, yranyl, benzotetrahydrofiaranyl,
benzotetrahydrothienyl, hiopyranyl, azinyl, B-carbolinyl, chromanyl, chromonyl,
cinnolinyl, coumarinyl, decahydroisoquinolinyl, dihydrobenzisothiazinyl,
dihydrobenzisoxazinyl, dihydrofuryl, dihydroisoindolyl, opyranyl, dihydropyrazolyl,
dihydropyrazinyl, dihydropyridinyl, opyrimidinyl, dihydropyrrolyl, anyl, 1,4-
dithianyl, furanonyl, olidinyl, imidazolinyl, indolinyl, isobenzotetrahydrofuranyl,
zotetrahydrothienyl, isochromanyl, isocoumarinyl, isoindolinyl, isothiazolidinyl,
isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, oxazolidinonyl,
oxazolidinyl, oxiranyl, piperazinyl, piperidinyl, 4-piperidonyl, lidinyl, pyrazolinyl,
pyrrolidinyl, pyrrolinyl, quinuclidinyl, tetrahydrofuryl, tetrahydroisoquinolinyl,
tetrahydropyranyl, tetrahydrothienyl, thiamorpholinyl, thiazolidinyl, tetrahydroquinolinyl,
and l,3,5-trithianyl. In certain ments, heterocyclic may also be ally tuted
with one or more substituents Q as described herein.
The term “heterocyclylene” refers to a divalent monocyclic non-aromatic ring
system or divalent polycyclic ring system that contains at least one non-aromatic ring,
wherein one or more of the non-aromatic ring atoms are heteroatoms independently selected
from O, S, and N; and the remaining ring atoms are carbon atoms. Heterocyclylene groups
are bonded to the rest of a molecule through the non-aromatic ring. In certain embodiments,
the heterocyclylene group has from 3 to 20, from 3 to 15, from 3 to 10, from 3 to 8, from 4 to
7, or from 5 to 6 ring atoms. In certain embodiments, the heterocyclylene is a monocyclic,
bicyclic, tricyclic, or tetracyclic ring system, which may be fused or bridged, and in which
nitrogen or sulfur atoms may be optionally oxidized, nitrogen atoms may be optionally
ized, and some rings may be partially or fully saturated, or ic. The
heterocyclylene may be attached to the main structure at any heteroatom or carbon atom
which results in the creation of a stable compound. Examples of such heterocyclylene groups
include, but are not d to, azepinylene, benzodioxanylene, benzodioxolylene,
benzofuranonylene, yranonylene, benzopyranylene, benzotetrahydrofuranylene,
benzotetrahydrothienylene, benzothiopyranylene, benzoxazinylene, B-carbolinylene,
chromanylene, chromonylene, cinnolinylene, coumarinylene, decahydroisoquinolinylene,
dihydrobenzisothiazinylene, dihydrobenzisoxazinylene, dihydrofurylene,
dihydroisoindolylene, dihydropyranylene, dihydropyrazolylene, dihydropyrazinylene,
dihydropyridinylene, dihydropyrimidinylene, dihydropyrrolylene, dioxolanylene, 1,4-
dithianylene, furanonylene, imidazolidinylene, imidazolinylene, indolinylene,
isobenzotetrahydrofuranylene, isobenzotetrahydrothienylene, isochromanylene,
isocoumarinylene, isoindolinylene, isothiazolidinylene, isoxazolidinylene, morpholinylene,
octahydroindolylene, octahydroisoindolylene, oxazolidinonylene, oxazolidinylene,
oxiranylene, piperazinylene, dinylene, 4-piperidonylene, pyrazolidinylene,
pyrazolinylene, pyrrolidinylene, pyrrolinylene, quinuclidinylene, ydrofurylene,
tetrahydroisoquinolinylene, ydropyranylene, tetrahydrothienylene, thiamorpholinylene,
thiazolidinylene, tetrahydroquinolinylene, and l,3,5-trithianylene. In certain embodiments,
heterocyclic may also be optionally substituted with one or more substituents Q as described
The term “halogen”, “halide” or “halo” refers to fluorine, chlorine, bromine,
and/or iodine.
The term “optionally substituted” is ed to mean that a group or
substituent, such as an alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene,
alkynyl, alkynylene, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, heteroaryl,
heteroarylene, heterocyclyl, or heterocyclylene group, may be substituted with one or more,
in one embodiment, one, two, three, or four, substituents Q, each of which is independently
selected from, e.g., (a) oxo (=0), cyano (—CN), halo, and nitro (—N02); (b) C1_6 alkyl, C2_6
alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, and heterocyclyl,
each of which is further optionally tuted with one or more, in one embodiment, one,
two, three, or four, substituents Qa; and (c) —C(O)Ra, —C(O)ORa, —C(O)NRbR°,
)NRbR°, —0Ra, —OC(O)Ra, —OC(O)ORa, —OC(O)NRbR°, Ra)NRbR°,
—OP(O)(ORa)2, Ra, —OS(O)2Ra, —OS(O)NRbR°, —OS(O)2NRbR°, —NRbR°,
—NRaC(O)Rd, —NRaC(O)ORd, —NRaC(O)NRbR°, —NRaC(=NRd)NRbR°, —NRaS(O)Rd,
—NRaS(O)2Rd, —NRaS(O)NRbR°, —NRaS(O)2NRbR°, —SRa, —S(O)Ra, —S(O)2Ra, —S(O)NRbR°,
and —S(O)2NRbR°, wherein each Ra, Rb, RC, and Rd is independently (i) hydrogen; (ii) C1_6
alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 lkyl, C644 aryl, C745 aralkyl, heteroaryl, or
heterocyclyl, each of which is optionally substituted with one or more, in one embodiment,
one, two, three, or four, substituents Qa; or (iii) Rb and Rc together with the N atom to which
they are attached form heterocyclyl, optionally substituted with one or more, in one
embodiment, one, two, three, or four, substituents Qa. As used herein, all groups that can be
substituted are “optionally tuted,” unless otherwise specified.
In one embodiment, each Qa is independently selected from the group
consisting of (a) oxo, cyano, halo, and nitro; (b) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7
cycloalkyl, C644 aryl, C7_1 5 aralkyl, aryl, and heterocyclyl; and (c) —C(O)Rf, —C(O)ORf,
—C(O)NRth, —C(NRf)NRth, —ORf, Rf, —OC(O)ORf, NRth,
—OC(=NRf)NRth, —OP(O)(ORf)2, —OS(O)Rf, —OS(O)2Rf, —OS(O)NRth, —OS(O)2NRth,
—NRth, —NRfC(O)Rk, —NRfC(O)ORk, —NRfC(O)NRth, —NRfC(=NRk)NRth, —NRfS(O)Rk,
—NRfS(O)2Rk, —NRfS(O)NRth, —NRfS(O)2NRth, —SRf, —S(O)Rf, Rf, —S(O)NRth,
and —S(O)2NRth; wherein each Rf, Rg, Rh, and Rk is independently (i) hydrogen; (ii) C1_6
alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, or
heterocyclyl; or (iii) Rg and Rh together with the N atom to which they are attached form
heterocyclyl.
The terms “optically active” and ”enantiomerically active” refer to a collection
of les, which has an enantiomeric excess of no less than about 50%, no less than about
70%, no less than about 80%, no less than about 90%, no less than about 91%, no less than
about 92%, no less than about 93%, no less than about 94%, no less than about 95%, no less
than about 96%, no less than about 97%, no less than about 98%, no less than about 99%, no
less than about 99.5%, or no less than about 99.8%. In certain embodiments, the compound
comprises about 95% or more of one enantiomer and about 5% or less of the other
enantiomer based on the total weight of the te in question.
In bing an optically active compound, the prefixes R and S are used to
denote the absolute configuration of the molecule about its chiral center(s). The (+) and (-)
are used to denote the optical rotation of the compound, that is, the direction in which a plane
of polarized light is rotated by the optically active compound. The (-) prefix indicates that
the nd is levorotatory, that is, the compound rotates the plane of polarized light to the
left or counterclockwise. The (+) prefix indicates that the compound is dextrorotatory, that
is, the compound rotates the plane of polarized light to the right or clockwise. However, the
sign of optical rotation, (+) and (-), is not d to the absolute configuration of the
molecule, R and S.
The term “isotopic variant” refers to a compound that contains an unnatural
proportion of an isotope at one or more of the atoms that constitute such a compound. In
certain embodiments, an “isotopic variant” of a compound contains unnatural proportions of
one or more isotopes, including, but not limited to, hydrogen (1H), deuterium (2H), tritium
(3H), carbon-ll (11C), -12 (12C), carbon-l3 (13C), carbon-l4 (14C), nitrogen-l3 (EN),
nitrogen- 1 4 (MN), nitrogen-15 (UN), - 1 4 (140), oxygen- 1 5 (150), oxygen- 1 6 (160),
oxygen- 1 7 (170), oxygen-18 (180), fiuorine- l 7 (17F), fiuorine- l 8 (18F), phosphorus-31 (3 1P),
orus-32 (32F), phosphorus-33 (33P), sulfur-32 (328), -33 (33 S), sulfur-34 (34S),
sulfur-35 (35$), sulfur-36 (36S), chlorine-35 (”Cl), chlorine-36 (36C1), chlorine-37 (”0),
2015/021455
bromine-79 (79130, bromine-81 (81130, -123 (1231), -125 (1251), -127 (1271),
iodine-129 (1291), and iodine-l3l (1311). In certain embodiments, an “isotopic variant” of a
compound is in a stable form, that is, non-radioactive. In certain embodiments, an “isotopic
variant” of a compound contains unnatural proportions of one or more isotopes, including,
but not limited to, hydrogen (1H), ium (2H), carbon-12 (12C), carbon-l3 (13C), nitrogen-
14 (MN), nitrogen-15 (UN), oxygen-l6 (160), oxygen-l7 (170), oxygen-18 (180), fluorine-l7
(17F), phosphorus-31 (31F), sulfur-32 (32$), -33 (33S), sulfur—34 (34S), sulfur-36 (36S),
chlorine-35 (35Cl), ne-37 (37Cl), bromine-79 (79Br), bromine-81 , and iodine-127
(1271). In certain embodiments, an pic variant” of a nd is in an unstable form,
that is, radioactive. In certain embodiments, an “isotopic variant” of a compound contains
unnatural proportions of one or more isotopes, including, but not d to, tritium (3H),
carbon-ll (11C), carbon-l4 (14C), nitrogen-l3 (EN), oxygen-l4 (140), oxygen-15 (150),
fluorine-l8 (18F), phosphorus-32 (32F), phosphorus-33 (33P), sulfiJr-35 (358), chlorine-36
(36c1), iodine-123 (1231), iodine-125 (1251), iodine-129 (1291), and iodine-131 (1311). It will be
understood that, in a nd as provided , any hydrogen can be 2H, for example, or
any carbon can be 13C, as example, or any nitrogen can be 15N, as example, and any oxygen
can be 180, Where feasible according to the judgment of one of skill. In certain embodiments,
an “isotopic variant” of a compound contains unnatural proportions of ium.
The term “solvate” refers to a complex or aggregate formed by one or more
molecules of a solute, e.g., a compound provided herein, and one or more molecules of a
solvent, which present in stoichiometric or non-stoichiometric amount. Suitable ts
include, but are not limited to, water, methanol, ethanol, n-propanol, isopropanol, and acetic
acid. In certain embodiments, the solvent is pharmaceutically acceptable. In one
embodiment, the complex or aggregate is in a crystalline form. In another embodiment, the
complex or aggregate is in a noncrystalline form. Where the solvent is water, the solvate is a
hydrate. Examples of hydrates include, but are not limited to, a hemihydrate, drate,
dihydrate, trihydrate, tetrahydrate, and ydrate.
The phrase “a single enantiomer, a racemic mixture, a mixture of
diastereomers, or an isotopic variant thereof; or a ceutically acceptable salt, solvate, or
prodrug thereof” has the same meaning as the phrase “(i) a single enantiomer, a racemic
mixture, a mixture of diastereomers, or an isotopic variant of the compound referenced
therein; (ii) a pharmaceutically acceptable salt, solvate, or prodrug of the compound
referenced therein; or (iii) a pharmaceutically acceptable salt, solvate, or prodrug of a single
enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant of the
compound nced therein.”
As used herein, the abbreviations for any protective groups, amino acids and
other compounds, are, unless indicated otherwise, in accord with their common usage or
recognized abbreviations including abbreviations found in J. Org. Chem. 2007, 72, A
or abbreviations established by the IUPAC-IUB Commission on Biochemical Nomenclature
(Biochem. 1972, I], 942-944).
Compounds
In one ment, provided herein is a compound of a I:
or a single omer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug f;
WR”NER
l 16 1f lg 0 la 16 1f 1
R 1s—C(O)CR =CR CR-
, ,—N C(O)CR =CR CR g,
Rla O
A R1? 0
R1e _g ‘40) le
0 ,—S(O)CR13=CR1fCR1g, R16 ,—S(02)CR13=CR1fCR1g,
O Rg1 Ra1 0
II A I 0 W
—fi le
Rle /N\g/P<R1f
0 ,—NR1aS(O)CRle=CR1fCR1g, R” ,—NR1aS(Oz)CRle=CR1fCR1g, or
I o W
/NԤ RIf
bl R
R2 is C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C340 cycloalkyl, C644 aryl, C745
aralkyl, heteroaryl, or heterocyclyl;
L1 is a bond, —O—, —S—, —N(R1A)—, or —C(R1AR1B)—, wherein each R1A and R113
is independently hydrogen, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, or heterocyclyl;
L2 is C340 cycloalkylene, C644 arylene, C7_1 5 lene, heteroarylene, or
heterocyclylene;
nd, o s
, , N—, N(R4), C(R4)—, or C(R“)2 ;
Uisabond, o, s
, N—, N(R5), C(R5)—, or C(R5)2;
Visabond, o s
, , N—, N(R6) , C(R6)—, or C(R6)2;
Wisabond, o s
, , N—, N(R7) , C(R7)—, or C(R7)2;
X and Y are each independently C or N;
Z is NR2A or CRZARZB, wherein each R2A and R213 is independently en,
halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl,
or heterocyclyl;
each R4, R5, R6, and R7 is independently (a) hydrogen, cyano, halo, or nitro;
(b) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C340 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl,
or heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1°, —C(NR1a)NR1bR1°, —0Rla,
—OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1°, —OC(=NR1a)NR1bR1°, —OS(O)R1a, 2R1a,
—OS(O)NR1bR1°, 2NR1bR1°, —NR1bR1°, —NR1aC(O)R1d, —NR1aC(O)OR1d,
—NR1aC(O)NR1bR1°, —NR1aC(=NR1d)NR1bR1°, —NR1aS(O)R1d, —NR1aS(O)2R1d,
—NR1aS(O)NR1bR1°, —NR1aS(O)2NR1bR1°, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1°, or
—S(O)2NR1bR1°;
each R”, Rlb, R”, and R1d is independently hydrogen, C1_6 alkyl, C2_6 alkenyl,
C2_6 alkynyl, C3_7 lkyl, C644 aryl, C745 aralkyl, heteroaryl, or heterocyclyl; or R1&1 and
R10 er with the C and N atoms to which they are attached form cyclyl; or R1b and
R10 together with the N atom to which they are attached form cyclyl; and
each R13, R”, and ng is independently hydrogen, halo, C1_6 alkyl, C2_6 alkenyl,
C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, aryl, or heterocyclyl;
with the proviso that no more than one of T, U, V, and W is a bond; and
with the o that, when L1 is a bond, at least one of R4, R5, R6, and R7 is
bromo, —OR1a, or —NR1bR1°, wherein R1&1 is C4_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7
cycloalkyl, C644 aryl, C7_1 5 l, heteroaryl, or heterocyclyl;
wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, aryl, arylene,
aralkyl, aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally
substituted with one or more, in one embodiment, one, two, three, or four, substituents Q,
where each Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) C1_6 alkyl,
C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, and
heterocyclyl, each of which is filrther optionally tuted with one or more, in one
embodiment, one, two, three, or four, substituents Qa; and (c) —C(O)Ra, —C(O)ORa,
RbR°, —C(NRa)NRbR°, —0Ra, —OC(O)Ra, —OC(O)ORa, —OC(O)NRbR°,
—OC(=NRa)NRbR°, —OP(O)(ORa)2, Ra, —OS(O)2Ra, —OS(O)NRbR°, —OS(O)2NRbR°,
—NRbR°, —NRaC(O)Rd, —NRaC(O)ORd, —NRaC(O)NRbR°, —NRaC(=NRd)NRbR°,
—NRaS(O)Rd, —NRaS(O)2Rd, —NRaS(O)NRbR°, —NRaS(O)2NRbR°, —SRa, —S(O)Ra, —S(O)2Ra,
—S(O)NRbR°, and —S(O)2NRbR°, wherein each Ra, Rb, RC, and Rd is independently (i)
hydrogen; (ii) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 l,
heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one
embodiment, one, two, three, or four, substituents Qa; or (iii) Rb and Rc together with the N
atom to which they are attached form heterocyclyl, optionally tuted with one or more,
in one embodiment, one, two, three, or four, substituents Qa;
wherein each Qa is independently selected from the group consisting of (a)
oxo, cyano, halo, and nitro; (b) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, and heterocyclyl; and (c) —C(O)Rf, —C(O)ORf, —C(O)NRth,
—C(NRf)NRth, —ORf, —OC(O)Rf, —OC(O)ORf, —OC(O)NRth, —OC(=NRf)NRth,
—OP(O)(ORf)2, —OS(O)Rf, —OS(O)2Rf, —OS(O)NRth, 2NRth, —NRth,
—NRfC(O)Rk, —NRfC(O)ORk, —NRfC(O)NRth, —NRfC(=NRk)NRth, —NRfS(O)Rk,
—NRfS(O)2Rk, —NRfS(O)NRth, —NRfS(O)2NRth, —SRf, —S(O)Rf, —S(O)2Rf, —S(O)NRth,
and —S(O)2NRth; wherein each Rf, Rg, Rh, and Rk is independently (i) hydrogen; (ii) C1_6
alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, or
cyclyl; or (iii) Rg and Rh together with the N atom to which they are attached form
heterocyclyl.
In another embodiment, provided herein is a compound of Formula I:
Uf—RY’N >_R2
H ,'| \>—z
V\ ~ ’ X\N
LLLZ
or a single enantiomer, a racemic mixture, a mixture of reomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or g thereof;
R1 is (a) hydrogen, cyano, halo, or nitro; (b) C1_6 alkyl, C2_6 l, C2_6
alkynyl, C340 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, or cyclyl; or (c) —C(O)R1a
WO 43148
—C(O)OR1a, —C(O)NR1bR1°, —C(NR1a)NR1bR1°, —0R1a, —OC(O)R1a, —OC(O)OR1a,
—OC(O)NR1bR1°, R1a)NR1bR1°, —OS(O)R1a, —OS(O)2R1a, NR1bR1°,
—OS(O)2NRle1°, —NR1bR1°, (O)R1d, —NR1aC(O)ORld, (O)NR1bR1°,
—NR1aC(=NR1d)NR1bR1°, —NR1aS(O)R1d, —NR1aS(O)2Rld, —NR1aS(O)NR1bR1°,
—NR1aS(O)2NR1bR1°, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1°, or —S(O)2NR1bR1°;
R2 is C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C340 cycloalkyl, C644 aryl, C745
aralkyl, heteroaryl, or heterocyclyl;
L2 is C340 cycloalkylene, C644 arylene, C7_1 5 lene, heteroarylene, or
heterocyclylene;
T is a bond, 0 s
, , N—, N(R4) , C(R4)—, or C(R“)2 ;
U is a bond, 0 s
, , N—, N(R5) , C(R5)—, or C(R5)2 ;
V is a bond, 0 s
, , N—, N(R6) , C(R6)—, or C(R6)2 ;
W is a bond, 0 s
, , N—, N(R7) , C(R7)—, or C(R7)2 ;
X and Y are each independently C or N;
Z is NR2A or CRZARZB, wherein each R2A and R213 is independently hydrogen,
halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl,
or heterocyclyl;
R4, R5, R6, R7, and L1 are:
(i) each R4, R5, and R6 is independently (a) hydrogen, cyano, halo, or
nitro; (b) C1_6 alkyl, C2_6 alkenyl, C2_6 l, C340 cycloalkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a, —
C(O)OR1a,
—C(O)NR1bR1°, —C(NR1a)NR1bR1°, —0R1a, —OC(O)R1a, —OC(O)OR1a,
—OC(O)NR1bR1°, R1a)NR1bR1°, —OS(O)R1a, —OS(O)2R1a,
—OS(O)NR1bR1°, —OS(O)2NR1bR1°, 1°, —NR1aC(O)R1d,
—NR1aC(O)OR1d, —NR1aC(O)NR1bR1°, —NR1aC(=NR1d)NR1bR1°,
—NR1aS(O)Rld, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1°,
—NR1aS(O)2NR1bR1°, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1°, or
—S(O)2NR1bR1°;
each R7 is independently bromo, —OR7a, or —NR7bR7°;
R7&1 is C4_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl,
C7_1 5 aralkyl, heteroaryl, or heterocyclyl;
R7b and R70 is independently hydrogen, C1_6 alkyl, C2_6 alkenyl, C2_6
alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, or
WO 43148
heterocyclyl; or R7b and R70 together with the N atom to which they are
attached form heterocyclyl; and
Idisabond;
(ii) each R4, R5, R6, and R7 is independently (a) hydrogen, cyano, halo, or
nitro; (b) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C340 cycloalkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a,
—C(O)OR1a, —C(O)NR1bR1°, —C(NR1a)NR1bR1°, —0R1a, —OC(O)R1a,
—OC(O)OR1a, —OC(O)NR1bR1°, —OC(=NR1a)NR1bR1°, —OS(O)R1a,
—OS(O)2R1a, —OS(O)NR1bR1°, —OS(O)2NR1bR1°, —NR1bR1°,
—NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1°,
(=NR1d)NR1bR1°, —NR1aS(O)R1d, —NR1aS(O)2Rld,
—NR1aS(O)NR1bR1°, —NR1aS(O)2NR1bR1°, —SR1a, 1a, —S(O)2R1a,
—S(O)NRle1°, or —S(O)2NR1bR1°; with the proviso that at least one of
R4, R5, R6, and R7 is not hydrogen; and
L1 is —O—, —S—, )—, or —C(R1AR1B)—, wherein each R1A and R113
is independently hydrogen, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl,
C3_7 cycloalkyl, C644 aryl, C7_1 5 l, aryl, or heterocyclyl;
each R”, Rlb, R”, and R1d is independently hydrogen, C1_6 alkyl, C2_6 alkenyl,
C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, or heterocyclyl; or R1&1 and
R10 er with the C and N atoms to which they are attached form heterocyclyl; or R1b and
R10 together with the N atom to which they are attached form heterocyclyl;
with the o that no more than one of T, U, V, and W is a bond;
wherein each alkyl, alkenyl, alkynyl, cycloalkyl, lkylene, aryl, arylene,
l, aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally
substituted with one or more, in one embodiment, one, two, three, or four, substituents Q,
where each Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) C1_6 alkyl,
C2_6 l, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, and
heterocyclyl, each of which is filrther optionally substituted with one or more, in one
embodiment, one, two, three, or four, substituents Qa; and (c) —C(O)Ra, —C(O)ORa,
—C(O)NRbR°, —C(NRa)NRbR°, —0Ra, —OC(O)Ra, —OC(O)ORa, —OC(O)NRbR°,
—OC(=NRa)NRbR°, —OP(O)(ORa)2, Ra, —OS(O)2Ra, —OS(O)NRbR°, —OS(O)2NRbR°,
—NRbR°, —NRaC(O)Rd, —NRaC(O)ORd, —NRaC(O)NRbR°, —NRaC(=NRd)NRbR°,
—NRaS(O)Rd, —NRaS(O)2Rd, —NRaS(O)NRbR°, —NRaS(O)2NRbR°, —SRa, —S(O)Ra, —S(O)2Ra,
—S(O)NRbR°, and —S(O)2NRbR°, wherein each Ra, Rb, RC, and Rd is independently (i)
hydrogen; (ii) C1_6 alkyl, C2_6 l, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl,
heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one
embodiment, one, two, three, or four, substituents Qa; or (iii) Rb and Rc er with the N
atom to which they are attached form heterocyclyl, optionally substituted with one or more,
in one embodiment, one, two, three, or four, tuents Qa;
wherein each Qa is independently selected from the group consisting of (a)
oxo, cyano, halo, and nitro; (b) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, and heterocyclyl; and (c) —C(O)Rf, —C(O)ORf, —C(O)NRth,
—C(NRf)NRth, —ORf, —OC(O)Rf, ORf, —OC(O)NRth, —OC(=NRf)NRth,
—OP(O)(ORf)2, —OS(O)Rf, —OS(O)2Rf, —OS(O)NRth, —OS(O)2NRth, —NRth,
—NRfC(O)Rk, —NRfC(O)ORk, —NRfC(O)NRth, —NRfC(=NRk)NRth, O)Rk,
—NRfS(O)2Rk, —NRfS(O)NRth, —NRfS(O)2NRth, —SRf, —S(O)Rf, —S(O)2Rf, —S(O)NRth,
and —S(O)2NRth; wherein each Rf, Rg, Rh, and Rk is independently (i) hydrogen; (ii) C1_6
alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 lkyl, C644 aryl, C745 aralkyl, heteroaryl, or
heterocyclyl; or (iii) Rg and Rh together with the N atom to which they are attached form
heterocyclyl.
In yet another embodiment, provided herein is a compound of Formula II:
(11)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic t
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2, L1,
L2, T, U, V, W, X Y, and Z are each as defined herein.
In yet r embodiment, provided herein is a compound of Formula 111:
WO 43148
or a single omer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2, R4,
R5, R6, R7, L1, L2, and Z are each as defined .
In yet another embodiment, provided herein is a com ound of Formula IV:p
R5 N R2
\>—z
R6 N
R7 LLLz
(IV)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a ceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2, R4,
R5, R6, R7, L1, L2, and Z are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula V:
o wN R2
R6 N
R7 LLLz
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2, R4,
R5, R6, R7, L1, L2, and Z are each as defined herein, and the symbol represents that the
6-membered ring contains one N atom in the ring.
In yet r embodiment, ed herein is a com ound of Formula VI:p
o wN R2
R6 N
R7 LLLZ
(V1)
or a single enantiomer, a racemic e, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2, R4,
R5, R6, R7, L1, L2, and Z are each as defined ; and the symbol represents that the
6-membered ring contains one N atom in the ring.
In yet r embodiment, provided herein is a compound of Formula V11:
(V11)
or a single omer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a ceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2, R4,
R5, R7, L1, L2, and Z are each as defined herein.
In yet another ment, provided herein is a compound of Formula VIII:
R5 1% >—R2
O LLLZ
(VIII)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or g thereof; wherein:
R7a lS (l) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, €3-10 cycloalkyl, C6—14 aryl, €7-15
aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more
substituents Q; or (ii) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1°, —C(NR1a)NR1bR1°, 1°,
—NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1°, —NR1aC(=NR1d)NR1bR1°,
—NR1aS(O)Rld, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1°, —NR1aS(O)2NR1bR1°, —S(O)R1a,
—S(O)2R1a, —S(O)NR1bR1°, or —S(O)2NR1bR1°; and
R1, R2, R4, R5, R6, R”, Rlb, R”, R“, L1, L2, Q, and z are each as defined
herein.
2015/021455
In yet r embodiment, provided herein is a compound of Formula IX:
R6 N
/0 2m
R7a ‘N
(RL)n \
(1X)
or a single enantiomer, a racemic e, a mixture of diastereomers, or an isotopic variant
thereof; or a ceutically acceptable salt, solvate, or prodrug thereof; wherein:
m is an integer ofO, l, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
n is an integer ofO, l, 2, 3, 4, 5, or 6;
each RL is independently (i) hydrogen; or (ii) C1_6 alkyl, C2_6 alkenyl, C2_6
alkynyl, C340 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, or heterocyclyl, each of which is
optionally substituted with one or more substituents Q; or (iii) —C(O)R1a, —C(O)OR1a,
—C(O)NR1bR1°, —C(NR1a)NR1bR1°,—OR1a, —OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1°,
—OC(=NR1a)NR1bR1°, —OS(O)R1a, —OS(O)2R1a, —OS(O)NR1bR1°, —OS(O)2NR1bR1°,
—NR1bR1°,—NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1°, —NR1aC(=NR1d)NR1bR1°,
(O)Rld, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1°, —NR1aS(O)2NR1bR1°, —SR1a, —S(O)R1a,
—S(O)2R1a, —S(O)NR1bR1°, or —S(O)2NR1bR1°; or
two RL together, when there are two or more RL attached to the same ring, are
linked together to form (i) a bond, —O—, —NRN—, or —S—; or (ii) C1_6 alkylene, C1_6
heteroalkylene, C2_6 alkenylene, or C2_6 heteroalkenylene, each of which is optionally
substituted with one or more substituents Q;
RN is (a) hydrogen; (b) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl,
C644 aryl, C745 aralkyl, heteroaryl, or cyclyl, each of which is optionally substituted
with one or more substituents Q; (c) —C(O)OR1a, —C(O)NR1bR1°, —C(NR1a)NR1bR1°, —OR1a,
—OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1°, —OC(=NR1a)NR1bR1°, —OS(O)R1a, 2R1a,
NR1bR1°, —OS(O)2NR1bR1°, —NR1bR1°, —NR1aC(O)R1d, —NR1aC(O)OR1d,
—NR1aC(O)NR1bR1°, —NR1aC(=NR1d)NR1bR1°, —NR1aS(O)R1d, —NR1aS(O)2R1d,
—NR1aS(O)NRle1°, —NR1aS(O)2NR1bR1°, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1°, or
—S(O)2NR1bR1°; and
R1, R2, R4, R5, R6, Rla, Rlb, R”, R“, R”, and Q are each as defined herein.
2015/021455
In yet another embodiment, provided herein is a compound of Formula X:
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2, R4,
R5 and R781 are each as defined herein.
, R6,
In yet another embodiment, ed herein is a compound of Formula XI:
(X1)
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug
thereof; n R1 and R7&1 are each as defined herein.
In yet another ment, provided herein is a compound of Formula XIa:
$»—NHN RZn
o \ /N
(XIa)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a ceutically acceptable salt, solvate, or prodrug thereof; wherein R2n is C1_6
alkyl optionally substituted with one or more substituents Q or —OR1a, and R1, R”, R”, and Q
are each as defined herein; in one embodiment, R2n is methyl, monofluoromethyl,
difluoromethyl, trifluoromethyl, —OH, or —OCH3.
In certain embodiments, in Formula VIII, IX, X, X1, or XIa, R7&1 is:
h ”i? 29> W
Ed3}o l 2})
O O
1F 1.“ N r
Rla j: Rla ’ Rla
’ ’ Rla O ’
I? UK I? EliN’0 x):
O N O N O N 0 O N’0
Rla 1|{13 fila
’ ’ ’ fila fila
o o o
o o N\ E gm
O O Egp N\
X \ , q q q
’ ’
as; W saw
q, q 01' q
a ;
each R1&1 and R1b is as defined herein; in one embodiment, R1&1 is hydrogen,
methyl, ethyl, difluoromethyl, or romethyl; in another embodiment, R1b is hydrogen,
methyl, methyl, ethyl, difluoromethyl, trifluoromethyl, 2-hydroxyethyl, or ethenyl;
2015/021455
p and q are each independently an r of 0, l, or 3, with the proviso that
the total of p and q is no less than 1;
each r is independently an integer of 0, l, 2, 3, 4, 5, or 6.
In certain embodiments, in a VIII, IX, X, XI, or XIa, R7&1 is:
N N
, J
, F3CJ A k0
9 9
A S
’ or 0” Q0,
In one embodiment, provided herein is a compound of Formula XIb:
(XIb)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a ceutically acceptable salt, solvate, or prodrug thereof; Wherein u and v
are each independently an integer of 0, l, 2, or 3; and R1 and R2n are each as defined herein.
In another embodiment, provided herein is a compound of Formula XIc:
@N @N\>—NH _
AWE}?Oo ( Gil/8’’
(XIc)
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug
thereof; wherein u and v are each as defined herein.
In yet r embodiment, provided herein is a compound of Formula XId:
(XId)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically able salt, solvate, or prodrug thereof; wherein R1, R2“, u,
and V are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula XIe:
g\>—NHN _
\ /N
O O
<(U), N
u 4:
(XIe)
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug
thereof; wherein u and v are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula XIf:
g\>—NHN RZn
\ /N
(X10
or a single enantiomer, a racemic e, a mixture of diastereomers, or an isotopic t
thereof; or a ceutically acceptable salt, solvate, or g thereof; wherein R1, R2“, u,
and v are each as defined herein.
In yet another embodiment, ed herein is a compound of Formula XIg:
@‘HWNN o o\ /N
mO N4;
(Xlg)
or an isotopic t thereof; or a pharmaceutically acceptable salt, solvate, or prodrug
thereof; wherein u and V are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula XIh:
Q: \>—NHN RZn
\ /N
(XIh)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug f; wherein R1, R2“, u,
and v are each as defined herein.
In yet r ment, ed herein is a compound of Formula XIi:
E1”idNN o o\ /N
:U0 N4:
(XIi)
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug
thereof; wherein u and v are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula XII:
R5 N9—)—R2
N L\L2
or a single enantiomer, a racemic mixture, a mixture of reomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein:
R7b is (i) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C340 cycloalkyl, C644 aryl, C745
aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more
substituents Q; or (ii) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1°, —C(NR1a)NR1bR1°, —0R1a,
—OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1°, R1a)NR1bR1°, —OS(O)R1a, 2R1a,
—OS(O)NR1bR1°, —OS(O)2NR1bR1°, —NR1bR1°, (O)R1d, —NR1aC(O)OR1d,
—NR1aC(O)NR1bR1°, —NR1aC(=NR1d)NR1bR1°, —NR1aS(O)R1d, —NR1aS(O)2R1d,
—NR1aS(O)NR1bR1°, —NR1aS(O)2NR1bR1°, 1a, —S(O)2R1a, —S(O)NR1bR1°, or
—S(O)2NR1bR1°;
R70 is (i) hydrogen; or (ii) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C340
cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, or cyclyl, each of which is ally
substituted with one or more substituents Q; or (iii) —C(O)R1a, R1a, —C(O)NR1bR1°,
—C(NR1a)NR1bR1°, —0R1a, R1a, —OC(O)OR1a, —OC(O)NR1bR1°, —OC(=NR1a)NR1bR1°,
—OS(O)R1a, —OS(O)2R1a, NR1bR1°, —OS(O)2NR1bR1°, —NR1bR1°, —NR1aC(O)R1d,
—NR1aC(O)OR1d, —NR1aC(O)NR1bR1°, —NR1aC(=NR1d)NR1bR1°, —NR1aS(O)R1d,
—NR1aS(O)2R1d, —NR1aS(O)NR1bR1°, —NR1aS(O)2NR1bR1°, —S(O)R1a, —S(O)2R1a,
—S(O)NR1bR1°, or —S(O)2NR1bR1°; or
R7b and R70 together with the N atom to which they are attached form
heterocyclyl, optionally substituted with one or more substituents Q; and
R1, R2, R4, R5, R6, R”, Rlb, R”, R“, L1, L2, Q, and z are each as defined
herein.
In yet another embodiment, provided herein is a compound of Formula XIII:
R6 N
R7b/ \ N’Rl
(x111)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2, R4,
R5, R6, R7b, and R70 are each as d herein.
In yet another ment, provided herein is a compound of Formula XIV:
(XIV)
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug
thereof; wherein R1, R71), and R70 are each as defined herein.
In yet r ment, provided herein is a compound of Formula XIVa:
(XIVa)
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug
thereof; wherein R1, R71), and R70 are each as defined herein.
In certain embodiments, in Formula XII, XIII, XIV, or XIVa, R7b is:
h ‘21 2; m
Ed3}o A db
O O
1'“ 1'“ N r
Rla Rla 9 Rla
’ ’ Rla3;O ’
If“ 13’2”“ if“ #17 lb
0 1y 0 N o N o N") o N’0
Rla fila fila
’ ’ ’ fila fila
’ ’
ii; 4442,.
04 :N’0 :9: if:
o N'N‘Rlb o N’N‘R1b o N’N‘R1b ?~\O
fila fila fila o
Rla \J
’ ’
9 R13, Rla O)
O 0 O
E Fixi—</ g 11% g liq—s?) HE p
E COOH
Rla Rla R13 HN\ ,NH
q q q q
, , , O”S\\O
wherein:
each R1&1 and R1b is as defined herein; in one embodiment, R1&1 is hydrogen,
methyl, ethyl, difluoromethyl, or trifluoromethyl; in another embodiment, R1b is hydrogen,
, , ethyl, difluoromethyl, trifluoromethyl, 2-hydroxyethyl, or ethenyl;
each p and q is independently an integer of 0, l, 2, or 3, with the proviso that
the total of p and q is no less than 1; and
each r is independently an integer of 0, l, 2, 3, 4, 5, or 6.
In certain embodiments, in Formula XII, XIII, XIV, or XIVa, R70 is hydrogen,
methyl, ethyl, difluoromethyl, or trifluoromethyl.
In certain embodiment, in a XII, XIII, XIV, or XIVa, the moiety
—NR7aR7b is:
W “T"
| | HNO
% N
X A a O,
9 o, |
“T” W WIW MIN
N 111
EN1 N1
N X
ll” Rla’ Rla’gO, /O
or O\;
wherein each R1&1 is as defined herein; in one embodiment, R1&1 is hydrogen, methyl, ethyl,
omethyl, or trifluoromethyl.
In yet another embodiment, provided herein is a compound of Formula XV:
(XV)
or a single enantiomer, a racemic mixture, a mixture of reomers, or an isotopic variant
f; or a ceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2, R4,
R5, R6, L1, and L2, and Z are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula XVI:
(XVI)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2, R4,
R5, and R6 are each as d herein.
In yet another embodiment, provided herein is a compound of Formula XVII:
0 _N
R5 N\>—N\I>i—<\:<\N
R6 N
N’RI
(XVII)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R4, R5,
and R6 are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula XVIIa:
0 _N
R5 Ny—Nii—Q‘N
R6 N R3n
N’RI
(XVIIa)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an ic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; n
R3n is C1_6 alkyl ally substituted with one or more substituents Q or —OR1a, and R1, R4,
R5, R6, R”, and Q are each as d herein; in one embodiment, R3n is methyl,
monofluoromethyl, omethyl, trifluoromethyl, —OH, or —OCH3.
] In yet another embodiment, provided herein is a compound of Formula XVIII:
R5 N >—R2
R63 \>—Z
\O N
R7 LLLz
(XVIII)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein:
R6a18 (1) C1_6 alkyl, C2_6 l, C2_6 alkynyl, €3-10 cycloalkyl, C6—14 aryl, €7-15
aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more
substituents Q; or (ii) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1°, —C(NR1a)NR1bR1°, —NR1bR1°,
—NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1°, —NR1aC(=NR1d)NR1bR1°,
—NR1aS(O)Rld, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1°, —NR1aS(O)2NR1bR1°, —S(O)R1a,
—S(O)2R1a, —S(O)NR1bR1°, or —S(O)2NR1bR1°; and
R1, R2, R4, R5, R7, R”, Rlb, R”, R“, L1, L2, Q, and z are each as defined
herein.
In yet another embodiment, provided herein is a compound of Formula XIX:
R5 N >~R2
6a \>—NH
R\O N
N’RI
(XIX)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2, R4,
R5, R681, and R7 are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula XX:
R63 \>—NH _
\O N
\ N
O /
(XX)
or an isotopic variant thereof; or a pharmaceutically able salt, solvate, or prodrug
thereof; n R1, R7, and R6&1 are each as defined herein; in one ment, R7 is methyl,
omethyl, trifluoromethyl, or —OR1a, where R181 is as defined herein.
In still another embodiment, provided herein is a compound of Formula XXa:
N RZn
R6a \>—NH —
\O N
\ N
O /
09(3)
or a single enantiomer, a c e, a e of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R2n is C1_6
alkyl optionally substituted with one or more substituents Q or —OR1a, and R1, R7, Rla, R681,
and Q are each as defined herein; in one embodiment, R7 is chloro, methyl,
oromethyl, difluoromethyl, trifluoromethyl, or —OR1a, where R181 is as defined ;
in another embodiment, R2n is methyl, monofluoromethyl, difluoromethyl, trifluoromethyl,
—OH, or —OCH3.
In certain embodiments, in a XVIII, XIX, XX, or XXa, R6&1 is:
h “in 9; m
Rla Rla R13
’ ’ Rla 0 ’
it 13/3 I?“ if]? E
0 N O N o N’0 o N’0
Rla fila Rla
’ fila £113.
9:; x x: xi, w
04 :N’0 o u’N‘RIb NR“) 0 N’N‘R1b O
fiia o\J
Rla Rla fiia ,
O O NJ
O O O 0 RNNK
fl OW 0w
’ \/<Rla \/<R1a 0,
gfigN—SFOp 9 A 1" HE
Rla HN\ /NH §{}COOH o
0 o
q S\
’ 0” \O 7<
’ ’ O)‘N
O O
p 5 p p
- N5 5
0 O \ \
X O 0
q q
wherein R- 1 a, R1b and r are each as defined herein..
, p, q,
In certain embodiments, in Formula XVIII, XIX, XX, or XXa, R6&1 is:
X O2h ”b ““23 “b-
, E O O O
9 9 9
JVVV
:1 5,?S
a O O
9 1 ¢
In one embodiment, provided herein is a nd of Formula XXb:
[TwoN RZn
O N
o \ /N
)Cl N’Rl
(XXb)
or a single enantiomer, a c mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug f; wherein R1, R2“, u,
and V are each as defined herein.
In another embodiment, provided herein is a compound of Formula XXc:
(XXc)
or an isotopic variant thereof; or a pharmaceutically acceptable salt, e, or prodrug
thereof; wherein u and V are each as defined herein.
In yet r embodiment, provided herein is a compound of Formula XXd:
N RZn
0£1W6 N N
o \ /
(XXd)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
f; or a pharmaceutically acceptable salt, e, or prodrug thereof; wherein R1, R2“, u,
and v are each as defined herein.
In still another embodiment, provided herein is a compound of Formula XXe:
Cy[:;I:N>—§§—<:i§N‘g OCH3
0 /
)V N
(_11: /
/Nf0
C€X®
or an isotopic variant thereof; or a pharmaceutically able salt, solvate, or prodrug
thereof; wherein u and v are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula XXf:
WO 43148
N R2n
fir—NH __
O N
\ /N
L N’Rl
( uO
(BCKD
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2“, u,
and V are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula XXg:
N OCH3
fir—NH
C) N ::N__
V N
(110 J;
(XXg)
or an isotopic variant thereof; or a ceutically acceptable salt, solvate, or prodrug
thereof; wherein u and v are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula XXh:
N R2n
sf—NH __
O N
\ /N
) t N’Rl
(XXh)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically able salt, solvate, or prodrug thereof; wherein R1, R2“, u,
and v are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula XXi:
1?“idN OCH3
0 N
\ N
o /
)5“ N
(. /
(XXi)
or an ic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug
thereof; wherein s andt are each as defined herein.
In yet another embodiment, provided herein is a compound of a XXj:
(XXi)
or a single enantiomer, a racemic e, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2“, u,
and v are each as defined herein.
In yet r embodiment, provided herein is a compound of Formula XXk:
1?“idN OCH3
0 N
\ N
o O
(XXk)
or an isotopic variant thereof; or a ceutically acceptable salt, solvate, or prodrug
thereof; wherein u and v are each as defined .
In yet another embodiment, provided herein is a compound of Formula XXI:
R6 N
(XXI)
or a single enantionier, a racemic mixture, a e of diastereoniers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof;
WR”NERe
1- 1:32 If lg 0 laC(O)CR1:32 If
R lg
is _ CR CR _N CR CR
, , ,
E1a O W
/ file (o)
—§ :ng
0 ,—S(O)CR e=CR CR1 1f 1 g, Re1 ,—S(02)CR e=CR CR1 1f 1 g,
0 Rg1 R1a “A 0
I 0 Q
_fi le :ng
R1e /N\§ RH
0 ,—NR1aS(O)CRle=CR1fCR1g, Re1 ,—NR1aS(Oz)CRle=CR1fCR1g, or
R13 0
IO W
/NԤ RIf
RIe (1)1
R2 is C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C340 cycloalkyl, C644 aryl, C745
aralkyl, heteroaryl, or heterocyclyl;
L1 is a bond, —O—, —S—, —N(R1A)—, or —C(R1AR1B)—, wherein each R1A and R113
is independently hydrogen, halo, C1_6 alkyl, C2_6 l, C2_6 alkynyl, C3_7 cycloalkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, or heterocyclyl;
L2 is C340 lkylene, C644 arylene, C7_1 5 aralkylene, heteroarylene, or
heterocyclylene;
Z is NR2A or CRZARZB, wherein each R2A and R213 is independently hydrogen,
halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl,
or heterocyclyl;
R4 and R6 are each independently (a) hydrogen, cyano, halo, or nitro; (b) C1_6
alkyl, C2_6 alkenyl, C2_6 alkynyl, C340 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, or
heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1°, —C(NR1a)NR1bR1°,—OR1a,
—OC(O)R1a, OR1a, —OC(O)NR1bR1°, —OC(=NR1a)NR1bR1°, —OS(O)R1a, —OS(O)2R1a,
—OS(O)NR1bR1°, —OS(O)2NR1bR1°, —NR1bR1°, (O)R1d, —NR1aC(O)OR1d,
2015/021455
—NR1aC(O)NR1bR1°, —NR1aC(=NR1d)NR1bR1°, —NR1aS(O)R1d, (O)2R1d,
—NR1aS(O)NRle1°, —NR1aS(O)2NR1bR1°, —SR1a, —S(O)R1a, R1a, —S(O)NR1bR1°, or
—S(O)2NR1bR1°;
R5&1 is C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745
aralkyl, heteroaryl, or heterocyclyl;
each R”, Rlb, R”, and R1d is independently hydrogen, C1_6 alkyl, C2_6 alkenyl,
C2_6 l, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, or heterocyclyl; or R1&1 and
R10 together with the C and N atoms to which they are attached form heterocyclyl; or R1b and
R10 together with the N atom to which they are attached form heterocyclyl; and
each R13, R”, and ng is independently hydrogen, halo, C1_6 alkyl, C2_6 alkenyl,
C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, or heterocyclyl;
n each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, aryl, arylene,
aralkyl, aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally
substituted with one or more, in one embodiment, one, two, three, or four, substituents Q,
where each Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) C1_6 alkyl,
C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl, heteroaryl, and
heterocyclyl, each of which is filrther optionally substituted with one or more, in one
embodiment, one, two, three, or four, substituents Qa; and (c) —C(O)Ra, —C(O)ORa,
—C(O)NRbR°, —C(NRa)NRbR°, —0Ra, —OC(O)Ra, —OC(O)ORa, —OC(O)NRbR°,
—OC(=NRa)NRbR°, —OP(O)(ORa)2, —OS(O)Ra, —OS(O)2Ra, —OS(O)NRbR°, —OS(O)2NRbR°,
—NRbR°, —NRaC(O)Rd, —NRaC(O)ORd, O)NRbR°, —NRaC(=NRd)NRbR°,
—NRaS(O)Rd, —NRaS(O)2Rd, —NRaS(O)NRbR°, —NRaS(O)2NRbR°, —SRa, —S(O)Ra, —S(O)2Ra,
—S(O)NRbR°, and —S(O)2NRbR°, wherein each Ra, Rb, RC, and Rd is independently (i)
hydrogen; (ii) C1_6 alkyl, C2_6 alkenyl, C2_6 l, C3_7 cycloalkyl, C644 aryl, C7_1 5 aralkyl,
heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one
embodiment, one, two, three, or four, substituents Qa; or (iii) Rb and Rc together with the N
atom to which they are attached form heterocyclyl, optionally tuted with one or more,
in one embodiment, one, two, three, or four, substituents Qa;
n each Qa is ndently selected from the group consisting of (a)
oxo, cyano, halo, and nitro; (b) C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 lkyl, C644
aryl, C7_1 5 aralkyl, heteroaryl, and heterocyclyl; and (c) —C(O)Rf, —C(O)ORf, —C(O)NRth,
—C(NRf)NRth, —ORf, —OC(O)Rf, —OC(O)ORf, —OC(O)NRth, —OC(=NRf)NRth,
—OP(O)(ORf)2, Rf, —OS(O)2Rf, —OS(O)NRth, 2NRth, —NRth,
—NRfC(O)Rk, —NRfC(O)ORk, —NRfC(O)NRth, =NRk)NRth, —NRfS(O)Rk,
—NRfS(O)2Rk, —NRfS(O)NRth, —NRfS(O)2NRth, —SRf, f, —S(O)2Rf, Rth,
and —S(O)2NRth; wherein each Rf, Rg, Rh, and Rk is ndently (i) hydrogen; (ii) C1_6
alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C644 aryl, C745 aralkyl, heteroaryl, or
heterocyclyl; or (iii) Rg and Rh together with the N atom to which they are attached form
heterocyclyl.
In yet another embodiment, provided herein is a compound of Formula XXII:
(XXII)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2, R4,
R6, and R581 are each as defined herein.
In yet another embodiment, ed herein is a compound of a XXIII:
\>—Nii—<\:<0 —N
0 N N
Rsa/
R6 N
N’RI
(XXIII)
or a single enantiomer, a racemic mixture, a mixture of reomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R4, R6,
and R581 are each as defined .
In still another embodiment, provided herein is a compound of Formula
XXIII:
2015/021455
0 N N
RSa/ \
\>_NH /
R6 N
N’RI
(XXIV)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R4, R6,
R2“, and R581 are each as defined herein.
In certain embodiments, in any of Formulae XXI to XXIV, R5&1 is:
O O
P >— P 5 E N/ E ... N/
E N\ E' N\ \ \
q or q
q q a 3
wherein p and q are each as defined herein.
In one embodiment, provided herein is a compound of Formula XXIVa:
l N W\ N
0 /
)L U HH
N v N
I Cl
N’Rl
(XXIVa)
or a single enantiomer, a racemic mixture, a mixture of reomers, or an ic variant
thereof; or a pharmaceutically acceptable salt, solvate, or g thereof; wherein R1, R2“, u,
and v are each as defined herein.
In another embodiment, provided herein is a nd of Formula XXIVb:
O _
AME}?UM0o < Ti H3“/
| 0
(XXIVb)
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug
thereof; wherein u and V are each as defined herein.
In yet antoher embodiment, provided herein is a compound of Formula
XXIVc:
R211
0 _
(UO N \ N
\>_ /
u NH
0 )v N
N’Rl
(XXIVc)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a ceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2“, u,
and v are each as defined .
In yet another embodiment, provided herein is a compound of Formula
XXIVd:
C1 NJE’
or an isotopic variant thereof; or a pharmaceutically able salt, solvate, or prodrug
thereof; wherein u and v are each as defined herein.
] In yet antoher embodiment, provided herein is a compound of Formula
XXIVe:
oO N WvN
)V N
N’Rl
(XXIVe)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein R1, R2“, u,
and V are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula
XXIVf:
o __
(WWW\ /N
V N
C1 N’éLZ
(XXIVf)
or an isotopic variant thereof; or a pharmaceutically able salt, solvate, or prodrug
f; wherein u and v are each as defined herein.
In yet antoher ment, provided herein is a compound of Formula
XXIVg:
O _
( N N
u N>_\
\ /
0§ )V
N’Rl
(XXIVg)
or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, e, or prodrug f; wherein R1, R2“, u,
and v are each as defined herein.
In yet another embodiment, provided herein is a compound of Formula
XXIVh:
O _
(g0 N\ @
02s )V UN>—NH
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug
thereof; wherein u and V are each as defined herein.
The groups, R1, R2, R4, R5, R6, R7, R2“, R3“, R52 R“, R72 R7b, R7
, L1, L2, T,
U, V, W, X, Y, Z, m, n, p, q, r, u and V in formulae described herein, including Formulae I to
XXIV, XIa to XIi, XVIIa, XXa to XXk, and XXIVa to XXIVh, are further defined .
All combinations of the embodiments ed herein for such groups are within the scope of
this disclosure.
In certain embodiments, R1 is hydrogen. In certain embodiments, R1 is cyano.
In certain embodiments, R1 is halo. In certain embodiments, R1 is fiuoro, chloro, bromo, or
iodo. In certain embodiments, R1 is fiuoro or chloro. In certain embodiments, R1 is nitro. In
n embodiments, R1 is C1_6 alkyl, optionally substituted with one or more tuents Q.
In certain embodiments, R1 is C2_6 alkenyl, optionally substituted with one or more
substituents Q. In certain embodiments, R1 is C2_6 l, optionally substituted with one or
more substituents Q. In certain embodiments, R1 is C3_7 cycloalkyl, optionally substituted
with one or more substituents Q. In certain embodiments, R1 is €6-14 aryl, ally
substituted with one or more substituents Q. In certain embodiments, R1 is C7_1 5 aralkyl,
optionally substituted with one or more substituents Q. In certain embodiments, R1 is
heteroaryl, ally tuted with one or more substituents Q. In certain ments,
R1 is heterocyclyl, optionally substituted with one or more substituents Q.
In certain embodiments, R1 is —C(O)R1a, wherein R1&1 is as defined herein. In
certain embodiments, R1 is —C(O)OR1a, wherein R1&1 is as defined herein. In certain
embodiments, R1 is —C(O)NR1bR1°, n R1b and R10 are each as defined herein. In
certain ments, R1 is —C(NR1a)NR1bR1°, wherein R”, Rlb, and R10 are each as defined
herein. In certain embodiments, R is —OR1a, wherein R1&1 is as defined herein. In certain
embodiments, R1 is —OC(O)R1a, wherein R1&1 is as defined herein. In certain embodiments, R1
is —OC(O)OR1a, n R1&1 is as defined herein. In certain embodiments, R1 is
—OC(O)NR1bR1°, wherein R1b and R10 are each as defined herein. In n embodiments, R1
is —OC(=NR1a)NR1bR1°, wherein R”, Rlb, and R10 are each as defined herein. In certain
embodiments, R1 is —OS(O)R1a, wherein R1&1 is as defined herein. In certain ments, R1
is —OS(O)2R1a, wherein R1&1 is as defined herein. In certain ments, R1 is
—OS(O)NR1bR1°, wherein R1b and R10 are each as defined herein. In n embodiments, R1
is —OS(O)2NR1bR1°, wherein R1b and R10 are each as defined herein. In certain embodiments,
R1 is —NR1bR1°, wherein R1b and R10 are each as defined herein. In certain embodiments, R1
is —NR1aC(O)R1d, wherein R1&1 and R1d are each as defined herein. In n embodiments,
R1 is —NR1aC(O)OR1d, wherein R1&1 and R1d are each as defined herein. In certain
embodiments, R1 is —NR1aC(O)NR1bR1°, wherein R”, Rlb, and R10 are each as defined herein.
In certain embodiments, R1 is —NR1aC(=NR1d)NR1bR1°, wherein R”, Rlb, R”, and R1d are
each as defined . In certain embodiments, R1 is —NR1aS(O)R1d, wherein R1&1 and R1d are
each as defined herein. In certain embodiments, R1 is —NR1aS(O)2R1d, wherein R1&1 and R1d
are each as defined herein. In n embodiments, R1 is —NR1aS(O)NR1bR1°, wherein R”,
Rlb, and R10 are each as defined herein. In certain embodiments, R1 is (O)2NR1bR1°,
wherein R”, Rlb, and R10 are each as defined herein. In certain embodiments, R1 is —SR1a,
wherein R1&1 is as defined herein. In certain embodiments, R1 is —S(O)R1a, wherein R1&1 is as
defined herein. In certain embodiments, R1 is —S(O)2R1a, wherein R1&1 is as defined herein. In
certain embodiments, R1 is —S(O)NR1bR1°, wherein R1b and R10 are each as defined herein. In
certain embodiments, R1 is —S(O)2NRle1°, wherein R1b and R10 are each as defined herein.
In certain embodiments, R1 is —C(O)CR13=CR1fCR1g, wherein R”, R”, and ng
WK”R1 g
are each as defined herein. In certain ments, R1 is 0 wherein R13, R”,
and ng are each as defined herein. In certain ments, R1 is O)CRle=CR1fCR1g,
where1n R. 1 a, R 1e, R1f and R g are each as defined here1n.1 . In certa1n ments, R1 1s. . .
Ii 1a O W
0 wherein R”, R13, R”, and ng are each as defined herein. In certain
embodiments, R1 is —S(O)CRle=CR1fCR1g, wherein R13, R”, and ng are each as defined
O 1
_IS| :R g
herein.. In certain embodiments, R. . 1 . where1n R13, R”, and ng are each as. is R16
defined . In certain embodiments, R1 is —NR1aS(O)CRle=CR1fCR1g, wherein R”, R13,
Rla O
I o 5 E
/NԤ .ng
II R 1 e
R”, and ng are each as defined herein. In certain ments, R1 is 0
wherein R”, R13, R”, and ng are each as defined herein. In certain embodiments, R1 is
certain embodiments, R1 is —NR1aS(02)CRle=CR1fCR1g, wherein R”, R13, R”, and ng are
Rla O
I o 5 E .ng
/N\% le
each as defined herein. In certain embodiments, R1 is 0 wherein R”, R13, R”,
and ng are each as defined herein. In certain embodiments, Rla, R13, R”, and ng are all
hydrogen.
In certain embodiments, R1 is selected from:
O O /
39V ammo0 / N /
,MEO
O l/\ O /N
o o o l/ ‘ 2M1“?
O O 0 O 1/\I=N\
gMMN/go
H 3M EMNKN
0 AN,
or EMNAO
In certain embodiments, R1 is selected from:
@iNJK/ ;\NJJ\/\/N\/O AN / N /
H H
, H a
OYo O l/\O O N
0 f\
/\/N\) ;\I}\IIJJ\/\/N\«
H 0 r‘é\1}\IIJ\/\/N\<N
In certain embodiments, R2 is C1_6 alkyl, optionally substituted with one or
more substituents Q. In certain embodiments, R2 is C2_6 alkenyl, optionally tuted with
one or more substituents Q. In certain embodiments, R2 is C2_6 alkynyl, optionally substituted
with one or more substituents Q. In certain embodiments, R2 is C3_7 lkyl, optionally
substituted with one or more substituents Q. In certain embodiments, R2 is €6-14 aryl,
optionally substituted with one or more tuents Q. In certain embodiments, R2 is 6- to
bered monocyclic or bicyclic aryl, optionally substituted with one or more
substituents Q. In certain embodiments, R2 is phenyl, optionally tuted with one or more
substituents Q. In certain embodiments, R2 is phenyl or methyl-phenyl. In n
embodiments, R2 is phenyl, 3-methyl-phenyl, or 4-((2-(methylcarbamoyl)pyridin
yl)oxy)phenyl. In certain embodiments, R2 is C7_1 5 aralkyl, optionally substituted with one or
more substituents Q. In certain embodiments, R2 is heteroaryl, ally substituted with
one or more substituents Q. In certain ments, R2 is 5- to lO-membered aryl,
optionally substituted with one or more substituents Q. In certain embodiments, R2 is 5- to
lO-membered heteroaryl comprising 1 to 4 hetereoatoms selected from N, O, and S, which is
optionally tuted with one or more substituents Q. In certain embodiments, R2 is
monocyclic heteroaryl, optionally substituted with one or more substituents Q. In certain
embodiments, R2 is 5-membered heteroaryl, optionally tuted with one or more
substituents Q. In certain embodiments, R2 is 6-membered aryl, optionally substituted
with one or more substituents Q. In n embodiments, R2 is pyridinyl or pyridazinyl,
optionally substituted with one or more substituents Q. In certain embodiments, R2 is
hydroxy-pyridinyl, methoxy-pyridinyl, methyl-pyridinyl, difluoromethyl-pyridinyl,
trifluoromethyl-pyridinyl, methylaminocarbonyl-pyridinyl, or methyl-pyridazinyl. In certain
embodiments, R2 is 2—hydroxy-pyridinyl, 2-methoxy-pyridinyl, 2-methyl-pyridinyl,
2-monofluoromethyl-pyridinyl, 2-difluoromethyl-pyridinyl, 2-trifluoromethyl-pyridin-
4-yl, 2-methylaminocarbonyl-pyridinyl, or 3-methyl-pyridazinyl. In certain
embodiments, R2 is bicyclic heteroaryl, optionally tuted with one or more substituents
Q. In certain embodiments, R2 is 5,6-fused heteroaryl, optionally substituted with one or
more substituents Q. In certain embodiments, R2 is benzo[c][l,2,5]oxodiazolyl or
benzo[c][l,2,5]thiodiazolyl, each optionally substituted with one or more substituents Q. In
certain embodiments, R2 is benzo[c][l,2,5]oxodiazolyl or benzo[c][l,2,5]thiodiazolyl,
each optionally tuted with one or more substituents Q. In certain embodiments, R2 is
heterocyclyl, optionally substituted with one or more substituents Q. In certain embodiments,
R2 is 4- to lZ-membered monocyclic or bicyclic heterocyclyl comprising 1 to 4 heteroatoms
selected from N, O, and S, which is optionally substituted with one or more substituents Q.
In n embodiments, R4 is hydrogen. In n ments, R4 is cyano.
. . 4
In certain embodiments, R . . . .
is halo. In certain embodiments, R4 is fluoro, chloro, bromo, or
iodo. In certain embodiments, R4 is nitro. In certain embodiments, R4 is C1_6 alkyl,
optionally substituted with one or more substituents Q. In certain embodiments, R4 is C2_6
alkenyl, optionally substituted with one or more substituents Q. In certain embodiments, R4
is C2_6 l, optionally substituted with one or more substituents Q. In n
embodiments, R4 is C3_7 cycloalkyl, optionally substituted with one or more substituents Q.
In certain embodiments, R4 is €6-14 aryl, optionally substituted with one or more substituents
Q. In certain embodiments, R4 is C7_1 5 aralkyl, optionally substituted with one or more
tuents Q. In certain embodiments, R4 is aryl, optionally substituted with one or
more substituents Q. In certain embodiments, R4 is heterocyclyl, optionally substituted with
one or more substituents Q.
In certain embodiments, R4 is —C(O)R1a, where R181 is as defined herein. In
n embodiments, R4 is —C(O)OR1a, where R181 is as defined herein. In certain
ments, R4 is R1bR1°, where R1b and R10 are each as defined herein. In certain
embodiments, R4 is —C(NR1a)NR1bR1°, where R”, Rlb, and R10 are each as defined herein. In
certain embodiments, R4 is —OR1a, where R181 is as defined herein. In certain embodiments,
R4 is —OC(O)R1a, where R181 is as defined herein. In certain embodiments, R4 is —OC(O)OR1a,
where R181 is as defined herein. In certain ments, R4 is —OC(O)NR1bR1°, where R1b
and R10 are each as defined herein. In certain embodiments, R4 is —OC(=NR1a)NR1bR1°,
where R”, Rlb, and R10 are each as defined herein. In certain embodiments, R4 is —OS(O)R1a,
where R181 is as defined herein. In certain embodiments, R4 is —OS(O)2R1a, where R181 is as
defined herein. In certain embodiments, R4 is —OS(O)NR1bR1°, where R1b and R10 are each as
defined herein. In n ments, R4 is —OS(O)2NR1bR1°, where R1b and R10 are each
as defined herein. In certain embodiments, R4 is —NRle1°, where R1b and R10 are each as
defined herein. In n embodiments, R4 is —NR1aC(O)R1d, where R181 and R1d are each as
defined herein. In certain embodiments, R4 is —NR1aC(O)OR1d, where R181 and R1d are each
as defined herein. In n embodiments, R4 is —NR1aC(O)NR1bR1°, where R”, Rlb, and R10
are each as defined herein. In certain embodiments, R4 is —NR1aC(=NR1d)NR1bR1°, where R”,
Rlb, R”, and R1d are each as defined herein. In certain embodiments, R4 is —NR1aS(O)R1d,
where R181 and R1d are each as defined herein. In certain embodiments, R4 is —NR1aS(O)2R1d,
where R181 and R1d are each defined . In certain embodiments, R4 is —NR1aS(O)NR1bR1°,
where R”, Rlb, and R10 are each as defined herein. In certain embodiments, R4 is
—NR1aS(O)2NR1bR1°, where R”, Rlb, and R10 are each as defined herein. In certain
embodiments, R4 is —SR1a, where R181 is as defined . In certain embodiments, R4 is
WO 43148
—S(O)R1a, where R181 is as defined herein. In certain embodiments, R4 is —S(O)2R1a, where
R181 is as defined herein. In certain ments, R4 is —S(O)NR1bR1°, where R1b and R10 are
each as defined herein. In certain embodiments, R4 is —S(O)2NR1bR1°, where R1b and R10 are
each as defined herein. In certain embodiments, two R4 are linked together to form =0.
In certain embodiments, R5 is hydrogen. In certain ments, R5 is cyano.
In certain embodiments, R5 is halo. In certain embodiments, R5 is fiuoro, chloro, bromo, or
iodo. In n embodiments, R5 is nitro. In certain embodiments, R5 is C1_6 alkyl,
optionally substituted with one or more substituents Q. In n embodiments, R5 is C2_6
alkenyl, ally substituted with one or more substituents Q. In certain embodiments, R5
is C2_6 alkynyl, optionally substituted with one or more substituents Q. In certain
embodiments, R5 is C3_7 cycloalkyl, optionally substituted with one or more substituents Q.
In certain embodiments, R5 is C644 aryl, optionally substituted with one or more substituents
Q. In certain embodiments, R5 is C7_1 5 aralkyl, optionally substituted with one or more
substituents Q. In certain embodiments, R5 is aryl, optionally substituted with one or
more substituents Q. In n embodiments, R5 is heterocyclyl, optionally substituted with
one or more substituents Q. In n embodiments, R5 is zinyl, optionally substituted
with one or more substituents Q. In certain embodiments, R5 is 4-acetylpiperazinyl.
In certain embodiments, R5 is —C(O)R1a, where R181 is as defined herein. In
certain embodiments, R5 is —C(O)OR1a, where R181 is as defined herein. In certain
embodiments, R5 is —C(O)NR1bR1°, where R1b and R10 are each as defined herein. In certain
embodiments, R5 is —C(NR1a)NR1bR1°, where R”, Rlb, and R10 are each as defined herein. In
certain embodiments, R5 is —OR1a, where R181 is as defined herein. In certain embodiments,
R5 is —OC1_6 alkyl, ally substituted with one or more substituents Q. In certain
embodiments, R5 is —OCH3, optionally substituted with one or more substituents Q. In
certain embodiments, R5 is trifluoromethoxy. In certain embodiments, R5 is —O-heterocyclyl,
optionally substituted with one or more substituents Q. In certain embodiments, R5 is —O-
piperidyl, optionally substituted with one or more substituents Q. In n embodiments, R5
is piperidyloxy, optionally substituted with one or more substituents Q. In certain
embodiments, R5 is 1-ethyl-piperidyloxy. In certain embodiments, R5 is —OC(O)R1a,
where R181 is as defined . In certain embodiments, R5 is —OC(O)OR1a, where R181 is as
defined herein. In certain ments, R5 is —OC(O)NR1bR1°, where R1b and R10 are each
as defined herein. In certain embodiments, R5 is —OC(=NR1a)NR1bR1°, where R”, Rlb, and
R10 are each as defined herein. In certain embodiments, R5 is —OS(O)R1a, where R181 is as
defined herein. In certain embodiments, R5 is —OS(O)2R1a, where R181 is as defined . In
certain embodiments, R5 is NR1bR1°, where R1b and R10 are each as defined . In
certain embodiments, R5 is —OS(O)2NR1bR1°, where R1b and R10 are each as defined herein.
In certain embodiments, R5 is —NR1bR1°, where R1b and R10 are each as defined herein. In
certain embodiments, R5 is —NR1aC(O)R1d, where R181 and R1d are each as defined herein. In
certain embodiments, R5 is —NHC(O)—C1_6 alkyl, optionally tuted with one or more
substituents Q. In certain embodiments, R5 is )—methyl, optionally substituted with
one or more substituents Q. In certain ments, R5 is acetamido. In certain
embodiments, R5 is —NR1aC(O)OR1d, where R181 and R1d are each as defined herein. In
certain embodiments, R5 is —NR1aC(O)NR1bR1°, where R”, Rlb, and R10 are each as defined
herein. In certain embodiments, R5 is —NR1aC(=NR1d)NR1bR1°, where R”, Rlb, R”, and R1d
are each as defined herein. In certain embodiments, R5 is —NR1aS(O)R1d, where R181 and R1d
are each as defined herein. In certain embodiments, R5 is —NR1aS(O)2R1d, where R181 and R1d
are each defined herein. In certain ments, R5 is —NR1aS(O)NR1bR1°, where R”, Rlb,
and R10 are each as defined herein. In certain ments, R5 is —NR1aS(O)2NR1bR1°, where
R”, Rlb, and R10 are each as defined . In certain embodiments, R5 is —SR1a, where R181
is as defined herein. In certain embodiments, R5 is —S(O)R1a, where R181 is as defined herein.
In certain ments, R5 is —S(O)2R1a, where R181 is as defined herein. In certain
embodiments, R5 is —S(O)NR1bR1°, where R1b and R10 are each as defined herein. In certain
embodiments, R5 is —S(O)2NR1bR1°, where R1b and R10 are each as defined herein. In certain
embodiments, two R5 are linked together to form =0.
In certain embodiments, R6 is hydrogen. In certain embodiments, R6 is cyano.
In n embodiments, R6 is halo. In certain embodiments, R6 is fluoro, chloro, bromo, or
iodo. In certain ments, R6 is nitro. In certain embodiments, R6 is C1_6 alkyl,
optionally substituted with one or more substituents Q. In certain embodiments, R6 is C2_6
alkenyl, optionally substituted with one or more tuents Q. In certain embodiments, R6
is C2_6 alkynyl, optionally substituted with one or more substituents Q. In certain
embodiments, R6 is C3_7 cycloalkyl, optionally substituted with one or more substituents Q.
In certain embodiments, R6 is €6-14 aryl, optionally substituted with one or more substituents
Q. In certain embodiments, R6 is C7_1 5 aralkyl, optionally substituted with one or more
substituents Q. In certain ments, R6 is heteroaryl, optionally substituted with one or
more substituents Q. In certain embodiments, R6 is heterocyclyl, optionally substituted with
one or more substituents Q.
In certain embodiments, R6 is —C(O)R1a, where R181 is as defined herein. In
certain embodiments, R6 is —C(O)OR1a, where R181 is as defined herein. In certain
embodiments, R6 is R1bR1°, where R1b and R10 are each as defined herein. In certain
embodiments, R6 is —C(NR1a)NR1bR1°, where R”, Rlb, and R10 are each as defined herein. In
certain embodiments, R6 is —OR1a, where R181 is as defined herein. In certain embodiments,
R6 is —O-C1_6 alkyl, optionally substituted with one or more substituents Q. In certain
embodiments, R6 is —O-ethyl, optionally substituted with one or more substituents Q. In
certain embodiments, R6 is 2-methoxy-ethoxy. In certain embodiments, R6 is —O-
heterocyclyl, optionally substituted with one or more substituents Q. In n embodiments,
R6 is —O-piperidyl, optionally substituted with one or more substituents Q. In certain
embodiments, R6 is piperidyloxy, optionally substituted with one or more substituents Q.
In certain embodiments, R6 is l-piperidyloxy. In certain embodiments, R6 is
—OC(O)R1a, where R181 is as defined herein. In certain embodiments, R6 is OR1a,
where R181 is as defined herein. In certain embodiments, R6 is —OC(O)NR1bR1°, where R1b
and R10 are each as defined herein. In certain embodiments, R6 is R1a)NR1bR1°,
where R”, Rlb, and R10 are each as defined herein. In n ments, R6 is —OS(O)R1a,
where R181 is as defined herein. In certain ments, R6 is —OS(O)2R1a, where R181 is as
defined herein. In n embodiments, R6 is —OS(O)NR1bR1°, where R1b and R10 are each as
defined herein. In certain embodiments, R6 is —OS(O)2NR1bR1°, where R1b and R10 are each
as defined herein. In certain embodiments, R6 is —NRle1°, where R1b and R10 are each as
defined herein. In n ments, R6 is —NR1aC(O)R1d, where R181 and R1d are each as
defined herein. In certain embodiments, R6 is —NR1aC(O)OR1d, where R181 and R1d are each
as defined herein. In certain embodiments, R6 is (O)NR1bR1°, where R”, Rlb, and R10
are each as defined herein. In certain embodiments, R6 is —NR1aC(=NR1d)NR1bR1°, where R”,
Rlb, R”, and R1d are each as defined herein. In certain embodiments, R6 is (O)R1d,
where R181 and R1d are each as defined herein. In certain embodiments, R6 is —NR1aS(O)2R1d,
where R181 and R1d are each defined herein. In certain embodiments, R6 is —NR1aS(O)NR1bR1°,
where R”, Rlb, and R10 are each as defined herein. In certain embodiments, R6 is
—NR1aS(O)2NR1bR1°, where R”, Rlb, and R10 are each as defined herein. In certain
embodiments, R6 is —SR1a, where R181 is as defined herein. In certain embodiments, R6 is
—S(O)R1a, where R181 is as defined herein. In certain embodiments, R6 is —S(O)2R1a, where
R181 is as defined . In certain embodiments, R6 is —S(O)NR1bR1°, where R1b and R10 are
each as defined herein. In certain ments, R6 is —S(O)2NR1bR1°, where R1b and R10 are
each as defined herein. In certain embodiments, two R6 are linked er to form =0.
] In n embodiments, R7 is en. In certain embodiments, R7 is cyano.
In certain embodiments, R7 is halo. In certain embodiments, R7 is fiuoro, chloro, bromo, or
iodo. In certain embodiments, R7 is chloro. In certain embodiments, R7 is bromo. In certain
ments, R7 is nitro. In certain embodiments, R7 is C1_6 alkyl, optionally substituted
with one or more substituents Q. In certain embodiments, R7 is C2_6 alkenyl, ally
substituted with one or more substituents Q. In certain embodiments, R7 is C2_6 alkynyl,
optionally substituted with one or more substituents Q. In n embodiments, R7 is C3_7
cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments,
R7 is C644 aryl, optionally substituted with one or more substituents Q. In certain
embodiments, R7 is C7_1 5 aralkyl, ally substituted with one or more substituents Q. In
certain embodiments, R7 is heteroaryl, optionally substituted with one or more substituents Q.
In certain embodiments, R7 is heterocyclyl, optionally substituted with one or more
substituents Q.
In certain embodiments, R7 is 1a, where R181 is as defined herein. In
certain embodiments, R7 is —C(O)OR1a, where R181 is as defined herein. In certain
embodiments, R7 is —C(O)NR1bR1°, where R1b and R10 are each as defined herein. In certain
ments, R7 is —C(NR1a)NR1bR1°, where R”, Rlb, and R10 are each as defined herein. In
certain embodiments, R7 is —OR1a, where R181 is as defined herein. In certain embodiments,
R7 is —O-C1_6 alkyl, optionally substituted with one or more substituents Q. In certain
embodiments, R7 is —O-ethyl, optionally substituted with one or more substituents Q. In
certain embodiments, R7 is 2-methoxy-ethoxy. In n embodiments, R7 is —O-
heterocyclyl, optionally substituted with one or more substituents Q. In certain embodiments,
R7 is eridyl, optionally substituted with one or more substituents Q. In certain
embodiments, R7 is piperidyloxy, optionally substituted with one or more substituents Q.
In certain embodiments, R6 is l-ethyl-piperidyloxy, l-acetyl-piperidyloxy, or 1-
acryloyl-piperidyloxy. In certain embodiments, R7 is —OC(O)R1a, where R181 is as defined
. In certain ments, R7 is —OC(O)OR1a, where R181 is as defined herein. In
certain embodiments, R7 is —OC(O)NR1bR1°, where R1b and R10 are each as defined herein.
In certain embodiments, R7 is —OC(=NR1a)NR1bR1°, where R”, Rlb, and R10 are each as
defined herein. In certain embodiments, R7 is —OS(O)R1a, where R181 is as defined herein. In
2015/021455
certain embodiments, R7 is —OS(O)2R1a, where R181 is as defined . In certain
embodiments, R7 is —OS(O)NR1bR1°, where R1b and R10 are each as defined herein. In certain
embodiments, R7 is —OS(O)2NR1bR1°, where R1b and R10 are each as defined herein. In
certain embodiments, R7 is —NR1bR1°, where R1b and R10 are each as defined herein. In
certain embodiments, R7 is —NR1aC(O)R1d, where R181 and R1d are each as defined herein. In
certain embodiments, R7 is —NR1aC(O)OR1d, where R181 and R1d are each as defined herein.
In certain embodiments, R7 is (O)NR1bR1°, where R”, Rlb, and R10 are each as
defined herein. In certain ments, R7 is (=NR1d)NR1bR1°, where R”, Rlb, R”,
and R1d are each as defined herein. In certain embodiments, R7 is —NR1aS(O)R1d, where R181
and R1d are each as defined herein. In n embodiments, R7 is —NR1aS(O)2R1d, where R181
and R1d are each defined herein. In certain embodiments, R7 is (O)NR1bR1°, where
R”, Rlb, and R10 are each as defined herein. In certain embodiments, R7 is
—NR1aS(O)2NR1bR1°, where R”, Rlb, and R10 are each as defined herein. In certain
embodiments, R7 is —SR1a, where R181 is as defined herein. In certain embodiments, R7 is
—S(O)R1a, where R181 is as defined herein. In certain embodiments, R7 is —S(O)2R1a, where
R181 is as defined herein. In certain embodiments, R7 is —S(O)NR1bR1°, where R1b and R10 are
each as defined herein. In certain embodiments, R7 is —S(O)2NR1bR1°, where R1b and R10 are
each as defined herein. In certain embodiments, two R7 are linked er to form =0.
In certain embodiments, R2n is C1_6 alkyl, optionally substituted with one or
more substituents Q. In certain embodiments, R211 is methyl or ethyl, each optionally
tuted with one or more substituents Q. In certain embodiments, R211 is methyl,
monofluoromethyl, difluoromethyl, or trifluoromethyl. In certain embodiments, R2n is
—OR1a, where R181 is as defined herein. In certain embodiments, R2n is —OH. In certain
embodiments, R2n is —O-C1_6 alkyl, optionally substituted with one or more substituents Q. In
n embodiments, R2n is methoxy.
In certain embodiments, R3n is C1_6 alkyl, ally substituted with one or
more substituents Q. In certain embodiments, R311 is methyl or ethyl, each optionally
substituted with one or more substituents Q. In certain embodiments, R311 is methyl,
monofluoromethyl, omethyl, or trifluoromethyl. In certain embodiments, R3n is
—OR1a, where R181 is as defined . In certain embodiments, R3n is —OH. In certain
embodiments, R3n is —O-C1_6 alkyl, optionally substituted with one or more substituents Q. In
certain embodiments, R3n is methoxy.
In certain embodiments, R5&1 is C1_6 alkyl, optionally substituted with one or
more tuents Q. In certain embodiments, R5&1 is methyl or ethyl, each optionally
substituted with one or more substituents Q. In certain embodiments, R581 is romethyl
or 2-methoxyethyl. In certain embodiments, R5&1 is C2_6 alkenyl, optionally substituted with
one or more substituents Q. In certain embodiments, R581 is C2_6 alkynyl, optionally
substituted with one or more tuents Q. In certain embodiments, R581 is C3_7 cycloalkyl,
optionally substituted with one or more substituents Q. In certain embodiments, R5&1 is €6-14
aryl, optionally substituted with one or more substituents Q. In certain embodiments, R5&1 is
€7-15 aralkyl, optionally substituted with one or more substituents Q. In certain embodiments,
R5&1 is heteroaryl, optionally substituted with one or more substituents Q. In certain
embodiments, R581 is cyclyl, optionally substituted with one or more substituents Q. In
certain embodiments, R581 is piperidyl, optionally substituted with one or more substituents Q.
In certain embodiments, R5&1 is piperidyl, optionally tuted with one or more
substituents Q. In certain ments, R5&1 is 1-ethyl-piperidyl.
In certain embodiments, R6&1 is C1_6 alkyl, optionally substituted with one or
more substituents Q. In certain embodiments, R6&1 is methyl or ethyl, each optionally
substituted with one or more substituents Q. In certain embodiments, R681 is romethyl
or 2-methoxyethyl. In certain embodiments, R6&1 is C2_6 alkenyl, optionally substituted with
one or more substituents Q. In certain embodiments, R681 is C2_6 alkynyl, ally
substituted with one or more tuents Q. In n embodiments, R681 is C3_7 cycloalkyl,
optionally substituted with one or more substituents Q. In certain ments, R6&1 is €6-14
aryl, ally substituted with one or more substituents Q. In certain embodiments, R6&1 is
€7-15 aralkyl, optionally substituted with one or more substituents Q. In certain embodiments,
R6&1 is heteroaryl, optionally substituted with one or more substituents Q. In certain
embodiments, R681 is heterocyclyl, optionally substituted with one or more substituents Q. In
certain embodiments, R681 is piperidyl, optionally substituted with one or more substituents Q.
In certain embodiments, R6&1 is piperidyl, optionally substituted with one or more
substituents Q. In certain embodiments, R6&1 is 1-ethyl-piperidyl.
In n embodiments, R6&1 is —C(O)R1a, where R181 is as defined herein. In
certain embodiments, R681 is —C(O)OR1a, where R181 is as defined herein. In certain
embodiments, R6&1 is R1bR1°, where R1b and R10 are each as defined herein. In certain
embodiments, R6&1 is —C(NR1a)NR1bR1°, where R”, Rlb, and R10 are each as defined herein. In
certain ments, R6&1 is —NRle1°, where R1b and R10 are each as defined herein. In
certain ments, R6&1 is —NR1aC(O)R1d, where R181 and R1d are each as defined herein. In
n embodiments, R6&1 is (O)OR1d, where R181 and R1d are each as defined herein.
In certain embodiments, R6&1 is —NR1aC(O)NR1bR1°, where R”, Rlb, and R10 are each as
defined herein. In certain embodiments, R6&1 is (=NR1d)NR1bR1°, where R”, Rlb, R”,
and R1d are each as defined . In certain embodiments, R6&1 is —NR1aS(O)R1d, where R181
and R1d are each as defined herein. In certain embodiments, R6&1 is —NR1aS(O)2R1d, where R181
and R1d are each defined herein. In certain embodiments, R6&1 is —NR1aS(O)NR1bR1°, where
R”, Rlb, and R10 are each as defined herein. In certain embodiments, R6&1 is
—NR1aS(O)2NR1bR1°, where R”, Rlb, and R10 are each as defined herein. In certain
embodiments, R6&1 is —S(O)R1a, where R181 is as defined herein. In certain embodiments, R681 is
R1a, where R181 is as defined herein. In certain embodiments, R681 is —S(O)NR1bR1°,
where R1b and R10 are each as defined herein. In certain embodiments, R6&1 is —S(O)2NR1bR1°,
where R1b and R10 are each as defined herein.
In certain embodiments, R7&1 is C4_6 alkyl, optionally substituted with one or
more tuents Q. In certain embodiments, R7&1 is C2_6 alkenyl, optionally substituted with
one or more substituents Q. In certain embodiments, R781 is C2_6 alkynyl, optionally
substituted with one or more substituents Q. In certain embodiments, R781 is C3_7 cycloalkyl,
optionally substituted with one or more substituents Q. In certain embodiments, R7&1 is €6-14
aryl, optionally substituted with one or more substituents Q. In certain embodiments, R7&1 is
C745 aralkyl, optionally substituted with one or more substituents Q. In certain embodiments,
R7&1 is heteroaryl, optionally substituted with one or more substituents Q. In certain
embodiments, R781 is cyclyl, optionally substituted with one or more substituents Q.
In certain embodiments, R7b is C4_6 alkyl, optionally substituted with one or
more substituents Q. In certain embodiments, R7b is C2_6 alkenyl, optionally tuted with
one or more substituents Q. In certain embodiments, R7b is C2_6 alkynyl, optionally
substituted with one or more substituents Q. In certain embodiments, R7b is C3_7 cycloalkyl,
optionally substituted with one or more substituents Q. In certain embodiments, R7b is €6-14
aryl, optionally substituted with one or more substituents Q. In n embodiments, R7b is
€7-15 aralkyl, optionally substituted with one or more substituents Q. In n embodiments,
R7b is aryl, optionally substituted with one or more substituents Q. In n
embodiments, R7b is heterocyclyl, optionally substituted with one or more substituents Q.
In certain embodiments, R70 is hydrogen. In n embodiments, R70 is C4_6
alkyl, optionally substituted with one or more substituents Q. In certain ments, R70 is
C2_6 alkenyl, optionally substituted with one or more substituents Q. In certain embodiments,
R70 is C2_6 alkynyl, optionally substituted with one or more substituents Q. In certain
embodiments, R70 is C3_7 cycloalkyl, optionally substituted with one or more substituents Q.
In n embodiments, R70 is €6-14 aryl, optionally substituted with one or more substituents
Q. In certain embodiments, R70 is C7_1 5 l, optionally substituted with one or more
substituents Q. In certain embodiments, R70 is heteroaryl, optionally substituted with one or
more substituents Q. In certain embodiments, R70 is cyclyl, optionally substituted with
one or more substituents Q.
In certain embodiments, R7b and R70 together with the N atom to which they
are attached form heterocyclyl, optionally substituted with one or more substituents Q.
In certain embodiments, L1 is a bond. In certain embodiments, L1 is —O—. In
certain ments, L1 is —S—. In n embodiments, L1 is —N(R1A)—, wherein R1A is as
defined herein. In certain ments, L1 is —N(R1A)—, wherein R1A is hydrogen or methyl.
In certain embodiments, L1 is —C(R1AR1B)—, wherein R1A and R1B are each as defined herein.
In certain embodiments, L1 is —CH2—.
In certain embodiments, L2 is €3-10 cycloalkylene, optionally substituted with
one or more substituents Q. In certain embodiments, L2 is €6-14 arylene, optionally
substituted with one or more tuents Q. In n embodiments, L2 is €7-15 aralkylene,
optionally substituted with one or more tuents Q. In certain embodiments, L2 is
heteroarylene, optionally substituted with one or more substituents Q. In certain
embodiments, L2 is heterocyclylene, optionally substituted with one or more substituents Q.
In certain embodiments, L2 is:
"1% ”1% ”‘31,
(ES/({()(E/%()RL RL
r r (Rig)RrL
N N N
\ \ \
* * *
’ ’01-
wherein:
sis an r of0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and
RL and r are each as defined herein.
In certain embodiments, L2 is:
"we "but "ya
‘ ré ‘ $9 ‘ 13
N N N
\ \ \
* *
or *
9 9 9
wherein s is as defined .
In certain embodiments, L2 is:
"I’LL
‘ E 4N, (RL)r
where1n R. L and s are each as defined here1n..
, r,
In certain embodiments, L2 is:
"74,
( [11>
wherein s is as defined .
In certain embodiments, L2 is:
tis an integer of0, 1, 2, 3, 4, 5, or 6; and
RL and r are each as defined herein.
In certain embodiments, L2 is:
HN ‘
wherein t is as defined herein.
In certain embodiments, L2 is:
N—>X<
(R)rL/\MtJ
whereln R. L and t are each as defined here1n..
, r,
] In certain embodiments, L2 is:
N—>x<
wherein t is as defined herein.
In certain embodiments, Ll—L2 is:
,«w w w:
Cw Cw
9 a HN\*
/N' NH|—
\ \* 171 N\*
* a
N N [i\N
08; \* es; \* es; \*
O O O O O O
WO 43148
/N /N
/* /
O N ,>I< \AN/>x<
V\* N/* N N
m It "LN is“
45L %N
E 3 Sr?“ 5% d
| HN HN
a * \>X< \*
9 9
wherein the symbol ents that the 6-membered ring contains one to three N atoms
in the ring, and each sulfur is optionally oxidized as sulfoxide or sulfone.
In certain embodiments, Ll-L2 is:
s‘\_ f
N N ON
i ii E is
N\* ©\* 1?] ©5q\$
9 9 * 9
N\ N\*
.. m\w ’ ,
CO 8 Q 9
W “T” a“
*‘N/fi“ *0
X0 K/0 O N\
9 *
In certain ments, T is a bond. In certain embodiments, T is —O—. In
certain embodiments, T is —S—. In certain embodiments, T is —N=. In certain embodiments,
T is —N(R4)—, wherein R4 is as defined herein. In certain embodiments, T is —C(R4)=,
wherein R4 is as defined herein. In certain embodiments, T is —C(R4)2—, wherein R4 is as
defined herein.
In certain embodiments, U is a bond. In certain embodiments, U is —O—. In
certain embodiments, U is —S—. In certain ments, U is —N=. In certain embodiments,
U is —N(R5)—, wherein R5 is as defined . In n embodiments, U is —C(R5)=,
wherein R5 is as defined herein. In certain embodiments, U is —C(R5)2—, wherein R5 is as
defined herein.
In certain embodiments, V is a bond. In certain embodiments, V is —O—. In
n embodiments, V is —S—. In certain embodiments, V is —N=. In n embodiments,
V is —N(R6)—, wherein R6 is as defined herein. In certain embodiments, V is —C(R6)=,
wherein R6 is as defined herein. In certain embodiments, V is —C(R6)2—, wherein R6 is as
defined herein.
In certain embodiments, W is a bond. In certain embodiments, W is —O—. In
certain embodiments, W is —S—. In certain embodiments, W is —N=. In certain embodiments,
W is —N(R7)—, n R7 is as defined herein. In n embodiments, W is —C(R7)=,
wherein R7 is as defined herein. In certain embodiments, W is 2—, wherein R7 is as
defined herein.
In certain embodiments, X is C. In certain embodiments, X is N.
In certain embodiments, Y is C. In certain ments, Y is N.
] In certain embodiments, Z is NRZA, wherein R2A is as defined herein. In
certain embodiments, Z is NH. In certain embodiments, Z is CRZARZB, wherein R2A and R2B
are each as defined herein. In certain embodiments, Z is CH2.
In certain embodiments, m is 0. In certain ments, m is 1. In certain
embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In
certain embodiments, m is 5. In certain embodiments, m is 6. In certain embodiments, m is 7.
In certain embodiments, m is 8. In certain embodiments, m is 9. In certain embodiments, m
is 10.
In certain embodiments, n is 0. In n embodiments, n is 1. In certain
embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 4. In
certain embodiments, n is 5. In certain ments, n is 6.
In certain embodiments, p is 0. In certain embodiments, p is 1. In certain
embodiments, p is 2. In certain ments, p is 3.
In certain embodiments, q is 0. In certain embodiments, q is 1. In certain
embodiments, q is 2. In certain embodiments, q is 3.
In certain embodiments, r is 0. In certain embodiments, r is 1. In certain
embodiments, r is 2. In certain embodiments, r is 3. In n embodiments, r is 4. In
certain ments, r is 5. In certain ments, r is 6.
] In certain embodiments, u is 0. In certain embodiments, u is 1. In certain
embodiments, u is 2. In certain embodiments, u is 3.
In certain embodiments, V is 0. In certain embodiments, V is 1. In certain
embodiments, V is 2. In certain embodiments, V is 3.
] In one embodiment, provided herein is a nd selected from the group
consisting of:
WO 43148
N \ N
\>—NH0%/
0 0
N4; \ /\/O
0 N4,
A7 A8
0 N @ N
y—NH W5C}0
\/N N ”U O N
0 0
C1 C1
N4: N4;
A9 A10
and 3
and isotopic variants thereof; and pharmaceutically able salts, solvates, and prodrugs
thereof.
In another embodiment, ed herein is a compound selected from the
group consisting of:
Blow B2
<E::}>—NH F3COgQ—NHN 0%
\ /
HNO/OQC“ C1
0% O
0 N
N \ N
\>_NH / \ @
o g \/N N>—NH
/ \/\O N
\O/\/O CNH NH
B7 BS
0 O _N
Cl Br
NH LNH
B9 310
o o _N
N @ N \ N
\>—NH \>—NH /
N N
BI‘ \N\ Br \N\
HbNH NH
, and 3
Bll BIZ
and isotopic variants thereof; and pharmaceutically acceptable salts, es, and prodrugs
thereof.
In yet another embodiment, provided herein is a compound selected from the
group consisting of:
WO 43148
C11 C12
2015/021455
C17 C18
and isotopic variants thereof; and pharmaceutically acceptable salts, solvates, and prodrugs
thereof.
In still another embodiment, provided herein is a compound selected from the
group consisting of:
2015/021455
and 0 ;
and isotopic ts thereof; and pharmaceutically acceptable salts, solvates, and prodrugs
thereof.
The compounds provided herein are intended to encompass all possible
stereoisomers, unless a particular stereochemistry is specified. Where the compound
ed herein contains an alkenyl or alkenylene group, the compound may exist as one or
mixture of geometric cis/trans (or Z/E) isomers. Where structural isomers are
onvertible, the compound may exist as a single tautomer or a mixture of tautomers.
This can take the form of proton tautomerism in the compound that contains, for example, an
imino, keto, or oxime group; or so-called valence tautomerism in the compound that contain
an aromatic moiety. It follows that a single compound may exhibit more than one type of
isomerism.
] For example, the compound of Formula I, when Z is —NH—, may exist in any
of the following tautomeric forms as shown below.
U7"\\Y’N sz ’N R2 Uf—RY’N >/'_R2
H\ "I \>—NH ll\ ,1: N |\ 1| \>—N
V\~' X\N V\~’_X\N V\~’ X\N
LL11} LL11} LL11}
R1 R1 R1
(i) (ii) (iii)
] The compounds provided herein may be enantiomerically pure, such as a
single enantiomer or a single diastereomer, or be stereoisomeric mixtures, such as a mixture
of enantiomers, e.g. a racemic mixture of two enantiomers; or a mixture of two or more
diastereomers. As such, one of skill in the art will recognize that administration of a
compound in its (R) form is equivalent, for compounds that undergo epimerization in vivo, to
administration of the compound in its (S) form. Conventional techniques for the
preparation/isolation of individual enantiomers e sis from a suitable optically
pure sor, asymmetric synthesis from achiral starting materials, or resolution of an
enantiomeric mixture, for example, chiral chromatography, recrystallization, resolution,
diastereomeric salt formation, or derivatization into diastereomeric s followed by
separation.
When the compound ed herein contains an acidic or basic moiety, it
may also be provided as a pharmaceutically acceptable salt. See, Berge et al., J. Pharm. Sci.
1977, 66, 1-19; and Handbook ofPharmaceutical Salts, Properties, and Use; Stahl and
Wermuth, Ed.; Wiley-VCH and VHCA: Zurich, Switzerland, 2002.
Suitable acids for use in the ation of pharmaceutically acceptable salts
include, but are not limited to, acetic acid, 2,2-dichloroacetic acid, acylated amino acids,
adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid,
4-acetamidobenzoic acid, boric acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1S)-
camphorsulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid,
ic acid, exanesulfamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid,
ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid,
gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucuronic acid, amic acid, 0L-
oxoglutaric acid, ic acid, hippuric acid, hydrobromic acid, hydrochloric acid,
hydroiodic acid, (+)-L-lactic acid, (::)-DL-lactic acid, lactobionic acid, lauric acid, maleic
acid, (-)—L-malic acid, malonic acid, (::)-DL-mandelic acid, methanesulfonic acid,
naphthalenesulfonic acid, alene-1,5-disulfonic acid, 1-hydroxynaphthoic acid,
nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid,
perchloric acid, phosphoric acid, L-pyroglutamic acid, saccharic acid, salicylic acid, 4-aminosalicylic
acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric
acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid, and valeric acid.
Suitable bases for use in the preparation of ceutically acceptable salts,
including, but not limited to, inorganic bases, such as magnesium hydroxide, calcium
hydroxide, potassium hydroxide, zinc ide, or sodium hydroxide; and organic bases,
such as y, secondary, tertiary, and quaternary, aliphatic and aromatic amines, including
L-arginine, amine, benzathine, choline, deanol, diethanolamine, diethylamine,
ylamine, dipropylamine, diisopropylamine, 2-(diethylamino)-ethanol, ethanolamine,
ethylamine, ethylenediamine, isopropylamine, N-methyl-glucamine, amine,
1H—imidazole, L-lysine, morpholine, 4-(2-hydroxyethyl)-morpholine, methylamine,
piperidine, piperazine, propylamine, pyrrolidine, 1-(2-hydroxyethyl)-pyrrolidine, pyridine,
quinuclidine, quinoline, isoquinoline, secondary amines, anolamine, trimethylamine,
triethylamine, N—methyl-D-glucamine, o(hydroxymethyl)-1,3-propanediol, and
tromethamine.
The compound provided herein may also be provided as a g, which is a
onal derivative of the compound, for example, of Formula 1, IA, or 1B and is readily
convertible into the parent compound in vivo. Prodrugs are often useful because, in some
situations, they may be easier to administer than the parent compound. They may, for
instance, be bioavailable by oral administration whereas the parent compound is not. The
prodrug may also have enhanced solubility in pharmaceutical itions over the parent
compound. A prodrug may be converted into the parent drug by various mechanisms,
including enzymatic processes and metabolic hydrolysis. See, Harper, Progress in Drug
Research 1962, 4, 221-294; Morozowich et al. in Design ofBiopharmaceutical Properties
through Prodrugs and Analogs; Roche Ed., APHA Acad. Pharm. Sci.: 1977; r et al.,
Des. Biopharm. Prop. Prodrugs Analogs, 1977, 409-421; Bundgaard, Arch. Pharm. Chem.
2015/021455
1979, 86, 1-39; Farquhar et al., J. Pharm. Sci. 1983, 72, 324-325; Wernuth in Drug Design.‘
Fact or Fantasy; Jolles et al. Eds.; Academic Press: London, 1984; pp 47-72; Design of
Prodrugs; Bundgaard et al. Eds.; Elsevier: 1985; Fleisher et al., Methods l. 1985, 112,
360-381; Stella et al., Drugs 1985, 29, 455-473; Bioreversible Carriers in Drug in Drug
Design, Theory and Application; Roche Ed.; APHA Acad. Pharm. Sci.: 1987; Bundgaard,
Controlled Drug Delivery 1987, 17, ; Waller et al., Br. J. Clin. Pharmac. 1989, 28,
7; Balant et al., Eur. J. Drug Metab. Pharmacokinet. 1990, 15, 143-53; Freeman et al.,
J. Chem. Soc., Chem. Commun. 1991, 875-877; Bundgaard, Adv. Drug Delivery Rev. 1992, 8,
1-38; Nathwani and Wood, Drugs 1993, 45, 866-94; Friis and ard, Eur. J. Pharm. Sci.
1996, 4, 49-59; er et al., Adv. Drug Delivery Rev. 1996, 19, 115-130; Sinhababu and
Thakker, Adv. Drug Delivery Rev. 1996, 19, 241-273; Taylor, Adv. Drug Delivery Rev. 1996,
19, 131-148; Gaignault et al., Pract. Med. Chem. 1996, 671-696; Browne, Clin.
Neuropharmacol. 1997, 20, 1-12; Valentino and Borchardt, Drug Discovery Today 1997, 2,
148-155; Pauletti et al., Adv. Drug. Delivery Rev. 1997, 27, 6; Mizen et al., Pharm.
Biotech. 1998, 11, 345-365; Wiebe and Knaus, Adv. Drug Delivery Rev. 1999, 39, 63-80; Tan
et al., Adv. Drug Delivery Rev. 1999, 39, 1; Balimane and Sinko, Adv. Drug Delivery
Rev. 1999, 39, 183-209; Wang et al., Curr. Pharm. Design 1999, 5, 265-287; Han et al.,
AAPS Pharmsci. 2000, 2, l-l l; Asgharnejad in Transport Processes in Pharmaceutical
Systems; Amidon et al., Eds.; Marcell Dekker: 2000; pp 185-218; Sinha et al., Pharm. Res.
2001, 18, 557-564; Anand et al., Expert Opin. Biol. Ther. 2002, 2, 0; Rao, Resonace
2003, 19-27; Sloan et al., Med. Res. Rev. 2003, 23, 763-793; Patterson et al., Curr. Pharm.
Des. 2003, 9, 2131-2154; Hu, [Drugs 2004, 7, 736-742; Robinson et al., Proc. Natl. Acad. Sci.
USA. 2004, 101, 14532; Erion et al., J. Pharmacol. Exp. Ther. 2005, 312, 554-560;
Fang et al., Curr. Drug Discov. Technol. 2006, 3, 211-224; Stanczak et al., Pharmacol. Rep.
2006, 58, 599-613; Sloan et al., Pharm. Res. 2006, 23, 2729-2747; Stella et al., Adv. Drug
Deliv. Rev. 2007, 59, 677-694; Gomes et al., Molecules 2007, 12, 2484-2506; Krafz et al.,
dChem 2008, 3, 20-53; Rautio et al., AAPSJ. 2008, 10, 92-102; Rautio et al., Nat.
Rev. Drug. Discov. 2008, 7, 255-270; Pavan et al., Molecules, 2008, 13, 1035-1065; Sandros
et al., Molecules 2008, 13, 1156-1178; Singh et al., Curr. Med. Chem. 2008, 15, 1802-1826;
Onishi et al., Molecules, 2008, 13, 2136-2155; Huttunen et al., Curr. Med. Chem. 2008, 15,
2346-2365; and Serafin et al., Mini Rev. Med. Chem. 2009, 9, 481-497.
Methods of Synthesis
The compounds provided herein can be prepared, isolated, or obtained by any
method known to one of skill in the art. For an example, a nd of Formula I can be
prepared as shown in Scheme 1.
Scheme 1
L1~L2
UF~?Y’N02 1-2 FT? ’N02 UFT‘TY’NHZ
I1\ I‘ll —> H‘ ’II —> '1‘ "1|
V\~v X\X1 V\ X\I\{H V\§i] X‘NH
L $121 L if1
1—3 R
1—4 R1
A ,N RZCOOH 41 ,N R2
U’ \Y UI
—> \ \Y
11‘“; I >—ZH —> |1\ \
1.. >—Z
V\ .X\N V\~' X\N
‘ ‘
L ~L21 L —L21
\ \
R1 R1
1—5 1
Compound 1-1 is treated with nucleophilic amine 1-2 to form compound 1-3,
wherein X1 is a leaving group, including, but not limited to fluoro, chloro, bromo, methoxy,
ethoxy, and nitro. The nitro group of compound 1-3 is reduced with a reducing agent, e.g.,
zinc, FeC12,NiC12, or Na2S203, to form nd 1-4. The reduction can also be
accomplished via hydrogenation using, e.g, ammonium formate or hydrogen in the ce
of Pd/C. Compound 1-5 is then cyclized to form compound 1-5 with the Z group led
simultaneously. When Z is NH, compound 1-5 is then coupled with an acid (RZCOOH) using
a coupling reagent, e.g., HATU, HBTU, , PyBOP, or EDCI, to form compound of
Formula 1.
Pharmaceutical Compositions
Provided herein are pharmaceutical compositions comprising a compound
provided herein, e.g., a compound of Formula I or XXI, as an active ient, including a
single enantiomer, a racemic e, a mixture of diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; and a
pharmaceutically able vehicle, carrier, diluent, or excipient, or a mixture thereof.
le excipients are well known to those skilled in the art, and non-limiting
examples of suitable excipients are provided herein. Whether a particular excipient is
suitable for incorporation into a pharmaceutical composition or dosage form depends on a
variety of factors well known in the art, including, but not limited to, the method of
administration. For example, oral dosage forms such as tablets may n excipients not
suited for use in eral dosage forms. The suitability of a particular ent may also
depend on the specific active ingredients in the dosage form. For example, the
decomposition of some active ingredients may be accelerated by some excipients such as
lactose, or when exposed to water. Active ingredients that comprise primary or secondary
amines are particularly susceptible to such accelerated decomposition. Consequently,
provided herein are pharmaceutical compositions and dosage forms that contain little, if any,
lactose, or other mono- or di-saccharides. As used herein, the term “lactose-free” means that
the amount of lactose present, if any, is insufficient to ntially se the degradation
rate of an active ingredient.
The compound provided herein may be administered alone, or in combination
with one or more other compounds provided herein. The pharmaceutical compositions that
comprise a compound ed herein, e.g., a compound of Formula I or XXI, or a single
enantiomer, a racemic e, a mixture of diastereomers, or an isotopic variant thereof; or a
ceutically able salt, solvate, or g thereof, can be formulated in various
dosage forms for oral, parenteral, and topical administration. The pharmaceutical
itions can also be formulated as modified e dosage forms, including delayed-,
extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated-, fast-, targeted-,
programmed-release, and c retention dosage forms. These dosage forms can be
prepared ing to conventional methods and techniques known to those skilled in the art
(see, Remington: The Science and Practice ofPharmacy, supra; Modified-Release Drug
Delivery Technology, 2nd ed.; ne et al., Eds.; Marcel Dekker, Inc.: New York, NY,
2008).
In one embodiment, the pharmaceutical compositions are provided in a dosage
form for oral administration, which comprise a compound provided herein, e.g., a compound
of Formula I or XXI, or a single enantiomer, a racemic mixture, a mixture of diastereomers,
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug
thereof; and a pharmaceutically acceptable salt, solvate, or prodrug thereof
2015/021455
In another embodiment, the pharmaceutical compositions are provided in a
dosage form for parenteral administration, which comprise a compound provided herein, e.g.,
a compound of Formula I or XXI, or a single enantiomer, a racemic mixture, a mixture of
diastereomers, or an isotopic variant f; or a pharmaceutically acceptable salt, solvate, or
prodrug thereof; and a pharmaceutically acceptable salt, solvate, or prodrug thereof.
In yet another embodiment, the pharmaceutical compositions are ed in a
dosage form for topical administration, which se a compound provided herein, e.g., a
nd of Formula I or XXI, or a single enantiomer, a c e, a mixture of
diastereomers, or an ic variant thereof; or a pharmaceutically acceptable salt, solvate, or
prodrug thereof; and a pharmaceutically acceptable salt, solvate, or prodrug thereof.
The pharmaceutical compositions provided herein can be provided in a unit-
dosage form or multiple-dosage form. A unit-dosage form, as used herein, refers to
physically discrete a unit le for administration to a human and animal subject, and
packaged individually as is known in the art. Each unit-dose contains a predetermined
quantity of an active ingredient(s) sufficient to produce the desired therapeutic effect, in
association with the required pharmaceutical carriers or excipients. Examples of a unitdosage
form include an ampoule, syringe, and individually packaged tablet and capsule. For
example, a 100 mg unit dose ns about 100 mg of an active ingredient in a packaged
tablet or capsule. A unit-dosage form may be administered in fractions or multiples thereof
A multiple-dosage form is a plurality of identical unit-dosage forms packaged in a single
container to be administered in segregated unit-dosage form. Examples of a multiple-dosage
form include a vial, bottle of tablets or capsules, or bottle of pints or gallons.
The ceutical compositions provided herein can be administered at
once, or le times at intervals of time. It is tood that the precise dosage and
duration of treatment may vary with the age, weight, and condition of the patient being
treated, and may be determined empirically using known testing protocols or by extrapolation
from in vivo or in vitro test or diagnostic data. It is further understood that for any particular
individual, specific dosage ns should be adjusted over time ing to the individual
need and the professional judgment of the person administering or supervising the
administration of the formulations.
A. Oral Administration
The ceutical compositions provided herein for oral stration can
be provided in solid, semisolid, or liquid dosage forms for oral administration. As used
herein, oral administration also includes buccal, lingual, and sublingual administration.
Suitable oral dosage forms include, but are not limited to, tablets, fastmelts, chewable tablets,
capsules, pills, strips, troches, es, pastilles, cachets, pellets, medicated g gum,
bulk powders, effervescent or non-effervescent powders or granules, oral mists, solutions,
emulsions, sions, , les, elixirs, and syrups. In addition to the active
ient(s), the pharmaceutical compositions can contain one or more pharmaceutically
acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents,
disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors,
ning agents, flavoring agents, emulsifying agents, suspending and dispersing agents,
preservatives, solvents, non-aqueous liquids, organic acids, and sources of carbon dioxide.
Binders or granulators impart cohesiveness to a tablet to ensure the tablet
remaining intact after compression. Suitable binders or granulators e, but are not
limited to, starches, such as corn starch, potato starch, and pre-gelatinized starch (e.g.,
STARCH 1500); n; sugars, such as sucrose, glucose, dextrose, molasses, and lactose;
natural and synthetic gums, such as acacia, alginic acid, alginates, extract of Irish moss,
panwar gum, ghatti gum, mucilage of isabgol husks, carboxymethylcellulose,
methylcellulose, polyvinylpyrrolidone (PVP), Veegum, larch arabogalactan, powdered
anth, and guar gum; celluloses, such as ethyl cellulose, cellulose acetate,
carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose,
hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropyl methyl
cellulose ; microcrystalline celluloses, such as AVICEL-PH- l 0 l, AVICEL-PH-103,
AVICEL RC-581, AVICEL-PH-lOS (FMC Corp., Marcus Hook, PA); and mixtures thereof
Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline
cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-
gelatinized starch, and es thereof. The amount of a binder or filler in the
ceutical compositions provided herein varies upon the type of formulation, and is
readily discernible to those of ry skill in the art. The binder or filler may be present
from about 50 to about 99% by weight in the pharmaceutical compositions provided herein.
Suitable diluents include, but are not limited to, dicalcium phosphate, calcium
sulfate, lactose, sorbitol, sucrose, inositol, cellulose, , mannitol, sodium chloride, dry
starch, and powdered sugar. n diluents, such as mannitol, lactose, sorbitol, sucrose, and
inositol, when present in sufficient quantity, can impart properties to some compressed tablets
that permit disintegration in the mouth by chewing. Such compressed tablets can be used as
chewable tablets. The amount of a diluent in the pharmaceutical itions provided
herein varies upon the type of formulation, and is readily discernible to those of ordinary skill
in the art.
Suitable disintegrants include, but are not limited to, agar; bentonite;
celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural
sponge; cation-exchange resins; alginic acid; gums, such as guar gum and Veegum HV; citrus
pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as
crospovidone; cross-linked starches; m carbonate; microcrystalline cellulose, such as
sodium starch ate; polacrilin potassium; starches, such as corn starch, potato starch,
tapioca starch, and pre-gelatinized starch; clays; aligns; and mixtures thereof. The amount of
a disintegrant in the pharmaceutical compositions ed herein varies upon the type of
formulation, and is readily discernible to those of ordinary skill in the art. The amount of a
disintegrant in the pharmaceutical compositions provided herein varies upon the type of
formulation, and is readily discernible to those of ordinary skill in the art. The
pharmaceutical compositions ed herein may contain from about 0.5 to about 15% or
from about 1 to about 5% by weight of a disintegrant.
Suitable lubricants include, but are not limited to, calcium stearate;
magnesium stearate; l oil; light l oil; glycerin; sorbitol; mannitol; glycols, such
as glycerol behenate and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate; talc;
hydrogenated vegetable oil, including peanut oil, cottonseed oil, sunflower oil, sesame oil,
olive oil, corn oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch;
lycopodium; silica or silica gels, such as AEROSIL® 200 (W.R. Grace Co., Baltimore, MD)
and CAB-O-SIL® (Cabot Co. of Boston, MA); and mixtures thereof. The pharmaceutical
compositions ed herein may contain about 0.1 to about 5% by weight of a lubricant.
Suitable glidants include, but are not limited to, dal silicon dioxide,
CAB-O-SIL® (Cabot Co. of Boston, MA), and os-free talc. Suitable coloring agents
include, but are not limited to, any of the approved, certif1ed, water soluble FD&C dyes, and
water ble FD&C dyes suspended on alumina e, and color lakes and mixtures
2015/021455
thereof. A color lake is the combination by adsorption of a water-soluble dye to a hydrous
oxide of a heavy metal, ing in an insoluble form of the dye. Suitable flavoring agents
include, but are not limited to, natural flavors extracted from plants, such as fruits, and
synthetic blends of compounds which e a pleasant taste sensation, such as peppermint
and methyl salicylate. Suitable sweetening agents include, but are not limited to, sucrose,
lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and
aspartame. Suitable emulsifying agents include, but are not limited to, gelatin, acacia,
tragacanth, bentonite, and surfactants, such as polyoxyethylene sorbitan monooleate
(TWEEN® 20), polyoxyethylene sorbitan eate 80 (TWEEN® 80), and triethanolamine
oleate. Suitable suspending and dispersing agents include, but are not limited to, sodium
carboxymethylcellulose, pectin, anth, Veegum, acacia, sodium carbomethylcellulose,
hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable preservatives include,
but are not limited to, glycerin, methyl and propylparaben, benzoic add, sodium benzoate and
alcohol. Suitable wetting agents include, but are not limited to, propylene glycol
monostearate, sorbitan monooleate, diethylene glycol monolaurate, and yethylene
lauryl ether. Suitable solvents include, but are not limited to, glycerin, sorbitol, ethyl alcohol,
and syrup. Suitable non-aqueous s utilized in emulsions include, but are not limited to,
mineral oil and cottonseed oil. Suitable organic acids e, but are not d to, citric
and tartaric acid. le sources of carbon dioxide include, but are not limited to, sodium
bicarbonate and sodium carbonate.
It should be tood that many carriers and ents may serve a plurality
of ons, even within the same ation.
The pharmaceutical compositions provided herein for oral administration can
be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving
tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated
tablets. Enteric-coated tablets are compressed tablets coated with nces that resist the
action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active
ingredients from the acidic nment of the stomach. Enteric-coatings include, but are not
limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and
cellulose acetate phthalates. Sugar-coated tablets are compressed tablets surrounded by a
sugar coating, which may be beneficial in covering up ionable tastes or odors and in
protecting the tablets from oxidation. Film-coated tablets are compressed tablets that are
covered with a thin layer or film of a water-soluble material. Film coatings include, but are
not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, hylene glycol
4000, and cellulose acetate phthalate. Film coating imparts the same general characteristics
as sugar coating. Multiple compressed tablets are compressed tablets made by more than one
compression cycle, including layered tablets, and press-coated or dry-coated tablets.
The tablet dosage forms can be prepared from the active ingredient in
powdered, crystalline, or granular forms, alone or in combination with one or more carriers or
excipients bed herein, ing binders, disintegrants, controlled-release polymers,
lubricants, diluents, and/or colorants. Flavoring and sweetening agents are especially useful
in the formation of chewable tablets and lozenges.
The pharmaceutical compositions ed herein for oral stration can
be provided as soft or hard capsules, which can be made from n, cellulose,
starch, or calcium alginate. The hard gelatin capsule, also known as the dry-filled capsule
(DFC), consists of two sections, one slipping over the other, thus tely enclosing the
active ingredient. The soft elastic capsule (SEC) is a soft, globular shell, such as a gelatin
shell, which is plasticized by the addition of glycerin, sorbitol, or a similar polyol. The soft
gelatin shells may contain a preservative to prevent the growth of microorganisms. Suitable
preservatives are those as described herein, including methyl- and propyl-parabens, and
sorbic acid. The liquid, semisolid, and solid dosage forms provided herein may be
ulated in a capsule. Suitable liquid and semisolid dosage forms include ons and
suspensions in propylene carbonate, vegetable oils, or triglycerides. es containing
such solutions can be prepared as bed in US. Pat. Nos. 4,328,245; 4,409,239; and
4,410,545. The capsules may also be coated as known by those of skill in the art in order to
modify or sustain dissolution of the active ingredient.
The pharmaceutical compositions provided herein for oral administration can
be provided in liquid and semisolid dosage forms, including emulsions, solutions,
suspensions, elixirs, and syrups. An emulsion is a two-phase system, in which one liquid is
dispersed in the form of small es throughout another liquid, which can be -water
or water-in-oil. Emulsions may include a pharmaceutically acceptable non-aqueous liquid or
solvent, emulsifying agent, and preservative. Suspensions may include a pharmaceutically
acceptable suspending agent and preservative. Aqueous alcoholic ons may include a
pharmaceutically acceptable , such as a di(lower alkyl) acetal of a lower alkyl aldehyde,
e.g., acetaldehyde diethyl ; and a miscible solvent having one or more hydroxyl
groups, such as propylene glycol and ethanol. Elixirs are clear, sweetened, and
hydroalcoholic solutions. Syrups are concentrated aqueous solutions of a sugar, for example,
sucrose, and may also contain a preservative. For a liquid dosage form, for example, a
solution in a polyethylene glycol may be diluted with a sufficient quantity of a
pharmaceutically acceptable liquid carrier, e.g., water, to be measured conveniently for
administration.
Other useful liquid and semisolid dosage forms include, but are not limited to,
those containing the active ient(s) provided , and a dialkylated mono- or poly-
alkylene glycol, including, 1,2-dimethoxymethane, diglyme, triglyme, lyme,
polyethylene glycoldimethyl ether, polyethylene glycoldimethyl ether,
hylene glycoldimethyl ether, wherein 350, 550, and 750 refer to the approximate
average molecular weight of the polyethylene . These formulations can r
comprise one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated
hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarins,
ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, bisulfite,
sodium metabisulfite, thiodipropionic acid and its esters, and dithiocarbamates.
The pharmaceutical compositions provided herein for oral administration can
be also provided in the forms of liposomes, micelles, microspheres, or nanosystems. Micellar
dosage forms can be prepared as bed in US. Pat. No. 6,350,458.
The pharmaceutical compositions provided herein for oral stration can
be provided as non-effervescent or effervescent, granules and s, to be tituted
into a liquid dosage form. Pharmaceutically acceptable carriers and ents used in the
non-effervescent granules or powders may include diluents, sweeteners, and g agents.
Pharmaceutically acceptable carriers and excipients used in the effervescent granules or
powders may include organic acids and a source of carbon dioxide.
Coloring and flavoring agents can be used in all of the above dosage forms.
The pharmaceutical compositions provided herein for oral administration can
be formulated as immediate or modified release dosage forms, including delayed-, sustained,
pulsed-, controlled, targeted-, and programmed-release forms.
B. Parenteral Administration
] The pharmaceutical compositions provided herein can be administered
parenterally by injection, infusion, or implantation, for local or systemic administration.
Parenteral administration, as used herein, include intravenous, rterial, intraperitoneal,
intrathecal, intraventricular, intraurethral, intrastemal, intracranial, intramuscular,
intrasynovial, intravesical, and subcutaneous stration.
The pharmaceutical compositions provided herein for parenteral
stration can be formulated in any dosage forms that are suitable for parenteral
administration, including solutions, suspensions, emulsions, micelles, liposomes,
pheres, nanosystems, and solid forms suitable for solutions or suspensions in liquid
prior to injection. Such dosage forms can be prepared according to conventional methods
known to those skilled in the art of pharmaceutical science (see, Remington: The Science and
Practice ofPharmacy, supra).
The pharmaceutical itions intended for parenteral administration can
include one or more pharmaceutically acceptable carriers and excipients, including, but not
d to, s vehicles, miscible vehicles, non-aqueous vehicles, antimicrobial
agents or preservatives against the growth of microorganisms, stabilizers, solubility
enhancers, ic agents, buffering agents, antioxidants, local anesthetics, suspending and
dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or
chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusting , and
inert gases.
Suitable aqueous vehicles include, but are not d to, water, saline,
physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringers
ion, isotonic dextrose injection, sterile water ion, dextrose and lactated Ringers
injection. Suitable non-aqueous vehicles include, but are not limited to, fixed oils of
vegetable origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil,
safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, hydrogenated soybean oil,
and medium-chain triglycerides of coconut oil, and palm seed oil. Suitable water-miscible
vehicles include, but are not limited to, ethanol, tanediol, liquid polyethylene glycol
(e.g., polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerin, N-
methylpyrrolidone, N,N-dimethylacetamide, and dimethyl sulfoxide.
Suitable antimicrobial agents or preservatives include, but are not limited to,
phenols, cresols, mercurials, benzyl l, chlorobutanol, methyl and propyl p-
hydroxybenzoates, thimerosal, benzalkonium chloride (6.g. , honium chloride), methyl-
and propyl-parabens, and sorbic acid. Suitable isotonic agents include, but are not limited to,
sodium chloride, glycerin, and dextrose. le ing agents include, but are not
limited to, phosphate and citrate. Suitable antioxidants are those as described herein,
including te and sodium metabisulfite. Suitable local anesthetics include, but are not
limited to, procaine hydrochloride. Suitable ding and dispersing agents are those as
described herein, including sodium carboxymethylcelluose, hydroxypropyl methylcellulose,
and polyvinylpyrrolidone. Suitable emulsifying agents are those described herein, including
polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan eate 80, and
anolamine oleate. Suitable sequestering or chelating agents include, but are not limited
to EDTA. Suitable pH adjusting agents include, but are not limited to, sodium hydroxide,
hydrochloric acid, citric acid, and lactic acid. Suitable complexing agents include, but are not
limited to, cyclodextrins, including lodextrin, B-cyclodextrin, hydroxypropyl-B-
cyclodextrin, utylether-B-cyclodextrin, and sulfobutylether
7-B-cyclodextrin (CAPTISOL®, CyDex, Lenexa, KS).
When the pharmaceutical compositions provided herein are formulated for
multiple dosage administration, the le dosage parenteral formulations must n an
antimicrobial agent at bacteriostatic or fiangistatic concentrations. All parenteral formulations
must be sterile, as known and practiced in the art.
] In one embodiment, the pharmaceutical compositions for eral
administration are provided as ready-to-use sterile solutions. In another embodiment, the
pharmaceutical compositions are provided as sterile dry soluble products, including
lyophilized powders and hypodermic tablets, to be tituted with a vehicle prior to use.
In yet another embodiment, the pharmaceutical compositions are provided as ready-to-use
sterile suspensions. In yet another embodiment, the pharmaceutical itions are
provided as sterile dry insoluble products to be tituted with a vehicle prior to use. In
still another embodiment, the pharmaceutical compositions are provided as ready-to-use
sterile emulsions.
The pharmaceutical compositions provided herein for parenteral
administration can be formulated as immediate or modified release dosage forms, including
delayed-, sustained, pulsed-, controlled, ed-, and programmed-release forms.
The pharmaceutical compositions provided herein for parenteral
administration can be formulated as a suspension, solid, semi-solid, or thixotropic , for
administration as an implanted depot. In one embodiment, the ceutical compositions
provided herein are dispersed in a solid inner matrix, which is surrounded by an outer
polymeric membrane that is insoluble in body fluids but allows the active ingredient in the
ceutical compositions diffilse through.
Suitable inner matrixes include, but are not limited to,
polymethylmethacrylate, polybutyl-methacrylate, plasticized or unplasticized
polyvinylchloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber,
polyisoprene, obutylene, polybutadiene, polyethylene, ethylene-vinyl acetate
mers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers,
hydrophilic polymers, such as hydrogels of esters of acrylic and methacrylic acid, collagen,
cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.
] Suitable outer polymeric membranes include but are not limited to,
polyethylene, polypropylene, ne/propylene copolymers, ethylene/ethyl acrylate
mers, ethylene/vinyl acetate mers, silicone rubbers, polydimethyl siloxanes,
neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinyl chloride copolymers with
vinyl acetate, vinylidene chloride, ethylene and ene, ionomer polyethylene
terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl l copolymer,
ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer.
C. Topical Administration
The ceutical compositions provided herein can be administered
topically to the skin, orifices, or mucosa. The topical administration, as used herein, includes
(intra)dermal, conjunctival, intracomeal, intraocular, ophthalmic, auricular, transdermal,
nasal, vaginal, urethral, respiratory, and rectal stration.
The ceutical compositions provided herein can be formulated in any
dosage forms that are suitable for topical administration for local or systemic effect, including
emulsions, solutions, suspensions, creams, gels, hydrogels, ointrnents, dusting powders,
dressings, elixirs, lotions, suspensions, tinctures, pastes, foams, films, aerosols, irrigations,
sprays, suppositories, bandages, and dermal patches. The topical formulation of the
ceutical compositions provided herein can also comprise liposomes, micelles,
microspheres, nanosystems, and mixtures thereof.
Pharmaceutically acceptable carriers and excipients suitable for use in the
topical ations provided herein e, but are not limited to, s es, water-
miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the
growth of rganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents,
idants, local anesthetics, suspending and dispersing agents, g or emulsifying
agents, complexing agents, sequestering or chelating agents, penetration enhancers,
cryoprotectants, lyoprotectants, thickening agents, and inert gases.
The pharmaceutical itions can also be administered topically by
oporation, iontophoresis, phonophoresis, sonophoresis, or microneedle or needle-free
injection, such as POWDERJECTTM (Chiron Corp., Emeryville, CA), and BIOJECTTM
(Bioject Medical Technologies Inc., Tualatin, OR).
The pharmaceutical compositions ed herein can be provided in the
forms of ointments, creams, and gels. Suitable ointment vehicles include oleaginous or
hydrocarbon es, including lard, benzoinated lard, olive oil, cottonseed oil, and other
oils, white petrolatum; emulsif1able or absorption vehicles, such as hydrophilic petrolatum,
hydroxystearin sulfate, and anhydrous lanolin; water-removable es, such as hydrophilic
ointment; water-soluble ointment vehicles, including polyethylene glycols of varying
molecular weight; emulsion vehicles, either water-in-oil (W/O) emulsions or oil-in-water
(O/W) emulsions, including cetyl alcohol, yl monostearate, lanolin, and stearic acid
(see, Remington: The e and Practice ofPharmacy, supra). These vehicles are
emollient but generally require addition of antioxidants and preservatives.
Suitable cream base can be oil-in-water or water-in-oil. Suitable cream
vehicles may be water-washable, and contain an oil phase, an fier, and an aqueous
phase. The oil phase is also called the "internal" phase, which is generally comprised of
petrolatum and a fatty alcohol such as cetyl or stearyl alcohol. The aqueous phase usually,
although not necessarily, exceeds the oil phase in , and generally contains a
humectant. The emulsifier in a cream formulation may be a ic, anionic, cationic, or
amphoteric surfactant.
2015/021455
Gels are semisolid, suspension-type systems. Single-phase gels contain
organic macromolecules distributed substantially uniformly throughout the liquid carrier.
Suitable gelling agents include, but are not limited to, crosslinked acrylic acid polymers, such
as carbomers, carboxypolyalkylenes, and OL®; hydrophilic polymers, such as
polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers, and polyvinylalcohol;
cellulosic polymers, such as hydroxypropyl ose, hydroxyethyl cellulose, ypropyl
methylcellulose, hydroxypropyl methylcellulose phthalate, and methylcellulose; gums, such
as tragacanth and n gum; sodium alginate; and gelatin. In order to prepare a uniform
gel, dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be
dispersed by trituration, mechanical mixing, and/or stirring.
The pharmaceutical compositions provided herein can be administered
rectally, ally, vaginally, or ginally in the forms of suppositories, pessaries,
bougies, poultices or cataplasm, pastes, powders, dressings, creams, plasters, contraceptives,
ointments, solutions, ons, suspensions, tampons, gels, foams, sprays, or .
These dosage forms can be manufactured using conventional processes as described in
Remington: The Science and Practice ofPharmacy, supra.
Rectal, urethral, and vaginal suppositories are solid bodies for insertion into
body orifices, which are solid at ordinary temperatures but melt or soften at body ature
to release the active ingredient(s) inside the orifices. Pharmaceutically acceptable carriers
utilized in rectal and vaginal suppositories include bases or vehicles, such as stiffening
agents, which e a melting point in the ity of body temperature, when
formulated with the pharmaceutical compositions provided herein; and antioxidants as
described herein, including bisulfite and sodium sulfite. Suitable vehicles include, but
are not limited to, cocoa butter (theobroma oil), glycerin-gelatin, carbowax (polyoxyethylene
glycol), spermaceti, paraffin, white and yellow wax, and appropriate mixtures of mono-, di-
and triglycerides of fatty acids, and els, such as polyvinyl alcohol, hydroxyethyl
methacrylate, and polyacrylic acid;. Combinations of the various vehicles can also be used.
Rectal and vaginal suppositories may be prepared by compressing or molding. The l
weight of a rectal and vaginal suppository is about 2 to about 3 g.
[0023 9] The pharmaceutical compositions provided herein can be administered
ophthalmically in the forms of solutions, suspensions, ointments, emulsions, gel-forming
solutions, s for solutions, gels, ocular inserts, and implants.
The ceutical compositions provided herein can be administered
intranasally or by inhalation to the respiratory tract. The pharmaceutical compositions can be
provided in the form of an l or solution for delivery using a pressurized container,
pump, spray, atomizer, such as an atomizer using electrohydrodynamics to produce a fine
mist, or nebulizer, alone or in combination with a suitable propellant, such as l, l ,l,2-
tetrafluoroethane or l,l,l,2,3,3,3-heptafluoropropane. The pharmaceutical compositions can
also be ed as a dry powder for insufflation, alone or in combination with an inert
r such as e or phospholipids; and nasal drops. For intranasal use, the powder can
comprise a bioadhesive agent, including chitosan or cyclodextrin.
Solutions or suspensions for use in a pressurized container, pump, spray,
atomizer, or nebulizer can be formulated to contain ethanol, aqueous ethanol, or a suitable
alternative agent for dispersing, solubilizing, or extending release of the active ingredient
provided herein; a propellant as solvent; and/or a tant, such as sorbitan trioleate, oleic
acid, or an oligolactic acid.
The ceutical compositions provided herein can be micronized to a size
suitable for ry by inhalation, such as about 50 micrometers or less, or about 10
micrometers or less. Particles of such sizes can be prepared using a comminuting method
known to those skilled in the art, such as spiral jet milling, fluid bed jet milling, supercritical
fluid processing to form rticles, high pressure homogenization, or spray drying.
Capsules, blisters, and cartridges for use in an inhaler or insufflator can be
formulated to contain a powder mix of the pharmaceutical compositions provided herein; a
suitable powder base, such as lactose or starch; and a performance modifier, such as [-
leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of
the monohydrate. Other suitable excipients or carriers include, but are not limited to, dextran,
glucose, maltose, sorbitol, l, fructose, sucrose, and trehalose. The pharmaceutical
compositions provided herein for inhaled/intranasal administration can further se a
le flavor, such as menthol and levomenthol; and/or sweeteners, such as saccharin and
saccharin sodium.
The pharmaceutical itions provided herein for topical stration
can be formulated to be immediate release or modified release, including delayed-,
sustained-, pulsed-, controlled-, targeted, and mmed release.
-lOl-
2015/021455
D. Modified Release
The pharmaceutical compositions provided herein can be formulated as a
modified release dosage form. As used herein, the term “modified release” refers to a dosage
form in which the rate or place of release of the active ingredient(s) is ent from that of
an ate dosage form when administered by the same route. Modified release dosage
forms include, but are not limited to, delayed-, extended-, prolonged-, ned-, pulsatile-,
controlled-, accelerated- and fast-, targeted-, mmed-release, and gastric retention
dosage forms. The pharmaceutical compositions in modified e dosage forms can be
prepared using a variety of modified release devices and methods known to those skilled in
the art, including, but not limited to, matrix controlled release devices, osmotic lled
release devices, multiparticulate controlled release devices, ion-exchange resins, enteric
gs, multilayered coatings, microspheres, liposomes, and ations thereof. The
release rate of the active ingredient(s) can also be modified by varying the particle sizes and
polymorphorism of the active ingredient(s).
Examples ofmodified release include, but are not limited to, those bed
in US. Pat. Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 533;
,059,595; 767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,639,480; 5,733,566;
,739,108; 5,891,474; 356; 5,958,458; 5,972,891; 5,980,945; 5,993,855; 6,045,830;
6,087,324; 6,113,943; 6,197,350; 6,248,363; 6,264,970; 6,267,981; 6,270,798; 6,375,987;
6,376,461; 6,419,961; 6,589,548; 6,613,358; 6,623,756; 6,699,500; 6,793,936; 6,827,947;
6,902,742; 6,958,161; 7,255,876; 7,416,738; 414; 322; Bussemer et al., Crit.
Rev. Ther. Drug Carrier Syst. 2001, 18, 433-458; Modified-Release Drug Delivery
Technology, 2nd ed.; Rathbone et al., Eds.; Marcel Dekker AG: 2005; Maroni et al., Expert.
Opin. Drug Deliv. 2005, 2, 855-871; Shi et al., Expert Opin. Drug Deliv. 2005, 2, 1039-1058;
Polymers in Drug Delivery; Ijeoma et al., Eds.; CRC Press LLC: Boca Raton, FL, 2006;
Badawy et al., J. Pharm. Sci. 2007, 9, 948-959; Modified-Release Drug Delivery Technology,
supra; Conway, Recent Pat. Drug Deliv. Formul. 2008, 2, 1-8; Gazzaniga et al., Eur. J.
Pharm. Biopharm. 2008, 68, 11-18; Nagarwal et al., Curr. Drug Deliv. 2008, 5, 282-289;
Gallardo et al., Pharm. Dev. l. 2008, 13, 413-423; Chrzanowski, AAPS
PharmSciTech. 2008, 9, 635-638; Chrzanowski, AAPS PharmSciTech. 2008, 9, 639-645;
Kalantzi et al., Recent Pat. Drug Deliv. Formul. 2009, 3, 49-63; Saigal et al., Recent Pat.
Drug Deliv. Formul. 2009, 3, 64-70; and Roy et al., J. Control Release 2009, 134, 74-80.
1. Matrix Controlled Release Devices
The pharmaceutical compositions provided herein in a modified release
dosage form can be fabricated using a matrix controlled release device known to those skilled
in the art. See, Takada et al. in Encyclopedia ofControlled Drug Delivery; Mathiowitz Ed.;
Wiley: 1999; Vol 2.
In certain embodiments, the pharmaceutical compositions provided herein in a
modified release dosage form is formulated using an erodible matrix device, which is water-
swellable, erodible, or soluble polymers, including, but not limited to, synthetic polymers,
and naturally occurring polymers and derivatives, such as polysaccharides and ns.
Materials useful in forming an erodible matrix include, but are not limited to,
chitin, chitosan, dextran, and pullulan; gum agar, gum arabic, gum karaya, locust bean gum,
gum tragacanth, carrageenans, gum ghatti, guar gum, n gum, and scleroglucan;
starches, such as dextrin and maltodextrin; hydrophilic ds, such as ; phosphatides,
such as lecithin; alginates; propylene glycol alginate; gelatin; collagen; cellulosics, such as
ethyl cellulose (EC), methylethyl cellulose (MEC), carboxymethyl cellulose (CMC), CMEC,
yethyl cellulose (HEC), hydroxypropyl cellulose (HPC), cellulose acetate (CA),
cellulose nate (CP), cellulose te (CB), cellulose acetate butyrate (CAB), CAP,
CAT, ypropyl methyl cellulose (HPMC), HPMCP, HPMCAS, hydroxypropyl methyl
cellulose acetate trimellitate (HPMCAT), and ethyl hydroxyethyl cellulose (EHEC);
polyvinyl pyrrolidone; polyvinyl alcohol; polyvinyl acetate; glycerol fatty acid esters;
polyacrylamide; polyacrylic acid; copolymers of ethacrylic acid or rylic acid
(EUDRAGIT®, Rohm America, Inc., Piscataway, NJ); -hydroxyethyl-methacrylate);
polylactides; copolymers of L-glutamic acid and ethyl-L-glutamate; degradable lactic acidglycolic
acid copolymers; poly-D-(-)hydroxybutyric acid; and other acrylic acid
derivatives, such as homopolymers and mers of butylmethacrylate, methyl
methacrylate, ethyl rylate, ethylacrylate, (2-dimethylaminoethyl)methacrylate, and
(trimethylaminoethyl)methacrylate de.
In certain embodiments, the pharmaceutical compositions provided herein are
formulated with a non-erodible matrix device. The active ingredient(s) is dissolved or
dispersed in an inert matrix and is released primarily by diffilsion through the inert matrix
once administered. als suitable for use as a odible matrix device include, but are
not limited to, insoluble plastics, such as polyethylene, polypropylene, polyisoprene,
obutylene, tadiene, polymethylmethacrylate, polybutylmethacrylate, chlorinated
polyethylene, polyvinylchloride, methyl acrylate-methyl rylate copolymers, ethylene-
vinyl acetate copolymers, ethylene/propylene copolymers, ne/ethyl te
copolymers, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and
propylene, ionomer polyethylene terephthalate, butyl rubbers, epichlorohydrin rubbers,
ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol ymer,
ethylene/vinyloxyethanol copolymer, polyvinyl chloride, plasticized nylon, plasticized
polyethylene terephthalate, natural rubber, ne rubbers, polydimethylsiloxanes, and
silicone carbonate copolymers; hydrophilic polymers, such as ethyl cellulose, cellulose
acetate, crospovidone, and cross-linked partially hydrolyzed polyvinyl acetate; and fatty
compounds, such as camauba wax, microcrystalline wax, and triglycerides.
[0025 1] In a matrix controlled release system, the desired release kinetics can be
controlled, for example, via the polymer type employed, the r viscosity, the particle
sizes of the polymer and/or the active ingredient(s), the ratio of the active ingredient(s) versus
the polymer, and other ents or carriers in the compositions.
The pharmaceutical compositions ed herein in a modified release
dosage form can be prepared by methods known to those skilled in the art, including direct
compression, dry or wet ation followed by compression, and melt-granulation followed
by compression.
2. Osmotic Controlled Release Devices
The pharmaceutical compositions provided herein in a ed release
dosage form can be fabricated using an osmotic controlled release device, including, but not
limited to, one-chamber system, two-chamber system, asymmetric ne technology
(AMT), and extruding core system (ECS). In l, such devices have at least two
components: (a) a core which contains an active ingredient; and (b) a semipermeable
membrane with at least one delivery port, which encapsulates the core. The semipermeable
membrane controls the influx of water to the core from an s environment of use so as
to cause drug release by extrusion through the delivery port(s).
] In addition to the active ingredient(s), the core of the osmotic device
optionally includes an osmotic agent, which creates a driving force for transport of water
—104—
from the environment of use into the core of the device. One class of osmotic agents is
water-swellable hydrophilic polymers, which are also referred to as “osmopolymers” and
“hydrogels.” Suitable water-swellable hydrophilic polymers as osmotic agents include, but
are not limited to, hydrophilic vinyl and c polymers, polysaccharides such as calcium
alginate, hylene oxide (PEO), polyethylene glycol (PEG), polypropylene glycol (PPG),
-hydroxyethyl methacrylate), poly(acrylic) acid, poly(methacrylic) acid,
polyvinylpyrrolidone (PVP), crosslinked PVP, polyvinyl alcohol (PVA), PVA/PVP
copolymers, PVA/PVP mers with hydrophobic monomers such as methyl methacrylate
and vinyl acetate, hydrophilic polyurethanes containing large PEO blocks, sodium
croscarmellose, eenan, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC),
hydroxypropyl methyl cellulose (HPMC), carboxymethyl cellulose (CMC) and carboxyethyl,
cellulose (CEC), sodium alginate, polycarbophil, gelatin, xanthan gum, and sodium starch
glycolate.
The other class of osmotic agents is osmogens, which are capable of imbibing
water to affect an osmotic pressure gradient across the barrier of the surrounding coating.
le osmogens include, but are not limited to, inorganic salts, such as magnesium e,
magnesium chloride, calcium chloride, sodium chloride, m chloride, ium sulfate,
potassium phosphates, sodium carbonate, sodium sulfite, lithium sulfate, potassium chloride,
and sodium sulfate; sugars, such as dextrose, fructose, glucose, inositol, lactose, maltose,
mannitol, raffinose, ol, sucrose, trehalose, and xylitol; organic acids, such as ascorbic
acid, benzoic acid, fiJmaric acid, citric acid, maleic acid, sebacic acid, sorbic acid, adipic acid,
edetic acid, glutamic acid, p-toluenesulfonic acid, succinic acid, and tartaric acid; urea; and
mixtures f.
c agents of different dissolution rates can be employed to influence
how rapidly the active ingredient(s) is initially delivered from the dosage form. For example,
amorphous sugars, such as MANNOGEMTM EZ (SPI Pharma, Lewes, DE) can be used to
provide faster ry during the first couple of hours to ly produce the desired
therapeutic effect, and gradually and continually release of the remaining amount to maintain
the desired level of therapeutic or prophylactic effect over an extended period of time. In this
case, the active ingredient(s) is released at such a rate to replace the amount of the active
ingredient metabolized and excreted.
The core can also include a wide variety of other excipients and carriers as
described herein to enhance the mance of the dosage form or to promote stability or
sing.
Materials useful in forming the semipermeable membrane include various
grades of acrylics, vinyls, ethers, polyamides, polyesters, and cellulosic derivatives that are
permeable and water-insoluble at logically nt pHs, or are susceptible to
being rendered water-insoluble by chemical alteration, such as crosslinking. Examples of
suitable polymers useful in forming the coating, include cized, unplasticized, and
reinforced cellulose acetate (CA), cellulose diacetate, cellulose triacetate, CA propionate,
cellulose nitrate, cellulose acetate butyrate (CAB), CA ethyl carbamate, CAP, CA methyl
ate, CA succinate, cellulose acetate trimellitate (CAT), CA dimethylaminoacetate, CA
ethyl carbonate, CA chloroacetate, CA ethyl oxalate, CA methyl sulfonate, CA butyl
sulfonate, CA p-toluene sulfonate, agar acetate, amylose triacetate, beta glucan acetate, beta
glucan triacetate, acetaldehyde dimethyl acetate, triacetate of locust bean gum, hydroxylated
ethylene-vinylacetate, EC, PEG, PPG, PEG/PPG mers, PVP, HEC, HPC, CMC,
CMEC, HPMC, HPMCP, HPMCAS, HPMCAT, poly(acrylic) acids and esters and poly-
(methacrylic) acids and esters and copolymers thereof, starch, dextran, dextrin, chitosan,
collagen, gelatin, polyalkenes, polyethers, polysulfones, hersulfones, polystyrenes,
polyvinyl halides, polyvinyl esters and ethers, natural waxes, and synthetic waxes.
] Semipermeable membrane can also be a hydrophobic microporous membrane,
wherein the pores are substantially filled with a gas and are not wetted by the aqueous
medium but are permeable to water vapor, as disclosed in US. Pat. No. 5,798,119. Such
hydrophobic but water-vapor permeable membrane are typically composed of hydrophobic
polymers such as polyalkenes, polyethylene, polypropylene, polytetrafluoroethylene,
polyacrylic acid derivatives, polyethers, polysulfones, polyethersulfones, polystyrenes,
nyl halides, polyvinylidene fluoride, polyvinyl esters and ethers, natural waxes, and
synthetic waxes.
The delivery ) on the semipermeable membrane can be formed post-
coating by mechanical or laser drilling. ry port(s) can also be formed in situ by erosion
of a plug of water-soluble material or by rupture of a thinner portion of the membrane over an
indentation in the core. In on, delivery ports can be formed during g process, as
in the case of asymmetric ne coatings of the type disclosed in US. Pat. Nos.
,612,059 and 5,698,220.
WO 43148
The total amount of the active ingredient(s) released and the release rate can
substantially by modulated via the thickness and porosity of the semipermeable membrane,
the composition of the core, and the number, size, and position of the delivery ports.
The pharmaceutical itions in an osmotic controlled-release dosage
form can fiarther comprise onal tional excipients or carriers as described herein
to promote performance or sing of the formulation.
The c controlled-release dosage forms can be prepared according to
conventional methods and techniques known to those skilled in the art. See, Remington: The
Science and Practice ofPharmacy, supra; Santus and Baker, J. Controlled Release 1995, 35,
l-2l; Verma et al. , Drug Development and Industrial Pharmacy 2000, 26, 8; and
Verma et al., J. Controlled Release 2002, 79, 7-27.
] In certain embodiments, the pharmaceutical compositions provided herein are
formulated as AMT controlled-release dosage form, which comprises an asymmetric osmotic
membrane that coats a core sing the active ingredient(s) and other pharmaceutically
acceptable excipients or carriers. See, US. Pat. No. 5,612,059 and International Pat. Appl.
Publ. No. . The AMT controlled-release dosage forms can be prepared
according to tional s and techniques known to those skilled in the art, including
direct compression, dry granulation, wet granulation, and a dip-coating method.
In certain embodiments, the pharmaceutical itions provided herein are
formulated as ESC controlled-release dosage form, which comprises an osmotic membrane
that coats a core comprising the active ingredient(s), a hydroxylethyl cellulose, and other
ceutically acceptable excipients or carriers.
3. Multiparticulate Controlled Release Devices
The pharmaceutical compositions provided herein in a modified release
dosage form can be fabricated as a multiparticulate controlled release device, which
comprises a multiplicity of particles, granules, or pellets, ranging from about 10 um to about
3 mm, about 50 um to about 2.5 mm, or from about 100 um to about 1 mm in diameter. Such
multiparticulates can be made by the processes known to those skilled in the art, including
wet-and dry-granulation, extrusion/spheronization, roller-compaction, melt-congealing, and
by spray-coating seed cores. See, for example, Multiparticulate Oral Drug Delivery; Ghebre-
Sellassie Ed.; Marcel Dekker: 1994; and Pharmaceutical Pelletz'zatz'on Technology; Ghebre-
sie Ed.; Marcel Dekker: 1989.
Other excipients or carriers as described herein can be blended with the
pharmaceutical compositions to aid in processing and forming the multiparticulates. The
resulting particles can themselves constitute the multiparticulate device or can be coated by
various film-forming als, such as enteric rs, water-swellable, and water-soluble
polymers. The multiparticulates can be r processed as a capsule or a tablet.
4. Targeted Delivery
The pharmaceutical compositions provided herein can also be formulated to be
targeted to a particular tissue, or, or other area of the body of the subject to be treated,
including liposome-, resealed ocyte-, and antibody-based delivery systems. Examples
include, but are not limited to, those disclosed in US. Pat. Nos. 5,709,874; 5,759,542;
,840,674; 5,900,252; 5,972,366; 5,985,307; 6,004,534; 6,039,975; 6,048,736; 6,060,082;
6,071,495; 6,120,751; 6,131,570; 6,139,865; 6,253,872; 6,271,359; 6,274,552; 6,316,652;
and 7,169,410.
Methods ofUse
In one embodiment, provided herein is a method for treating, preventing, or
ameliorating one or more symptoms of an ERBB-mediated condition, disorder, or disease in
a t, comprising administering to the t a compound disclosed herein, e.g, a
compound of Formula I or XXI, or a single enantiomer, a racemic mixture, a mixture of
diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or
g thereof.
In certain embodiments, the ERBB is a Wild-type ERBB. In certain
ments, the ERBB is an ERBB variant.
In certain ments, the ERBB is an EGFR. In certain embodiments, the
ERBB is a wild-type EGFR. In certain embodiments, the ERBB is an EGFR t. In
certain embodiments, the EGFR variant contains a deletion, insertion, or substitution. In
certain embodiments, the EGFR t contains one or more deletions, insertions, or
substitutions at the amino acid ons of 689, 700, 709, 715, 719, 720, 746-759, 761-765,
767-775, 783, 784, 790, 796, 826, 839, 846, 858, 861, and 863. In certain embodiments, the
EGFR variant contains one, two, or more deletions, insertions, and/or substitutions, each
independently selected from V689M, N700D, E709K, E709Q, E709V, E709A, E709G,
I715S, G7l9C, G719S, G719A, S720P, AE746-A750, AE746-T751, AE746-A750 (ins RP),
AE746-T751 (ins A/I), AE746-T751 (ins VA), AE746-S752 (ins A/V), L747S, AL747-E749
(A750P), AL747-A750 (ins P), T751, T751 (ins P/S), AL747-S752, AL747-
752 (E746V), AL747-752 (P753S), AL747-S752 (ins Q), AL747-P753, AL747-P753 (ins S),
AS752-I759, D76lY, AD761-E762 (ins EAFQ), AA763-Y764 (ins FQEA), V765A, AM766-
A767 (ins AI), AA767-S768 (ins TLA), S768 (ins SVA), S7681, D770 (dup
SVD), V769L, AV769-D770 (ins ASV), AD770-N771 (ins NPG), AD770-N771 (ins SVQ),
AD770-N771 (ins SVD), AD770-N771 (ins G), AD770-P772 (ins ASV),N771T, AP772-
H773 (ins PR), AP772-H773 (ins YNP), AH773-V774 (ins NPH), AH773-V774 (ins NP),
AH773-V774 (ins H), AH773-V774 (ins PH), AH773-V774 (ins GNPH), AV774-C775 (ins
HV), H775Y, P782R, T783A, T784A, T790M, G796A, N826S, A839T, K846R, L858R,
L86lQ, and G863D, provided that there is only one deletion and/or insertion, or substitution
at a given amino acid position in the EGFR variant. In certain embodiments, the EGFR
variant contains one, two, or more deletions, ions, and/or substitutions, each
ndently selected from G7l9C, G719S. G719A, AE746-A750, AE746-T751, AE746-
A750 (ins RP), T790M, and L85 8R. In certain embodiments, the EGFR variant contains
T790M and/or L85 8R. In n embodiments, the EGFR variant contains one, two, or more
deletions, insertions, and/or substitutions, each independently selected from AD761-E762 (ins
EAFQ), AS768-D770 (dup SVD), AV769-D770 (ins ASV), AD770-N771 (ins SVQ), AP772-
H773 (ins PR), AH773-V774 (ins NPH), AH773-V774 (ins H), AH773-V774 (ins PH), and
AH773-V774 (ins GNPH). In certain embodiments, the EGFR t contains a on,
insertion, or substitution in exon 19. In certain embodiments, the EGFR variant contains a
deletion, insertion, or substitution in exon 20.
In certain embodiments, the ERBB is a HER2. In certain embodiments, the
ERBB is a wild-type HER2. In certain embodiments, the ERBB is a HER2 variant. In
certain embodiments, the HER2 variant contains a on, ion, or substitution. In
certain embodiments, the HER2 variant contains one or more deletions, insertions, or
substitutions at the amino acid positions of 309, 310, 630, 717, 719, 726, 733, 755-759, 767,
769, 775-778, 780, 781, 783, 785, 798, 803, 812, 821, 835, 839, 842, 896, and 915. In certain
embodiments, the HER2 variant contains one, two, or more deletions, insertions, and/or
substitutions, each independently selected from G309A, G309E, S310F, C630Y, E717K,
E719G, E719K, L726F, T7331, L755S, L755W, AL755-T759, I767M, D769H, D769Y,
AA775-G776 (ins YVMA), , G776LC, AV777-G778 (ins CG), V777L, P780L,
AP780-Y781 (ins GSP), S783P, L785F, T7981, Y803N, E812K, D821N, Y835F, V839G,
V842I, R896C, and L915M, provided that there is only one deletion and/or insertion, or
substitution at a given amino acid position in the HER2 variant. In certain ments, the
HER2 t contains one, two, or more deletions, insertions, and/or substitutions, each
independently selected from G309A, L755S, AL755-T759, AA775-G776 (ins YVMA),
V777L, AP780-Y781 (ins GSP), V8421, and R896C.
In certain embodiments, the ERBB is a HER3. In certain ments, the
ERBB is a wild-type HER3. In certain embodiments, the ERBB is a HER3 variant. In
certain embodiments, the HER3 variant contains a deletion, insertion, or substitution.
] In certain embodiments, the ERBB is a HER4. In certain embodiments, the
ERBB is a wild-type HER4. In certain embodiments, the ERBB is a HER4 variant. In
certain embodiments, the HER4 t contains a on, insertion, or substitution.
In certain embodiments, the ERBB is a dimer. In n ments, the
ERBB is a homodimer. In certain embodiments, the ERBB is a heterodimer. In certain
embodiments, the ERBB is a heterodimer of EGFR, HER2, HER3, HER4, and variants
thereof.
] In certain embodiments, the compound provided herein is a selective inhibitor
of a mutant ERBB. In certain embodiments, the compound provided herein has a selectivity
against a mutant ERBB over a Wild-type ERBB ranging from about 2 fold, about 4 fold,
about 8 fold, about 20 fold, about 50 fold, about 100 fold, about 200 fold, about 500 fold, or
about 1000 fold.
In certain ments, the compound provided herein is a selective inhibitor
of a mutant EGFR. In certain embodiments, the compound provided herein has a selectivity
against a mutant EGFR over a wild-type EGFR ranging from about 2 fold, about 4 fold, about
8 fold, about 20 fold, about 50 fold, about 100 fold, about 200 fold, about 500 fold, or about
1000 fold.
In certain embodiments, the compound provided herein is a selective inhibitor
of a mutant HER2. In certain embodiments, the compound provided herein has a selectivity
against a mutant HER2 over a wild-type HER2 ranging from about 2 fold, about 4 fold, about
8 fold, about 20 fold, about 50 fold, about 100 fold, about 200 fold, about 500 fold, or about
1000 fold.
In certain embodiments, the nd ed herein is a selective inhibitor
of a mutant HER3. In certain embodiments, the compound provided herein has a selectivity
against a mutant HER3 over a wild-type HER3 ranging from about 2 fold, about 4 fold, about
8 fold, about 20 fold, about 50 fold, about 100 fold, about 200 fold, about 500 fold, or about
1000 fold.
In certain ments, the compound provided herein is a selective inhibitor
of a mutant HER4. In certain ments, the compound provided herein has a selectivity
against a mutant HER4 over a Wild HER4 ranging from about 2 fold, about 4 fold, about 8
fold, about 20 fold, about 50 fold, about 100 fold, about 200 fold, about 500 fold, or about
1000 fold.
In another embodiments, ed herein is a method for treating, preventing,
or ameliorating one or more symptoms of a proliferative disease in a subject, comprising
administering to the subject a therapeutically effective amount of a compound disclosed
herein, e.g., a compound of Formula I or XXI, or an enantiomer, a mixture of enantiomers, a
e of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically
acceptable salt, solvate, hydrate, or prodrug thereof.
] In certain embodiments, the subject is a . In certain embodiments, the
subject is a human. In certain embodiments, the subject is a primate other than a human, a
farm animal such as cattle, a sport animal, or a pet such as a horse, dog, or cat.
In certain embodiments, the ERBB-mediated condition, er, or disease is
a proliferative disease. In certain embodiments, the ERBB-mediated condition, disorder, or
disease is cancer. In certain embodiments, the ediated ion, disorder, or
disease is a drug-resistant cancer. In certain embodiments, the ERBB-mediated condition,
disorder, or disease is rug-resistant cancer. In certain embodiments, the ERBB-
mediated condition, disorder, or disease is relapsed rug-resistant cancer. In certain
embodiments, the ERBB-mediated condition, disorder, or disease is an inflammatory disease.
In certain embodiments, the ERBB-mediated condition, disorder, or disease is an immune
-lll-
disorder.
In certain embodiments, the erative disease is cancer. In certain
ments, the cancer is relapsed . In certain embodiments, the cancer is drug-
resistant cancer. In certain embodiments, the cancer is relapsed esistant cancer. In
certain embodiments, the cancer is multidrug-resistant cancer. In certain embodiments, the
cancer is ed multidrug-resistant cancer.
In certain embodiments, the cancer is ERBB inhibitor- resistant cancer. In
certain embodiments, the cancer is reversible ERBB tor— resistant cancer. In certain
embodiments, the cancer is irreversible ERBB tor- resistant cancer. In certain
embodiments, the cancer is relapsed ERBB inhibitor- resistant . In certain
embodiments, the cancer is relapsed reversible ERBB inhibitor- resistant cancer. In certain
embodiments, the cancer is relapsed irreversible ERBB tor- resistant cancer. In certain
embodiments, the cancer is resistant to afatinib, canertinib, dacomitinib, erlotinib, gefitinib,
icotinib, lapatinib, neratinib, pelitinib, varlitinib, or a combination thereof.
In certain embodiments, the cancer is EGFR inhibitor- resistant cancer. In
n embodiments, the cancer is reversible EGFR inhibitor— resistant cancer. In certain
embodiments, the cancer is irreversible EGFR inhibitor- resistant cancer. In certain
embodiments, the cancer is relapsed EGFR inhibitor— resistant cancer. In certain
embodiments, the cancer is relapsed reversible EGFR inhibitor- ant cancer. In certain
embodiments, the cancer is relapsed irreversible EGFR inhibitor— resistant .
In certain ments, the cancer is HER2 inhibitor- resistant cancer. In
certain embodiments, the cancer is reversible HER2 tor- resistant cancer. In certain
ments, the cancer is irreversible HER2 inhibitor— resistant cancer. In certain
embodiments, the cancer is relapsed HER2 inhibitor- resistant . In certain
embodiments, the cancer is relapsed reversible HER2 inhibitor- resistant cancer. In certain
embodiments, the cancer is relapsed irreversible HER2 tor- resistant cancer.
In certain embodiments, the cancer is HER3 inhibitor- resistant cancer. In
certain embodiments, the cancer is ible HER3 inhibitor- resistant cancer. In certain
embodiments, the cancer is irreversible HER3 inhibitor— resistant cancer. In certain
embodiments, the cancer is relapsed HER3 inhibitor- resistant cancer. In certain
embodiments, the cancer is relapsed reversible HER3 inhibitor- resistant cancer. In certain
-ll2-
embodiments, the cancer is relapsed irreversible HER3 inhibitor- resistant cancer.
In certain embodiments, the cancer is HER4 inhibitor- resistant . In
certain embodiments, the cancer is reversible HER4 inhibitor- resistant cancer. In certain
embodiments, the cancer is irreversible HER4 inhibitor— resistant cancer. In certain
embodiments, the cancer is relapsed HER4 tor- resistant cancer. In n
embodiments, the cancer is ed reversible HER4 inhibitor- resistant cancer. In certain
embodiments, the cancer is relapsed irreversible HER4 inhibitor- ant cancer.
In certain embodiments, the proliferative disease is an inflammatory disease.
In certain ments, the proliferative disease is an immune disorder.
The conditions, disorders, or diseases treatable with a compound provided
herein include, but are not limited to, (l) inflammatory or allergic diseases, including
systemic anaphylaxis and hypersensitivity disorders, atopic dermatitis, urticaria, drug
allergies, insect sting allergies, food allergies (including celiac disease and the like), and
mastocytosis; (2) atory bowel diseases, including Crohn's e, ulcerative colitis,
ileitis, and enteritis; (3) vasculitis, and Behcet's syndrome; (4) psoriasis and inflammatory
dermatoses, including dermatitis, eczema, atopic itis, allergic contact dermatitis,
urticaria, viral cutaneous pathologies including those derived from human papillomavirus,
HIV or RLV infection, bacterial, flugal, and other parasital cutaneous pathologies, and
cutaneous lupus matosus; (5) asthma and respiratory allergic diseases, including
ic asthma, exercise induced asthma, allergic rhinitis, otitis media, allergic conjunctivitis,
hypersensitivity lung diseases, and chronic obstructive pulmonary disease; (6) mune
diseases, including arthritis (including rheumatoid and psoriatic), systemic lupus
matosus, type I diabetes, myasthenia gravis, multiple sclerosis, ' disease, and
glomerulonephritis; (7) graft rejection (including allograft ion and graft-v-host disease),
e.g., skin graft rejection, solid organ transplant rejection, bone marrow transplant rejection; (8)
fever; (9) cardiovascular disorders, including acute heart failure, hypotension, hypertension,
angina pectoris, myocardial infarction, cardiomyopathy, congestive heart failure,
atherosclerosis, ry artery disease, restenosis, and vascular stenosis; (10)
cerebrovascular disorders, including traumatic brain injury, , ischemic reperfiasion
injury and aneurysm; (11) cancers of the breast, skin, prostate, , uterus, ovary, testes,
r, lung, liver, larynx, oral cavity, colon and gastrointestinal tract (e.g., esophagus,
stomach, pancreas), brain, thyroid, blood, and lymphatic system; (12) f1brosis, connective
-ll3-
2015/021455
tissue disease, and sarcoidosis, (13) genital and reproductive conditions, including erectile
dysfunction; (14) gastrointestinal disorders, including gastritis, ulcers, nausea, pancreatitis,
and ng; (15) neurologic disorders, including Alzheimer's disease; (16) sleep ers,
including insomnia, narcolepsy, sleep apnea syndrome, and Pickwick Syndrome; (17) pain;
(18) renal disorders; (19) ocular disorders, including glaucoma,; and (20) infectious diseases,
including HIV.
In n ments, the cancer treatable with a nd provided herein
includes, but is not limited to, (1) leukemias, including, but not limited to, acute leukemia,
acute lymphocytic leukemia, acute myelocytic leukemias such as myeloblastic,
locytic, myelomonocytic, monocytic, oleukemia leukemias and myelodysplastic
syndrome or a symptom thereof (such as , thrombocytopenia, neutropenia, bicytopenia
or pancytopenia), refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with
excess blasts (RAEB), RAEB in transformation (RAEB-T), preleukemia, and chronic
myelomonocytic leukemia (CMML), (2) chronic leukemias, including, but not d to,
c myelocytic locytic) leukemia, chronic lymphocytic leukemia, and hairy cell
leukemia; (3) polycythemia vera; (4) lymphomas, including, but not limited to, Hodgkin's
disease and non-Hodgkin's disease; (5) multiple myelomas, including, but not limited to,
smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell
leukemia, solitary cytoma, and extramedullary plasmacytoma; (6) Waldenstrom's
macroglobulinemia; (7) monoclonal gammopathy of rmined significance; (8) benign
monoclonal gammopathy; (9) heavy chain disease; (10) bone and connective tissue sarcomas,
including, but not limited to, bone sarcoma, osteosarcoma, chondrosarcoma, s
sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma,
soft-tissue as, angiosarcoma (hemangiosarcoma), f1brosarcoma, Kaposi’s sarcoma,
leiomyosarcoma, liposarcoma, lymphangiosarcoma, metastatic cancers, neurilemmoma,
rhabdomyosarcoma, and synovial sarcoma; (11) brain tumors, including, but not limited to,
glioma, ytoma, brain stem glioma, ependymoma, oligodendroglioma, nonglial tumor,
acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma,
pineoblastoma, and primary brain lymphoma; (12) breast cancer, including, but not limited to,
adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast
cancer, mucinous breast cancer, tubular breast cancer, ary breast , primary
cancers, Paget’s disease, and inflammatory breast cancer; (13) adrenal cancer, including, but
not limited to, romocytom and adrenocortical carcinoma; (14) thyroid cancer,
—114—
including, but not limited to, papillary or follicular thyroid cancer, medullary thyroid cancer,
and anaplastic d cancer; (15) pancreatic cancer, including, but not d to,
insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid
or islet cell tumor; (16) pituitary cancer, including, but limited to, Cushing’s disease,
prolactin-secreting tumor, acromegaly, and diabetes insipius; (l7) eye cancer, including, but
not limited, to ocular melanoma such as iris melanoma, choroidal melanoma, and ry
body ma, and retinoblastoma; (l 8) vaginal cancer, including, but not limited to,
us cell carcinoma, adenocarcinoma, and melanoma; (l9) vulvar cancer, including, but
not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma,
sarcoma, and Paget’s disease; (20) cervical cancers, including, but not limited to, squamous
cell oma, and adenocarcinoma; (21) uterine cancer, including, but not limited to,
endometrial carcinoma and uterine sarcoma; (22) ovarian cancer, including, but not limited to,
n epithelial carcinoma, borderline tumor, germ cell tumor, and l tumor; (23)
esophageal cancer, including, but not d to, squamous cancer, arcinoma, d
cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma,
melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; (24)
stomach cancer, including, but not limited to, adenocarcinoma, fiangating (polypoid),
ulcerating, superficial spreading, diffusely spreading, ant lymphoma, liposarcoma,
f1brosarcoma, and carcinosarcoma; (25) colon cancer; (26) rectal cancer; (27) liver cancer,
including, but not limited to, hepatocellular carcinoma and hepatoblastoma; (28) gallbladder
cancer but not limited to, adenocarcinoma; (29) cholangiocarcinomas, including,
, including,
but not limited to, pappillary, nodular, and e; (30) lung cancer, including, but not
limited to, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma),
adenocarcinoma, large-cell carcinoma, and small-cell lung cancer; (3 l) testicular cancer,
including, but not limited to, germinal tumor, seminoma, anaplastic, classic (typical),
spermatocytic, nonseminoma, embryonal oma, teratoma carcinoma, and
choriocarcinoma (yolk-sac tumor); (32) te cancer, including, but not limited to,
adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; (33) penal cancer; (34) oral
cancer, ing, but not limited to, squamous cell oma; (35) basal cancer; (36)
salivary gland cancer, including, but not limited to, adenocarcinoma, mucoepidermoid
carcinoma, and adenoidcystic carcinoma; (37) pharynx cancer, ing, but not limited to,
squamous cell cancer and verrucous; (38) skin cancer, including, but not limited to, basal cell
carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma,
nodular melanoma, lentigo ant melanoma, and acral lentiginous melanoma; (3 9)
-ll5-
WO 43148
kidney , including, but not limited to, renal cell cancer, adenocarcinoma,
hypemephroma, fibrosarcoma, and transitional cell cancer (renal pelvis and/or ); (40)
Wilms’ tumor; (41) bladder cancer, including, but not limited to, transitional cell oma,
squamous cell cancer, adenocarcinoma, and carcinosarcoma; and other , including, not
limited to, myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangio-
endotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, lial carcinoma,
cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland
carcinoma, ary carcinoma, and papillary adenocarcinomas (See n et al., 1985,
Medicine, 2d Ed., J.B. Lippincott Co., Philadelphia and Murphy et al., 1997, Informed
Decisions: The Complete Book ofCancer Diagnosis, Treatment, and Recovery, Viking
Penguin, Penguin Books U.S.A., Inc., United States of America).
In certain embodiments, the proliferative disease is bladder cancer, brain
tumor, breast cancer, cancer of the mouth and throat, colorectal cancer, lung cancer, or
pancreatic cancer, prostate cancer, h cancer, or c cancer.
In certain embodiments, the proliferative disease is lung cancer. In certain
embodiments, the proliferative disease is drug-resistant lung cancer. In certain embodiments,
the erative disease is multidrug-resistant lung cancer. In certain embodiments, the
proliferative e is relapsed lung cancer. In certain embodiments, the proliferative
disease is relapsed drug-resistant lung cancer. In certain ments, the proliferative
disease is relapsed multidrug-resistant lung cancer. In certain embodiments, the proliferative
disease is non-small cell lung cancer. In certain ments, the proliferative disease is
drug resistant non-small cell lung cancer. In certain embodiments, the proliferative disease is
multidrug resistant non-small cell lung cancer. In certain embodiments, the proliferative
disease is relapsed all cell lung cancer. In n embodiments, the proliferative
disease is relapsed drug resistant non-small cell lung cancer. In certain embodiments, the
proliferative disease is relapsed multidrug resistant non-small cell lung cancer.
Depending on the disorder, disease, or condition to be treated, and the
subject’s condition, the compounds or ceutical compositions provided herein can be
administered by oral, parenteral (e.g, intramuscular, intraperitoneal, intravenous, ICV,
intracistemal injection or infusion, subcutaneous injection, or implant), inhalation, nasal,
vaginal, rectal, sublingual, or topical (e.g., transdermal or local) routes of administration and
can be formulated, alone or together, in suitable dosage unit with ceutically acceptable
-ll6-
WO 43148
excipients, carriers, adjuvants, and vehicles appropriate for each route of administration.
Also provided is stration of the compounds or pharmaceutical compositions provided
herein in a depot formulation, in which the active ingredient is released over a predefined
time period.
In the treatment, prevention, or amelioration of one or more symptoms of the
disorders, es, or conditions described herein, an appropriate dosage level generally is
ranging from about 0.001 to 100 mg per kg subject body weight per day (mg/kg per day),
from about 0.01 to about 75 mg/kg per day, from about 0.1 to about 50 mg/kg per day, from
about 0.5 to about 25 mg/kg per day, or from about 1 to about 20 mg/kg per day, which can
be administered in single or multiple doses. Within this range, the dosage can be ranging
from about 0.005 to about 0.05, from about 0.05 to about 0.5, from about 0.5 to about 5.0,
from about 1 to about 15, from about 1 to about 20, or from about 1 to about 50 mg/kg per
day.
For oral administration, the ceutical compositions provided herein can
be formulated in the form of tablets containing from about 1.0 to about 1,000 mg of the active
ingredient, in one ment, about 1, about 5, about 10, about 15, about 20, about 25,
about 50, about 75, about 100, about 150, about 200, about 250, about 300, about 400, about
500, about 600, about 750, about 800, about 900, and about 1,000 mg of the active ingredient
for the symptomatic adjustment of the dosage to the patient to be treated. The pharmaceutical
compositions can be administered on a regimen of l to 4 times per day, including once,
twice, three times, and four times per day.
It will be understood, however, that the specific dose level and frequency of
dosage for any particular patient can be varied and will depend upon a variety of s
including the activity of the specific compound employed, the metabolic stability and length
of action of that compound, the age, body weight, general health, sex, diet, mode and time of
administration, rate of excretion, drug combination, the severity of the particular condition,
and the host undergoing therapy.
In one embodiment, provided herein is a method of inhibiting the growth of a
cell, sing ting the cell with a compound provided herein, e.g., a compound of
Formula I or XXI, or a single enantiomer, a racemic mixture, a mixture of reomers, or
an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
-ll7-
In another embodiment, provided herein is a method of inhibiting the growth
of a cell in a subject, comprising administering to the subject a compound disclosed herein,
e.g., a compound of Formula I or XXI, or a single enantiomer, a racemic e, a mixture
of diastereomers, or an ic variant thereof; or a pharmaceutically acceptable salt, solvate,
or g thereof.
In certain embodiments, the cell is a cancer cell. In n embodiments, the
cell contains an ERBB variant.
In one embodiment, provided herein is a method for modulating the activity of
a tyrosine kinase, in one embodiment, an ERBB , comprising contacting the ERBB
kinase with a compound disclosed herein, e.g., a compound of Formula I or XXI, or a single
enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant f; or a
pharmaceutically acceptable salt, solvate, or prodrug thereof.
] In another embodiment, ed herein is a method for modulating the
activity of a tyrosine kinase, in one embodiment, an ERBB kinase, in a subject, comprising
administering to the subject a compound disclosed herein, e.g., a compound of Formula I or
XXI, or a single enantiomer, a c e, a mixture of diastereomers, or an isotopic
variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
In certain embodiments, the ERBB is a wild-type ERBB. In certain
embodiments, the ERBB is an ERBB variant. In certain embodiments, the ERBB is an
EGFR. In certain embodiments, the ERBB is a wild-type EGFR. In certain embodiments,
the ERBB is an EGFR variant. In certain embodiments, the ERBB is a HER2. In certain
embodiments, the ERBB is a wild-type HER2. In certain embodiments, the ERBB is a HER2
variant. In certain embodiments, the ERBB is a HER3. In certain embodiments, the ERBB is
a wild-type HER3. In certain ments, the ERBB is a HER3 variant. In certain
embodiments, the ERBB is a HER4. In certain embodiments, the ERBB is a wild-type HER4.
In certain embodiments, the ERBB is a HER4 variant.
The compound ed herein, e.g., a compound of Formula I or XXI, or an
enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic
variant thereof; or a ceutically acceptable salt, solvate, hydrate, or g thereof;
can also be combined or used in combination with other agents or therapies useful in the
treatment, prevention, or amelioration of one or more symptoms of the conditions, disorders,
WO 43148
or diseases for which the compounds provided herein are useful.
Suitable other therapeutic agents can also include, but are not limited to, (1)
alpha-adrenergic agents; (2) antiarrhythmic agents; (3) anti-atherosclerotic agents, such as
ACAT tors; (4) antibiotics, such as anthracyclines, bleomycins, mitomycin,
dactinomycin, and plicamycin; (5) ncer agents and cytotoxic agents, e.g., alkylating
agents, such as nitrogen mustards, alkyl sulfonates, nitrosoureas, ethylenimines, and triazenes;
(6) anticoagulants, such as acenocoumarol, argatroban, rudin, din, fondaparinux,
heparin, phenindione, warfarin, and Ximelagatran; (7) anti-diabetic agents, such as ides
(e.g., metformin), idase inhibitors (e.g., acarbose), insulins, meglitinides (e.g.,
repaglinide), sulfonylureas (e.g., glimepiride, glyburide, and glipizide), thiozolidinediones
(e.g., troglitazone, rosiglitazone, and pioglitazone), and PPAR-gamma agonists; (8)
antifungal agents, such as amorolfine, amphotericin B, anidulafungin, bifonazole, butenafine,
butoconazole, caspofiangin, ciclopirox, clotrimazole, econazole, fenticonazole, filipin,
azole, isoconazole, itraconazole, ketoconazole, micafungin, miconazole, ne,
natamycin, nystatin, oxyconazole, nazole, posaconazole, din, sertaconazole,
sulconazole, terbinafine, terconazole, tioconazole, and voriconazole; (9) antiinflammatories,
e.g., non-steroidal anti-inflammatory agents, such as aceclofenac, acemetacin, amoxiprin,
aspirin, azapropazone, benorilate, nac, carprofen, celecoxib, e magnesium
salicylate, diclofenac, diflunisal, ac, etoricoxib, faislamine, fenbufen, fenoprofen,
flurbiprofen, ibuprofen, indometacin, ketoprofen, ketorolac, lomoxicam, loxoprofen,
lumiracoxib, meclofenamic acid, mefenamic acid, meloxicam, metamizole, methyl salicylate,
magnesium salicylate, nabumetone, naproxen, nimesulide, oxyphenbutazone, parecoxib,
phenylbutazone, piroxicam, salicyl salicylate, sulindac, yrazone, suprofen, tenoxicam,
tiaprofenic acid, and tolmetin; (10) antimetabolites, such as folate antagonists, purine
ues, and pyrimidine analogues; (11) anti-platelet agents, such as GPIIb/IIIa blockers
(e.g., abciximab, eptifibatide, and tirofiban), P2Y(AC) antagonists (e.g., clopidogrel,
ticlopidine and CS-747), azol, dipyridamole, and aspirin; (12) antiproliferatives, such as
methotrexate, FK506 (tacrolimus), and mycophenolate mofetil; (13) anti-TNF antibodies or
soluble TNF receptor, such as etanercept, rapamycin, and leflunimide; (14) aP2 inhibitors;
(15) drenergic agents, such as carvedilol and metoprolol; (l6) bile acid sequestrants,
such as questran; (l7) calcium channel blockers, such as amlodipine te; (18)
chemotherapeutic agents; (19) cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib and
rofecoxib; (20) cyclosporins; (21) xic drugs, such as azathioprine and
cyclophosphamide; (22) diuretics, such as chlorothiazide, hydrochlorothiazide, flumethiazide,
umethiazide, flumethiazide, methylchlorothiazide, trichloromethiazide,
polythiazide, benzothiazide, ynic acid, ticrynafen, chlorthalidone, furosenide,
muzolimine, bumetanide, triamterene, amiloride, and spironolactone; (23) endothelin
converting enzyme (ECE) inhibitors, such as phosphoramidon; (24) enzymes, such as L-
asparaginase; (25) Factor VIIa Inhibitors and Factor Xa Inhibitors; (26) famesyl-protein
transferase inhibitors; (27) fibrates; (28) growth factor inhibitors, such as modulators of
PDGF activity; (29) growth e secretagogues; (30) HMG CoA ase inhibitors,
such as pravastatin, lovastatin, atorvastatin, simvastatin, NK-104 (a.k.a. itavastatin,
nisvastatin, or nisbastatin), and ZD-4522 (also known as rosuvastatin, atavastatin, or
visastatin); neutral ptidase (NEP) inhibitors; (3 l) hormonal agents, such as
glucocorticoids (e.g., one), estrogens/antiestrogens, androgens/antiandrogens,
progestins, and luteinizing hormone-releasing hormone antagonists, and octreotide acetate;
(32) immunosuppressants; (33) mineralocorticoid receptor antagonists, such as
spironolactone and eplerenone; (34) ubule-disruptor agents, such as ecteinascidins; (35)
ubule-stabilizing agents, such as pacitaxel, docetaxel, and epothilones A-F; (36) MTP
Inhibitors; (37) niacin; (38) phosphodiesterase inhibitors, such as PDE III inhibitors (e.g.,
cilostazol) and PDE V inhibitors (e.g., sildenafil, tadalafil, and vardenafil); (39) plant-derived
products, such as vinca alkaloids, epipodophyllotoxins, and taxanes; (40) platelet activating
factor (PAF) antagonists; (41) um coordination complexes, such as cisplatin, satraplatin,
and carboplatin; (42) potassium channel openers; (43) prenyl-protein transferase inhibitors;
(44) protein ne kinase inhibitors; (45) renin inhibitors; (46) squalene synthetase
inhibitors; (47) steroids, such as erone, beclometasone, betamethasone,
deoxycorticosterone acetate, ortisone, hydrocortisone (cortisol), prednisolone,
prednisone, methylprednisolone, dexamethasone, and triamcinolone; (48) TNF-alpha
inhibitors, such as tenidap; (49) thrombin inhibitors, such as hirudin; (50) thrombolytic agents,
such as anistreplase, reteplase, tenecteplase, tissue plasminogen activator (tPA), recombinant
tPA, streptokinase, urokinase, prourokinase, and lated plasminogen streptokinase
activator complex (APSAC); (5 l) thromboxane receptor antagonists, such as ban; (52)
topoisomerase inhibitors; (53) vasopeptidase inhibitors (dual NEP-ACE inhibitors), such as
omapatrilat and gemopatrilat; and (54) other miscellaneous agents, such as, hydroxyurea,
procarbazine, mitotane, hexamethylmelamine, and gold nds.
] In certain embodiments, the other therapies that may be used in combination
-l20-
with the compounds provided herein include, but are not limited to, surgery, endocrine
therapy, biologic response modifiers (e.g. , interferons, interleukins, and tumor necrosis factor
(TNF)), hyperthermia and cryotherapy, and agents to attenuate any adverse effects (e.g.,
antiemetics).
In certain embodiments, the other therapeutic agents that may be used in
combination with the compounds provided herein include, but are not limited to, alkylating
drugs (mechlorethamine, chlorambucil, cyclophosphamide, melphalan, and ifosfamide),
antimetabolites (cytarabine (also known as cytosine arabinoside or Ara-C), HDAC (high dose
cytarabine), and rexate), purine nists and pyrimidine antagonists (6-
mercaptopurine, 5-fluorouracil, cytarbine, and abine), e s (vinblastine,
vincristine, and vinorelbine), podophyllotoxins (etoposide, irinotecan, and can),
antibiotics (daunorubicin, doxorubicin, bleomycin, and mitomycin), nitrosoureas (carmustine
and ine), enzymes (asparaginase), and hormones (tamoxifen, leuprolide, flutamide, and
megestrol), imatinib, adriamycin, dexamethasone, and cyclophosphamide. For a more
comprehensive discussion of updated cancer therapies; See, /www.nci.nih.gov/, a list of
the FDA approved oncology drugs at http://www.fda.gov/cder/cancer/druglistframe.htm, and
The Merck Manual, Seventeenth Ed. 1999, the entire contents of which are hereby
incorporated by reference.
In another embodiment, the method provided herein comprises administration
of a compound provided herein, e.g., a compound of Formula I or XXI, or an enantiomer, a
mixture of enantiomers, a e of two or more diastereomers, or an isotopic variant
thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, together
with administering one or more chemotherapeutic agents and/or therapies selected from:
alkylation agents (e.g., cisplatin, carboplatin); antimetabolites (e.g., methotrexate and S-FU);
antitumour antibiotics (e.g., adriamymycin and bleomycin); antitumour ble alkaloids
(e.g., taxol and ide); antitumor hormones (e.g., dexamethasone and tamoxifen);
mour immunological agents (e.g., interferon 0t, [3, and y); radiation therapy; and surgery.
In certain embodiments, the one or more chemotherapeutic agents and/or therapies are
administered to the t before, during, or after the administration of the compound
provided .
Such other agents, or drugs, can be administered, by a route and in an amount
commonly used therefor, aneously or sequentially with the compound provided herein,
-lZl-
e.g., a compound of Formula I or XXI, or an enantiomer, a mixture of enantiomers, a mixture
of two or more diastereomers, or an isotopic t thereof; or a ceutically acceptable
salt, solvate, hydrate, or prodrug thereof. When a compound provided herein is used
contemporaneously with one or more other drugs, a pharmaceutical composition containing
such other drugs in addition to the compound ed herein can be utilized, but is not
required. Accordingly, the pharmaceutical compositions provided herein include those that
also contain one or more other active ingredients or therapeutic agents, in addition to a
compound provided herein.
] The weight ratio of a compound provided herein to the second active
ingredient can be , and will depend upon the ive dose of each ingredient.
Generally, an effective dose of each will be used. Thus, for example, when a compound
provided herein is combined with a NSAID, the weight ratio of the compound to the NSAID
can range from about l,000:l to about l:l,000, or about 200:1 to about 1:200. Combinations
of a compound provided herein and other active ingredients will generally also be within the
aforementioned range, but in each case, an effective dose of each active ingredient should be
used.
] The compounds provided herein can also be provided as an article of
manufacture using packaging materials well known to those of skill in the art. See, 6.g. , US.
Pat. Nos. 5,323,907; 558; and 5,033,252. Examples ofpharmaceutical packaging
materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags,
vials, containers, syringes, and any packaging material suitable for a selected formulation and
intended mode of administration and treatment.
Provided herein also are kits which, when used by the l practitioner,
can fy the stration of appropriate amounts of active ingredients to a subject. In
certain embodiments, the kit provided herein includes a container and a dosage form of a
compound provided herein, e.g., a compound of Formula I or XXI, or an enantiomer, a
mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant
thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
In n embodiments, the kit includes a container comprising a dosage form
of the compound ed herein, e.g., a compound of Formula I or XXI, or an enantiomer, a
mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant
-l22-
thereof; or a pharmaceutically acceptable salt, solvate, e, or g thereof; in a
container comprising one or more other therapeutic agent(s) described herein.
Kits provided herein can further include devices that are used to administer the
active ingredients. es of such devices include, but are not limited to, syringes, needle-
less injectors drip bags, patches, and inhalers. The kits ed herein can also include
condoms for administration of the active ingredients.
Kits provided herein can further e pharmaceutically acceptable vehicles
that can be used to administer one or more active ingredients. For example, if an active
ingredient is provided in a solid form that must be reconstituted for parenteral administration,
the kit can comprise a sealed container of a le e in which the active ingredient can
be dissolved to form a particulate-free sterile solution that is suitable for parenteral
administration. Examples of pharmaceutically acceptable es include, but are not
limited to: aqueous vehicles, including, but not limited to, Water for Injection USP, Sodium
Chloride ion, Ringer’s Injection, Dextrose Injection, Dextrose and Sodium Chloride
Injection, and Lactated Ringer’s Injection; water-miscible vehicles, including, but not limited
to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and ueous es,
including, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate,
pyl myristate, and benzyl benzoate.
The disclosure will be fiarther understood by the following non-limiting
examples.
EXAMPLES
As used herein, the symbols and conventions used in these processes, schemes
and examples, regardless of whether a particular abbreviation is cally defined, are
consistent with those used in the porary scientific literature, for example, the Journal
of the American Chemical Society or the Journal of Biological Chemistry. Specifically, but
without limitation, the following abbreviations may be used in the examples and hout
the specification: g (grams); mg (milligrams); mL (milliliters); uL (microliters); L, (liter);
mM (millimolar); uM molar); Hz (Hertz); MHz (megahertz); mmol (millimoles); eq.
(equivalent); hr or hrs (hours); min (minutes); MS (mass spectrometry); NMR (nuclear
magnetic resonance); ESI (electrospray ionization); HPLC (high-performance liquid
chromatography or high pressure liquid chromatography); ACN, (acetonitrile); CDC13
(deuterated chloroform); DCM (dichloromethane); DMA (N,N-dimethylacetamide); DME
(dimethoxyethane); DMF (N,N—dimethylformamide); DMSO (dimethylsulfoxide); DMSO-d6
(deuterated dimethylsulfoxide); EtOAc (ethyl acetate); EtzO (diethyl ether); EtOH (ethanol);
MeOH (methanol); PE leum ether); THF (tetrahydrofuran); DIPEA (N,N-
diisopropylethylamine); TEA (triethylamine); TFA (trifluoroacetic acid); BOP
(benzotriazole- l -yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate); HATU
(2-(7-aza- 1H-benzotriazole- l -yl)-l , l ,3 ,3 -tetramethyluronium hexafluorophosphate); TBTU
nzotriazol- l -yl)-N,N,N’,N’-tetramethyluronium tetrafluoroborate); DIPC (l ,3-
diisopropylcarbodiimide); MszO (methanesulfonic anhydride); Me (methyl); Et (ethyl); z'Pr,
opyl); tBu (tert-butyl); Boc (tert—butoxylcarbony); Bn (benzyl); Ph (phenyl); Ms
(mesylate); and AcO (acetate).
HPLC-MS analyses were performed on Waters HPLC 2790 coupled with
Waters ass ZQ 4000 (Model MAA050) as a mass detector and with Waters 2487 UV
as a UV-visible detector, using a KINETEXTM reversed phase column (5 uM XB-Cl 8- 100 A,
50 x 4.6 mm; Phenomenex, 00BE0). The mobile phase were eluent A (water, 0.05%
TFA) and eluent B , 0.05% TFA). The HPLC was run at 1 mL/min with a linear
gradient from 10% B to 90% B for 8 min, followed by 90% B isocratic for 2 min, with the
total run time of 10 min.
For all of the following examples, standard p and cation methods
known to those skilled in the art can be utilized. Unless otherwise indicated, all temperatures
are expressed in 0C (degrees Centigrade). All reactions conducted at room temperature
unless otherwise noted. Synthetic methodologies herein are intended to exemplify the
applicable chemistry through the use of ic examples and are not indicative of the scope
of the sure.
Example lA
Cell Proliferation Assay
The biological activity of a test compound was determined using cell
proliferation assays. The activity against wild-type ERBBl was ined using A43l
human epidermoid carcinoma cells (ATCC) and human epidermal keratinocytes, neonatal, or
HEKn cells . The ty against mutant ERBBl was determined using HCC827
human NSCLC adenocarcinoma cells (ATCC), which has a deletion of E746-A759 in exon
—124—
19. The activity against a drug-resistant mutant ERBBl was ined using H1975 human
NSCLC adenocarcinoma cells (ATCC), which has the T790M mutation in-cz’s with the
L858R mutation.
A431 cells were grown in DMEM (Invitrogen) supplemented with 10% FBS
), 1% llin-streptomycin, and 2 mM glutamine (Invitrogen). HEKn cells were
grown in EPILIFE® rogen) supplemented with HKGS (Invitrogen). HCC827 and
H1975 were cultured in RPM11640 supplemented with 10% FBS ), 1% penicillin-
streptomycin, and 2 mM glutamine (Invitrogen). Cells were maintained and propagated at 37
0C and 5% C02 in a humidified cell e incubator. Aliquots of cells from early passages
were preserved for liquid nitrogen e. Frozen vials of cells were thawed at 37 0C water
bath. Cells were spun to remove freezing medium. The newly revived frozen cells were
adapted in e for 10 days before used for compound testing. Cells used in the assay were
less than 20 subculture passages or 3 months in culture.
The test compounds were dissolved in dimethylsulfoxide (DMSO) and stored
at -20 0C before testing. For the cell proliferation assays, cells were seeded in 96-well plates
(Costar, 3917) at various numbers: A431 cells at 2,000 cells per well, HEKn, HCC827, and
H1975 at 1,000 cells per well. The cells were placed in a culture incubator overnight. Next
day, test compounds in DMSO were added to the cells and placed back in the culture
incubator for 72 hrs. In the meantime, the cell numbers at time zero of the compound
treatment (T0) was ed by ENERCOUNT® (Codex BioSolutions). At the end of the
compound treatment, the cell numbers were again measured by EnerCount as T72 values.
The untreated controls (Ctrl) were cell numbers recorded from the 0.1% DMSO treatment.
The percent growth inhibition by the test compound was calculated by the formula: (1- (T72-
T0)/(Ctrl-T0)) x 100. The G150, the compound concentration at which 50% of cell growth is
inhibited, was determined from the 10-point dose-response growth inhibition using non-linear
sigmoidal curve fitting using ad Prism.
The results are summarized in Tables 1 and 2, wherein A represents a value no
greater than 500 nM, B represents a value greater than 500 nM but no greater than 1 uM, C
represents a value greater than 1 uM but no greater than 5 uM, and D ents a value
greater than 5 uM; and wherein A’ represents a ratio of greater than 10, B’ represents a ratio
of no greater than 10 but no less than 5, C’ represents a ratio of no greater than 5 but no less
than 2, and D’ ents a ratio of no greater than 2.
TABLE 1. Inhibition of Cell Proliferation
G150
Cmpd.
HCC827 H1975 HEKn A431
A1 —A C A
A2 —A D
A3 —A C
A4 —A C
A5 C
Erlotinib 7.0 4381 2200
Afatinib 1.0 —120 21 1.
C0—1686 32 109 2500
TABLE 2. Selectivity
Ratio ild-t e ERBBl/Mutant ERBBl
cmpd°
HEKn/H1975 A431/H1975
A1 A3 A3
A2 A3 D3
A3 A3 D3
A4 c3 D3
As A3 c3
DrDDnD—— D3
ADDnD—-_ D3 D3
co-msa—— A3
Example 1
sis of benzyl uoronitrophenoxy)piperidine-l-carboxylate 8
The synthesis of benzyl 4-(2-fluoronitrophenoxy)piperidine-l-carboxylate
8 is shown in Scheme 1.
Scheme 1
NYC OH
M320 013 F
O N\
EtsN Cbz K2C03 00N\
Step I Cbz
-l26-
2015/021455
] Step I: Dry benzyl 4-hydroxypiperidinecarboxylate (50 mmol, 11.8 g) was
dissolved in dry DCM (100 mL) at 0 0C. Methanesulfonic anhydride (50 mmol, 8.74 g) was
added, followed by addition of triethylamine (62.5 mmol, 8.70 mL). The on was stirred
for 30 min at room temperature. DCM was stripped. The residue obtained was dried under
high vacuum for 5 min to afford benzyl 4-((methylsulfonyl)oxy)piperidinecarboxylate 8,
which was directly used in the next step without fiarther treatment.
Step II: Benzyl 4-((methylsulfonyl)oxy)piperidinecarboxylate (estimated to
be 25 mmol) in DMF (25 mL) was added to a sion of 2-fluoronitrophenol (25
mmol, 4.33 g) and K2C03 (100 mmol, 13.8 g) in DMF (50 mL). The reaction was heated and
stirred at 80 0C for 4 hrs, then another equivalent of benzyl 4-((methylsulfonyl)oxy)-
piperidine-l-carboxylate (25 mmol estimated) in DMF (25 mL) was added. The mixture was
stirred at 70 0C overnight. DMF was stripped under reduced pressure. The residue obtained
was diluted with 250 mL of EtOAc. The EtOAc solution was washed with saturated
NaHCOg (40 mL), water (40 mL), and brine (40 mL), dried with Na2S04, and concentrated.
The residue obtained was ted to silica gel chromatography purification (0-40% EtOAc)
to afford benzyl 4-(2-fluoronitrophenoxy)piperidinecarboxylate 8 as brownish foam in
40% yield (3.8 g).
Example 2
Synthesis of tert—butyl (R)(7-((1-((benzyloxy)carbonyl)piperidinyl)oxy)(2-
methylisonicotinamido)- 1H—benzo[d]imidazolyl)azepanecarboxylate 4
The synthesis of utyl (R)-3 -(7-((1-((benzyloxy)carbonyl)piperidin
yl)oxy)(2-methylisonicotinamido)-1H—benzo[d]imidazolyl)azepanecarboxylate 4 is
shown in Scheme 2.
Step I: To benzyl 4-(2-fluoronitrophenoxy)piperidinecarboxylate 8 (10.1
mmol, 3.80 g) in DMF (20 mL) was added DIPEA (11.1 mmol, 1.94 mL) and tert—butyl (R)-
3-aminoazepane-l-carboxylate (10.1 mmol, 2.16 g). The reaction was stirred at 100 0C for 4
hrs, then ved in 150 mL of EtOAc, washed with water (20 mL), 0.1N HCl aq. (20 mL),
brine (20 mL), saturated NaHC03 (30 mL), and water, and dried over Na2S04. Then, the
solvent was stripped off under d pressure. The residue obtained was purified by silica
gel flash-chromatography (25% to 40% EtOAc in hexane) to afford tert—butyl (R)((2-((l-
((benzyloxy)carbonyl)piperidinyl)oxy)nitrophenyl)amino)azepanecarboxylate 7 as
yellow solid in 57.9% yield (3.3 g).
Scheme 2
N02 CN‘BOC N02 Zn/AcOH NH2
F —, —>
NH NH
step I 0 step H O
N—Boc
N—Boc
\Cbz N
Cbz/ O/
CK 7 Cbz’ 6
N \)—NH _
>—NH2 HO
—N N \ /N
BrCN N \
o I O
O —> N—Boc
g5 N_Boc N
HATU O/
Step m Cbz/ 4
Cbz/
Step II: To a mixture of tert—butyl (R)((2-((l-((benzyloxy)carbonyl)-
piperidinyl)oxy)nitrophenyl)amino)azepane-l-carboxylate 7 (3.30 g, 5.80 mmol) in
acetic acid (20 mL) was added zinc powder (5.57 g, 87 mmol) in batches under en at 0
0C. The reaction was stirred at 25 0C for 20 min. Then the reaction was filtered and the cake
was washed with DCM. The combined organic solution was stripped off solvents. The
residue obtained was stirred in 16 mL of 0.2 N NaOH aq. (130 mL) for 3 min, and then
extracted with EtOAc (200 mL x 3). The combined organic phase was washed with sodium
potassium tartrate solution (1 g in 30 mL of water), and brine, dried with NaZSO4 and
concentrated. The e obtained, containing tert—butyl (R)((2-amino((l-
((benzyloxy)carbonyl)piperidinyl)oxy)phenyl)amino)azepane- l -carboxylate 6, was
ly used in the next step of reaction without further ation.
[0033 1] Step III: A mixture of utyl ((2-amino((l-((benzyloxy)-
carbonyl)piperidinyl)oxy)phenyl)amino)azepane-l-carboxylate 6 (3. 12 g, 5.8 mmol) and
cyanogen bromide (9.7 mmol, 3.2 mL of 3M DCM on) dissolved in MeOH (30 mL) and
water (10 mL) was stirred at 52 0C for 2.5 hrs in a sealed tube. The solvents were stripped
and the residue obtained was basified with saturated sodium carbonate solution. The reaction
was then extracted with EtOAc (80 mL x 3). The combined organic layers were washed with
brine and water, dried over sodium sulfate, and evaporated to dryness. The residue obtained
was purified by silica gel chromatography (Eth/EtOAc, 5 to 20%), yielding tert—butyl (R)
(2-amino(( l -((benzyloxy)carbonyl)piperidinyl)oxy)- l H-benzo [d]imidazol- l -
-l28-
yl)azepanecarboxylate 5 as tanish powder in 76% yield (2.50 g).
Step IV: 2-Methylisonicotinic acid (0.392 g, 2.858 mmol) and HATU (1.09 g,
2.858 mmol) were dissolved in a DCM/DMF mixture (total 10 mL, 1:1). DIPEA (0.671 mL,
4.083 mmol) was added and the reaction was stirred for 10 min before adding to a solution of
tert-butyl (R)-3 -(2-amino(( 1 -((benzyloxy)carbonyl)piperidinyl)oxy)- 1H-
benzo[d]imidazolyl)azepanecarboxylate (1 . 15 g, 2.04 mmol) in F (10 mL,
1:1). After one hour of stirring, the on was stripped off ts. The residue was
dissolved in EtOAc (200 mL). The c solution was washed with NaOH aq. (1N, 40 mL
x 3), brine (40 mL), dried with Na2S04, and concentrated. The residue obtained was purified
on a silica gel column (0-2% methanol in DCM) to afford 1.2 g (86%) of tert—butyl (R)(7-
((1 -((benzyloxy)carbonyl)piperidinyl)oxy)(2-methylisonicotinamido)- 1H-
benzo[d]imidazolyl)azepanecarboxylate 4.
Example 3
Synthesis of utyl (R)-3 -(7-(( 1 -ethylpiperidinyl)oxy)(2-methylisonicotinamido)-
1H-benzo[d]imidazolyl)azepanecarboxylate 2 and tert—butyl (R)-3 -(7-((l -
acetylpiperidinyl)oxy)(2-methylisonicotinamido)- 1H-benzo[d]imidazolyl)azepane
carboxylate 2’
[003 3 3] The synthesis of tert—butyl (R)-3 -(7-((1-ethylpiperidinyl)oxy)(2-
methylisonicotinamido)-1H-benzo[d]imidazolyl)azepanecarboxylate 2 and tert—butyl
(R)-3 -(7-(( 1 -acetylpiperidinyl)oxy)(2-methylisonicotinamido)- 1H-benzo [d]imidazol
yl)azepanecarboxylate 2’ is shown in Scheme 3.
Step I: Tert—butyl (R)(7-((1-((benzyloxy)carbonyl)piperidinyl)oxy)(2-
methylisonicotinamido)-1H—benzo[d]imidazolyl)azepanecarboxylate 4 (1.2 g, 1.757
mmol) and Pd/C (0.1 g, 10% Pd on carbon) were stirred in EtOAc/methanol e (1 :1, 20
mL) under hydrogen atmosphere for 3 hrs. The reaction was filtered through celite and the
filtrate was concentrated to give tert—butyl (R)(2-(2-methylisonicotinamido)(piperidin-
4-yloxy)-1H—benzo[d]imidazolyl)azepanecarboxylate 3 in 78% yield (0.96 g).
] Step II: Ethyl iodide (30.66 uL) was dissolved in 1 mL ofDMA and 0.1 mL of
this on was added to a suspension of tert—butyl (R)(2-(2-methy1isonicotinamido)
(piperidin—4-yloxy)-1H—benzo[d]imidazolyl)azepanecarboxylate 3 (20 mg, 0.0365
mmol) and N32C03 (6.8 mg, 0.064 mmol) in 1 mL of DMA. The reaction was stirred at
room ature for 2 days, filtered through celite, and washed with ethanol. Then the
filtrate was stripped off solvents to afford tert—butyl (R)(7-((1-ethylpiperidinyl)oxy)
(2-methylisonicotinamido)-1H—benzo[d]imidazolyl)azepanecarboxylate 2 (21 mg).
LC/MS showed retention time of 0.43 min (HPLC column: 2.1 x 30 mm, 1.7 um c18; Eluent:
1-99% ACN in water with 5 mM HCl; 1 min run; t flow rate: 12 mL/min) and correct
mass ( M+1 calculated for Chemical Formula C32H44N6O4 is , observed 577.6). The
compound was directly used in the next step of reaction without purification.
Scheme 3
Step III: Acetic acid (0.185 mmol, 11.1 mg) and HATU (0.185 mmol, 70.3
mg) were mixed in DMA (1 mL), followed by addition of DIPEA (47.7 mg, 0.37 mmol).
After five minutes of stirring, the reaction was transferred to a solution of tert-butyl (2-
(2-methylisonicotinamido)(piperidinyloxy)-1H-benzo[d]imidazolyl)azepane
carboxylate 3 (94.2 mg, 0.1718 mmol) in DMA (1 mL). The reaction was filrther stirred for
1 hr, then filtered, and purified by HPLC (column 75 X 30 mm, 5 um c18, 1-99% ACN in
water with 5 mM HCl, mass triggered collection) to yield tert—butyl (7-((1-
acetylpiperidinyl)oxy)(2-methylisonicotinamido)-1H-benzo[d]imidazolyl)azepane
carboxylate 2’ in 51 mg.
Example 4
sis of (R)-N—(l-(azepanyl)(piperidinyloxy)-lH—benzo[d]imidazol- 2-yl)
methylisonicotinamide 1”
The synthesis of (R)-N—(l-(azepanyl)(piperidinyloxy)-1H-
benzo[d]imidazol- 2-yl)methylisonicotinamide 1” is shown in Scheme 4.
Scheme 4
QNOE>— N
\ NH \
HCl in e ©N>_NH —
—» \ /
CW O
N—Boc
1" C
[003 3 8] Tert—butyl (R)-3 -(2-(2-methylisonicotinamido)(piperidinyloxy)- 1H-
benzo[d]imidazol-l-yl)azepane-l-carboxylate (50 mg, 0.091 mmol) was dissolved in 1 mL of
MeOH. A solution of4M HCl in dioxane (3 mL, 12 mmol) was added. The reaction was
stirred at room temperature for 5 hrs and then HCl and solvents were stripped. The residue
obtained, a HCl salt of (R)-N—(l-(azepanyl)((l-ethylpiperidinyl)oxy)-1H-
benzo[d]imidazolyl)methylisonicotinamide, was directly used in the next step of
reaction without further treatment.
sis of (R)-N—(7-(( l -acetylpiperidinyl)oxy)- l -(azepan-3 -yl)- lH—benzo [d]imidazol
yl)methylisonicotinamide 1 ’
[003 3 9] The synthesis of (R)-N—(7-((l -acetylpiperidinyl)oxy)- l -(azepanyl)-1H-
benzo[d]imidazolyl)methylisonicotinamide 1’ is shown in Scheme 5.
Scheme 5
(DO/Q:WW— N
\ \
NH ©:N>_ IoNH _
TFA, DCM
\ /
N’Boc NH
N .
2' \n/ 1
Tert—butyl (R)-3 -(7-(( l -acetylpiperidinyl)oxy)(2-
-l3l-
isonicotinamido)-lH-benzo[d]imidazolyl)azepane-l-carboxylate 2’ (51 mg, 0.086
mmol) was dissolved in DCM. Trifluoroacetic acid (0.5 mL) was added and the reaction was
stirred at room temperature for 1 hr. The solvents were stripped. The residue obtained was
dissolved in 150 mL of a solvent (1 :2 volume ratio of IPA:DCM) and washed with aq.
NaHCOg (15 mL), brine (20 mL), dried with NazSO4, filtered, and concentrated to yield (R)-
N—(7-((1-acetylpiperidinyl)oxy)(azepanyl)-1H—benzo[d]imidazolyl)
methylisonicotinamide 1’ in 52 mg.
Example 6
Synthesis of (R)-N-( 1 -(azepan-3 -yl)((l piperidinyl)oxy)- 1H—benzo [d]imidazol
yl)methylisonicotinamide 1
The synthesis of (R)-N-(1-(azepanyl)((1-ethylpiperidinyl)oxy)-1H-
benzo[d]imidazolyl)methylisonicotinamide 1 is shown in Scheme 6.
Scheme 6
©N>—N\ N
NH _
HCl in dioxane \ NH
N _
A HCl salt of (1-(azepanyl)((1-ethylpiperidinyl)oxy)-1H-
benzo[d]imidazolyl)methylisonicotinamide 1 (23 mg) was prepared from compound 2,
following the synthetic procedures of compound 1”. LC/MS showed retention time of 0.45
min (HPLC column: 2.1 x 30 mm, 1.7 um c18; Eluent: 1-99% ACN in water with 5 mM
HCl; 1 min run; t flow rate: 12 mL/min) and correct mass ( M+l expected: 477.29,
observed 477.6).
Example 7
sis of (R)-N-(7-((1-acetylpiperidinyl)oxy)(1-acryloylazepan-3 -yl)- 1H-
benzo[d]imidazolyl)methylisonicotinamide A2
] The synthesis of (R)-N-(7-((1-acetylpiperidinyl)oxy)(1-acryloylazepan-
3-yl)-1H—benzo[d]imidazolyl)methylisonicotinamide A2 is shown in Scheme 7.
Scheme 7
@flidN\ N\>—NH
me“ E1 @
OH\ / O\ /
HATU o a
Acrylic acid (0.127 mmol, 9.1 mg) and HATU (48.4 mg, 0.127 mmol) were
mixed in DMA (1 mL), followed by addition of DIPEA (0.212 mmol, 27.4 mg). After 5
minutes of stirring, the mixture was transferred into a solution of (R)-N-(7-((1-acetyl-
piperidinyl)oxy)(azepan-3 -yl)- 1H-benzo[d]imidazolyl)methylisonicotinamide 1 ’
(52 mg, 0.106 mmol) in DMA (1 mL). The reaction was further d for 1 hr and then was
stripped off DMA, directly dry-loaded onto a silica gel column, and eluted with 1-10%
MeOH in DCM. The expected t was isolated in 33 mg. LC/MS showed the correct
mass of M+1 = 545.5 (calculated to be 545.28 for C30H36N6O4) with Rt = 0.42 min (HPLC
: 2.1 x 30 mm, 1.7 um c18; Eluent: 1-99% ACN in water with 5 mM HCl; 1 min run;
solvent flow rate: 12 mL/min). 1H NMR (400 MHz, chloroform-d) 5 12.59 (s, 1H), 8.68 (dd,
J: 15.1, 4.7 Hz, 1H), 7.96 (d, J: 13.2 Hz, 1H), 7.88 (dd, J: 12.1, 5.3 Hz, 1H), 7.27 — 7.11
(m, 1H), 6.99 (dd, J: 19.6, 8.1 Hz, 1H), 6.93 — 6.74 (m, 1H), 6.65 (dt, .1: 16.5, 11.4 Hz,
1H), 6.53 — 6.21 (m, 1H), 5.83 — 5.64 (m, 1H), 5.55 (q, .1: 10.6, 8.5 Hz, 1H), 4.81 (d, J: 7.4
Hz, 2H), 4.63 — 4.33 (m, 2H), 4.04 (t, J: 15.4 Hz, 1H), 3.91 (h, J: 8.6, 7.8 Hz, 2H), 3.85 —
3.59 (m, 3H), 3.59 — 3.10 (m, 5H), 2.69 (d, J: 3.7 Hz, 5H), 2.35 — 1.68 (m, 13H), 1.37 (t, J:
13.0 Hz, 1H).
Example 8
Synthesis of (R)-N-(1-(1-acryloylazepan-3 -((1 -acryloylpiperidinyl)oxy)- 1H-
benzo[d]imidazolyl)methylisonicotinamide A3
The synthesis of (R)-N-(1-(1-acryloylazepanyl)((1-acryloylpiperidin
yl)oxy)-1H—benzo[d]imidazolyl)methylisonicotinamide A3 is shown in Scheme 8.
Acrylic acid (0.2 mmol, 14.4 mg) and HATU (76.1 mg, 0.20 mmol) were
mixed in DMA (1 mL), followed by addition of DIPEA (0.575 mmol, 74.2 mg). After 5
s of stirring, the mixture was transferred into a solution of (R)-N-(1-(azepan-3 -yl)
(piperidin—4-yloxy)-1H—benzo[d]imidazolyl)methylisonicotinamide (0.091 mmol) in
DMA (1 mL). The reaction was further stirred for 1 hr and then was stripped off DMA,
directly dry-loaded onto silica gel column, and eluted with 1-10% MeOH in DCM. The
expected product was isolated in 17 mg. LC/MS showed the t mass of M+1 = 557.5
lated to be 557.28 for C31H36N6O4) with Rt = 0.45 min (HPLC column: 2.1 x 30 mm,
1.7 mm cl8; Eluent: 1-99% ACN in water with 5 mM HCl; 1 min run; t flow rate: 12
mL/min). 1H NMR (400 MHZ. cthroformwd) 6 12.57 (s, 1H), 8.70 (t. J: 4.9 Hz, 1H). 8.66
((81,144, 1.4112, 1H), 8.31 (dd,.1===~ 8.4, , 1H), 8.10 7.91 (m, 1H), 7.33 (dd, J====
8.4, 4.4 Hz, 1H), 7.27 — 7.15 (m. 1H), 7.03 (m, 03H), 6.99 (d, J: 8.0 Hz. 0.71%), 6.88 - 6.82
(m, 03H), 6.78 (d, .1 8.4 Hz, 0.711), 669 ~ 6.58 (m. 11:1), 647 — 6.194161, 11%),584 - 5.63
(111,211), 5.62 — 5.45 (m, 1H}, 4.86 (131‘ s, 1H), 4.66 4.33 (in, 1H), 4.29 3.29 (m, 7H}, 3.18
(q, .1 7.4 Hz, 1H), 2.75 (s, 2.11%), 12.73 (.0961). 1.57 — 1.99(D'1,7H).
Scheme 8
Example 9
Synthesis of (R)-N-(1-(1-Acryloylazepan-3 -yl)chloro(trifluoromethoxy)- 1H-
benzo[d]imidazolyl)methylisonicotinamide A4
The synthesis of (R)-N-(1-(1-Acryloylazepanyl)chloro
(trifluoromethoxy)-1H—benzo[d]imidazolyl)methylisonicotinamide A4 is shown in
Scheme 9.
] A solution of 2-nitrotrifluoromethoxy-aniline 21 (40.0 g, 0.180 mol) and N-
chlorosuccinimide (30.0 g, 0.225 mol) in ACN (300 mL) was heated at 70 0C for 4 hrs. The
mixture was then cooled down to room temperature and diluted with saturated NH4Cl
on (600 mL) and ethyl acetate (600 mL). The organic layer was washed with water
(200 mL) and dried over Na2S04. Evaporation of solvent under reduced pressure gave a dark
orange solid, which on trituration with hexane gave 2-chloronitro(trifluoromethoxy)-
aniline 22 as an orange solid in 50% yield (23.0 g). 1H NMR (400 MHZ, chloroform-d) 5
8.03 (dq, J: 2.7, 0.9 Hz, 1H), 7.52 — 7.46 (m, 1H), 6.60 (s, 2H).
—134—
Scheme 9
F3CO N02
F3CO(112: —» F3CO
CuClz Cl
[Bu-ONO Cl
N-Cl
22 23
HC ’BOC F3CO F3CO NHZ
Zn/AcOH C1
DIPEA
NzBoc N/Boc
24 25
F3CO :\>—NH2 F3CO N
HOOC \— N \>—NH _
—> N N BICN C10\ /
HATU C1
N,Boc N’B00
DIPEA
26 27
F3CO F3CO
\quNH\>—NH HOOC/\ N\>_NH —
N N
HATU C1
DIPEA
A4 N’é/
To a suspension of copper (II) chloride (12.6 g, 93.5 mmol) and t—butyl nitrite
(13.9 mL, 117 mmol) in anhydrous ACN (100 mL) at 61 0C was added a solution of ro-
6-nitro(trifluoromethoxy)aniline 22 (20.0 g, 78.0 mmol) in acetonitrile (100 mL) dropwise.
The mixture was stirred at 61 0C for 1 hr after the addition. The solvent was removed, and
the residue was treated with 4N HCl (350 mL) and extracted with EtOAc (150 mL x 3). The
extracts were combined, dried over NaZSO4, and purified by silica gel chromatography
e: EtOAc from 20:1 to 10: 1) to give nd 23 in 67% yield (14.5 g) as orange oil.
1H NMR (400 MHz, Chloroform—d) 7.61 (dq, J: 1.7, 0.8 Hz, 1H), 7.60 (dq, J = 2.7, 0.9 Hz,
1H).
nd 24 was prepared following the procedures in step I of Example 2.
1H NMR (400 MHz, chloroform-d) a 7.98 — 7.77 (m, 1H), 7.46 (d, .1: 21.0 Hz, 1H), 7.11 (d,
.1: 9.6 Hz, 0.5H), 6.61 (d, .1: 10.3 Hz, 0.5H), 4.28 (m, 0.5H), 4.08 (br s, 0.5H), 3.85 — 3.42
(m, 2.7H), 3.26-3.00 (m, 1.3H), 2.01-1.76 (m, 1.7H), 1.78 — 1.59 (m, 2.8H), 1.54—1.30 (m,
1.54H), 1.45 (s, 5.3H), 1.39 (s, 3.7H).
] Compound 25 was prepared following the procedures in step 11 of Example 2.
Compound 26 was prepared following the procedures in step 111 of Example 2.
MS ated for titled compound (M+1+) 449.15; ed 449.4 with HPLC retention time
0.59 min.
Compound 27 was prepared following the procedures in step IV of Example 2.
Compound 28 was prepared following the procedures in Example 5.
[003 5 5] (R)-N—(1-(1-Acryloylazepanyl)—7-chloro(trifluoromethoxy)-1H-
benzo[d]imidazolyl)methylisonicotinamide A4 was prepared following the procedures
in Example 7 or 8.: MS observed for C24H23C1F3N503 (M+H+): 522.3; HPLC retention time:
0.55 min. 1H NMR (400 MHz, acetonitrile-d3) 512.65 (s, 1H), 8.62 (t, J: 5.8 Hz, 1H), 8.49-
8.42 (m, 1H), 8.40-8.33 (m, 1H), .49 (m, 1H), .28 (m, 1H), 6.78 (ddd, J: 16.7,
13.2, 10.4 Hz, 1H), 6.27 (ddd, J: 16.7, 10.0, 2.3 Hz, 1H), 5.78-5.47 (m, 2H), 4.65 (ddd, J:
19.1, 14.0, 10.4 Hz, 1H), 4.29-3.89 (m, 2H), 3.84-3.67 (m, 1H), 2.95 (two singlets, total 3H),
2.73-2.60 (m, 2H), 2.19-2.00 (m, 2H), 1.55-1.46 (m, 2H).
Example 10
Synthesis of nds A1 and A5
Compounds A1 and A5 were prepared following the procedures as described
in Examples 7 and 8.
[003 5 7] (R)-N—(1-(1-Acryloylazepan-3 -yl)(( 1 -ethylpiperidinyl)oxy)- 1H-
benzo[d]imidazolyl)methylisonicotinamide A1: MS observed for C30H38N603 (M+H+):
531.4; HPLC retention time: 0.33 min.
[003 5 8] (R,E)-N—(7-Chloro(1-(4-(dimethylamino)butenoyl)azepan-3 -yl)
(trifluoromethoxy)-1H—benzo[d]imidazo1yl)methylisonicotinamide A5: MS observed
for C27H30ClF3N603 (M+H+): 579.3; HPLC retention time: 0.44 min. 1H NMR (400 MHz,
methanol-d4) 58.85 (dd, J: 6.1, 2.0 Hz, 1H), 8.56-8.43 (m, 2H), 7.60-7.51 (m, 1H), 7.43-
7.35 (m, 1H), 7.12-6.99 (m, 1H), 6.80 (dtd, J: 14.8, 7.2, 3.2 Hz, 1H), 5.78-5.51 (m, 1H),
4.79-4.68 (m, 1H), 4.38-4.15 (m, 2H), 4.02 (d, J: 7.2 Hz, 2H), 3.97-3.77 (m, 2H), 2.96 and
2.91 (two singlets, total 9H), 2.28-1.94 (m, 5H), 1.59-1.46 (m, 1H).
Example 11
Synthesis ofN—(l-((R)acryloylazepanyl)chloro((2-oxopyrrolidin-3 -yl)oxy)- 1H-
benzo[d]imidazolyl)methylisonicotinamide C1
The synthesis ofN—( 1 -((R)acryloylazepanyl)chloro((2-
oxopyrrolidinyl)oxy)-1H—benzo[d]imidazolyl)methylisonicotinamide C1 is shown in
Scheme 10.
Scheme 10
g\>—NHN N
_ 1. TFA _
O N N O N N
o \ / g\>—NHo O\ /
0 2. Hooc/\ C1
N’BOC N
HATU
“N “N
DIPEA /
] Step I: A mixture of tert-butyl (R)(6-(benzyloxy)chloro(2-
methylisonicotinamido)-1H—benzo[d]imidazolyl)azepanecarboxylate 31 (1.1 g) and
% Pd/C (0.194 g) in MeOH (5 mL) was purged by vacuume and then filled with hydrogen
from a balloon. The reaction mixture was stirred under hydrogen at room ature for 4
hrs. The catalyst Pd/C was filtered through a pad of celite and the pad was washed with
MeOH. The combined solution was concentrated to give nd 32 in a tative yield
(932 mg).
Step II: To a solution of 3-hydroxy-pyrrolidinone (200 mg, 1.97 mmol) in
DCM (5 mL) was added MszO (539 mg, 3.1 mmol) and pyridine (2 mL) at 0 0C. The
reaction mixture was stirred at 0 0C for 20 min and then overnight at room temperature. The
reaction mixture was concentrated under reduced pressure. The residue was dissolved in
isopropanol/CHC13 (1 :3; 40 mL),washed with saturated NaHCOg, dried over ous
Na2S04, and evaporated to dryness under reduced pressure to give 2-oxopyrrolidin-3 -yl
methanesulfonate 33 in 38% yield (137 mg).
To a solution of compound 32 (200 mg, 0.4 mmol) in DMF (2 mL) under N2
was added C82C03 (98 mg, 0.6 mmol) and compound 33 (108 mg, 0.6 mmol). The reaction
mixture was stirred at 55 0C overnight. After the mixture was cooled down to room
temperature, saturated NH4Cl (10 mL) was added. The reaction mixture was extracted with
isopropanol/CHClg (1 :3; 3 x 30 mL). The organic phase was washed with brine, dried over
anhydrous Na2S04, concentrated under reduced pressure, and purf1ed by column
chromatography on silica gel with DCM:MeOH (100:0 to 90: 10) to give tert—butyl (3R)(7-
(2-methylisonicotinamido)((2-oxopyrrolidin-3 -yl)oxy)-1H-benzo[d]imidazol
yl)azepane-l-carboxylate 34. MS observed for C29H35C1N605: 583.2 (M+H+); HPLC
retention time: 7.72 min.
Step III: To a solution of acrylic acid (20.4 mg, 0.28 mmol) in DMA (1 mL)
under N2 at -20 0C was added HATU (107 mg, 0.28 mmol) and DIPEA (61 mg, 0.47 mmol).
After stirred at 0 0C for 20 min, the mixture was added to a solution of compound 34 (120
mg, 0.25 mmol) in DMA (1 mL). After d at room temperature for 2 hrs, the reaction
mixture was diluted with isopropanol/CHClg (1 :3; 60 mL), washed with 1N NaOH (2 x 20
mL), dried over anhydrous Na2S04, concentrated under reduced pressure, and purified by
column tography on silica gel with DCM;MeOH (100:0 to 90:10) to give ofN—(l-
((R)acryloylazepanyl)chloro((2-oxopyrrolidin-3 y)- 1H-benzo dazol
yl)methylisonicotinamide C1 in 15.5% yield (20 mg) for the last 2 steps. 1H NMR (400
MHz,CDC13): 5 12.7 (bs, 1H), 8.64 (m, 1H), 7.90-7.93 (m, 1H), 7.81-7.84 (m, 1H), 7.34-7.40
(m, 1H), 7.17-7.23 (m, 1H), 6.64 (m, 1H), 6.37-6.43 (m, 1H), 5.96 (s, 1H), .75 (m, 1H),
4.74-4.88 (m, 2H), 4.41-4.58 (m, 1H), 3.83-4.23 (m, 2H), 3.40-3.64 (m, 4H), 1.45-2.79 (m,
10H); MS observed for C27H29C1N6O4: 537.7 (M+H+); HPLC retention time: 4.92 min.
Compounds 31 was prepared according to Scheme 11 and Example 17.
Scheme 11
N/Boc N02
N02 PhCHZONa
—,F NH —’
F F C1
C1 N/Boc
NO2 NH2
Zn/AcOH BrCN
BnO NH BnO NH _,
C1 C1
N/Boc N/Boc
30a 30b
\ _ N\
>_NH2 _
HOOC \ N N>_NH
B110 N / B110 N
0 \ /
Example 12
Synthesis ofN—(1-((R)acryloy1azepany1)chloro(((tetrahydrofi1ran-3 -y1)oxy)-1H-
benzo[d]imidazoly1)methy1isonicotinamide C2
The synthesis ofN—(1-((R)acryloy1azepan-3 -chloro
(((tetrahydrofi1rany1)oxy)-1H—benzo[d]imidazo1y1)methy1isonicotinamide C2 is
shown in Scheme 12.
Step I: To a solution of 3-hydroxytetrahydrofuran (200 mg, 1.55 mmol) in
DCM (5 mL) was added MszO (539 mg, 3.10 mmol) and pyridine (367 mg, 4.65 mmol) at
-10 0C. After stirred at room temperature overnight, the reaction e was diluted with
DCM (10 mL), washed with saturated NaHCOg, dried over anhydrous Na2S04, and
evaporated to dryness under d pressure to give tetrahydrofurany1methanesulfonate
in 89% yield (285 mg).
Scheme 12
OMS N
\>_N N
H o
_ 6 I?“HiN o 35 o \ /
HO N
\ N Cl
0 / —>
C1 CsZCO3
N/Boc O
1. TFA \>—NH _
—> O N
\ /N
O 0
2. Hooc/\ C1
HATU
DIPEA /
The conversion from compound 32 to compound 36 was performed according
to the procedures as described in Example ll. (3R)-Tert—butyl 3-(7-chloro(2-
methylisonicotinamido)((tetrahydrofuran-3 -yl)oxy)- lH-benzo dazol- l -yl)azepane- l -
carboxylate 36: MS calculated for C29H36ClN505: 570.6 (M+H+); HPLC retention time: 8.39
min.
Step II: The coversion from compound 36 to compound C2 was performed
according to the procedures as described in Example 11. N—(l-((R)-l-Acryloylazepanyl)—
7-chloro(((tetrahydrofuran-3 -yl)oxy)- lH-benzo[d]imidazolyl)methylisonicotinamide
C2: 1H NMR(400 MHz, CDClg): 5 12.7 (m, 1H), 8.64 (m, 1H), 7.90-7.93 (m, 1H), 7.81-7.83
(m, 1H), 7.14-7.21 (m, 1H), .66 (m, 1H), 6.36-6.43 (m,lH), .88 (m, 2H), 4.96-
4.99 (m, 1H), 4.41-4.58 (m, 1H), 3.84-4.08 (m, 6H), .68 (m, 1H), 1.49-2.79 (m, (m,
13H); MS observed for C27H30C1N504: 524.1 ; HPLC retention time: 7.14 min.
Example 13
Synthesis of (R)-N—(l -( l oylazepan-3 -yl)chloro((tetrahydro-2H-pyranyl)oxy)—
lH—benzo[d]imidazolyl)methylisonicotinamide C3
ogkmedN \ /N
6 00
O in
—140—
Compound C3 was prepared according to the procedures as described in
Example 12. MS observed for C28H32C1N504: 538.6 (M+H+); HPLC retention time: 2.09
min.
Example 14
Synthesis of (R)-N—(1-(1-acryloylazepanyl)chloro((tetrahydro-2H-pyranyl)oxy)—
1H—benzo[d]imidazolyl)(trifluoromethyl)isonicotinamide C4
£1”deN CF3
O N
o O\ /N
Compound C4 was prepared according to the procedures as described in
Example 12. MS observed for C28H29C1F3N504: 592.1 (M+H+); HPLC retention time: 2.14
min.
e 1 5
Synthesis of (R)-N—(1-(1-acryloylazepan-3 -yl)chloro((1 , 1 -dioxidotetrahydro-2H-
thiopyranyl)oxy)- 1H-benzo[d]imidazolyl)methylisonicotinamide C5
nd CS was prepared according to the procedures as described in
e 12. MS observed for eOsS: 586.0 (M+H+); HPLC retention time: 1.94
min.
—141—
Example 1 6
Synthesis of (R)-N—(1-(1-acryloylazepanyl)chloro(pyrimidinyloxy)- 1H-
benzo[d]imidazolyl)methylisonicotinamide C6
The synthesis of (R)-N—(1-(1-acryloylazepanyl)chloro(pyrimidin
yloxy)-1H—benzo[d]imidazolyl)methylisonicotinamide C6 is shown in Scheme 13.
Scheme 13
£1vaN 1-
—> O N
\ N
O /
2. Hooc/\ C1
HATU J
DIPEA \N /
Step I: To a solution of compound 32 (200 mg, 0.4 mmol) in DMF (2 mL)
was added C82C03 (99 mg, 0.6 mmol) and 2-chloropyrazine (90 mg, 0.6 mmol). After stirred
at 55 0C overnight, the reaction mixture was cooled down to room temperature and saturated
NH4C1 (10 mL) was added. The mixture was extracted with isopropanol/CHClg (1:3; 3 x 30
mL). The organic phase was washed with brine, dried over anhydrous , concentrated
under reduced pressure, and purfied by column chromatography on silica gel using
DCM:MeOH (100:0 to 90: 10) to give nd 37 in 30% yield (70 mg) HPLC retention
time: 8.15 min.
Step II: The sion from compound 37 to nd C6 was performed
according to the procedures as described in Example 11. MS observed for C27H26C1N703:
532.27 (M+H+); HPLC retention time: 7.01 min.
—142—
e 1 7
Synthesis of (R)-tert—butyl 3 inochloro(((R)-tetrahydrofuran-3 -yl)oxy)- 1H-
benzo[d]imidazol- l -yl)azepane- l -carboxylate 45
The synthesis of ((R)-tert—butyl 3-(2-aminochloro(((R)-tetrahydrofuran-
3-yl)oxy)-lH-benzo[d]imidazol-l-yl)azepane-l-carboxylate 45 is shown in Scheme 14.
Scheme 14
N /Boc N02 N02
—>F NH fl 0 NH
F F C1 C1
C1 N/Boc N/Boc
OQNHNH2 BrCN N
Zn/ACOH \>—NH2
C1 0 N
N’Boc 6C] O N/Boc
44 O
Step I: A on of 2-chloro-l,3-difluoronitrobenzene 41 (3.29 g, 16.99
mmol) and tert—butyl (R)aminoazepane-l-carboxylate (4.0 g, 18.69 mmol) in DME (80
mL) was stirred at 85 0C for 4 hrs. The reaction was quenched with water (100 mL) and
extracted with EtOAc (3 x 100 mL). The organic layers were combined and dried over
anhydrous Na2S04. The t was removed under reduced pressure and the residue was
purified by flash chromatography on silica (eluent PE/EtOAc = 10: l~5 : l) to give compound
42 in 85% yield (5.6 g). TLC Rf = 0.5 (PE/EtOAc = 5:1, UV 254 nm).
Step II: To a solution of (R)hydroxyltetrahedrofiJran (1.82 g, 20.63 mmol)
in DME (100 mL) at 0 0C was added NaHMDS (10.83 mL, 2 M in THF, 21.66 mmol)
dropwise. After stirred at 0 0C for 15 min, the e was then added dropwise to a solution
of tert—butyl (R)((2-chlorofluoronitrophenyl)amino)azepane-l-carboxylate 42 (4.0 g,
.31 mmol) in DME (50 mL) at 0 0C. The reaction mixture was heated at 50 0C for 2 hrs.
After the mixture was cooled to 0 0C, ice water (100 mL) was added and extracted with
EtOAc (3 x 200 mL). The organic layers were combined and dried over anhydrous Na2S04.
—143—
The solvent was removed under reduced pressure and the residue was purified by flash
chromatography on silica (eluent PE/EtOAc = 10: 1~2: 1) to give tert—butyl (R)((2-chloro
nitro(((R)-tetrahydrofuranyl)oxy)phenyl)amino)azepanecarboxylate 43 in 61% yield
(2.88 g). TLC Rf = 0.35 (PE/EtOAc = 2:1, UV 254 nm).
] Step III: The conversion from compound 43 to compound 45 was carried out
ing to the procedures as described in Example 2 and Scheme 2.
Example 1 8
Synthesis ofN-( 1 -((R)acryloylazepan-3 -chloro(((R)-tetrahydrofuran-3 y)-
zo[d]imidazolyl)methylisonicotinamide C7
The synthesis ofN—( 1 -((R)acryloylazepanyl)chloro(((R)-
tetrahydrofi1ranyl)oxy)-1H—benzo[d]imidazolyl)methylisonicotinamide C7 is shown
in Scheme 15.
Scheme 15
N —> OQuid\ N
0 /
2. Hooc/\ C1
HATU
DIPEA /
[003 80] The conversion from compound 45 to compound 46 was performed according
to the procedures as described Example 2 and Scheme 2. The conversion from compound 46
to compound C7 were performed according to the procedures as described in Example 11.
N—( 1 -((R)Acryloylazepan-3 -yl)chloro(((R)-tetrahydrofi1ran-3 -yl)oxy)-1H-
benzo[d]imidazolyl)methylisonicotinamide C7. MS observed for C27H30C1N504: 524.6
(M+H+); HPLC retention time: 2.14 min.
—144—
Example 1 9
Synthesis ofN-( l -((R)- l -acryloylazepan-3 -yl)chloro(((R)—tetrahydrofuran-3 -yl)oxy)-
1H-benzo[d]imidazolyl)(trifluoromethyl)isonicotinamide C8
[003 8 l] N—( l -((R)- l -Acryloylazepan-3 -yl)chloro(((R)-tetrahydrofi1ran-3 -yl)oxy)-
lH—benzo[d]imidazolyl)(trifluoromethyl)isonicotinamide C8 was sized according
to the procedures as described in e 18. MS observed for ClF3N504: 576.4
(M+H'), 578.2 (M+H+); HPLC retention time: 1.85 min.
Example 20
Synthesis ofN—( l -((R)- l -acryloylazepan-3 -chloro(((S)—tetrahydrofi1ran-3 -yl)oxy)-
lH—benzo[d]imidazolyl)methylisonicotinamide C9
01?:*2:de\ /
[003 82] N—( l -((R)- l -Acryloylazepan-3 -yl)chloro(((S)-tetrahydrofuran-3 -yl)oxy)-
lH—benzo[d]imidazolyl)methylisonicotinamide C9 was synthesized according to the
procedures as described in Example 18. MS observed for C27H30ClN504: 522.5 (M-H');
HPLC retention time: 2.05 min.
—145—
Example 21
Synthesis ofN—( 1 -((R)acryloylazepan-3 -yl)chloro(((S)—tetrahydrofi1ran-3 -yl)oxy)-
1H-benzo[d]imidazolyl)(trifluoromethyl)isonicotinamide C 10
0);:[E>—NHO\_CN
QC1 NJ;
[003 83] N—( 1 -((R)Acryloylazepan-3 -chloro(((S)-tetrahydrofuran-3 -yl)oxy)-
1H-benzo[d]imidazolyl)(trifluoromethyl)isonicotinamide C 10 was synthesized
according to the procedures as described in Example 18. MS observed for C27H27C1F3N504:
576.5 (M-H'); HPLC retention time: 1.85 min.
Example 22
Synthesis of (R)-N—(1-(1-(3-chloropropanoyl)azepanyl)((1-methylpiperidinyl)oxy)-
1H-benzo [d]imidazolyl)methylisonicotinamide D 1 and (R)-N—(1-(1-acryloylazepan-3 -
yl)((1 -methylpiperidinyl)oxy)-1H-benzo[d]imidazolyl)methylisonicotinamide D2
[003 84] The synthesis of (1-(1-(3-chloropropanoyl)azepan-3 -yl)((1-
methylpiperidinyl)oxy)- zo [d]imidazolyl)methylisonicotinamide D1 and (R)-
N—( 1 -( 1 -acryloylazepan-3 -(( 1 -methylpiperidinyl)oxy)- 1H-benzo [d]imidazolyl)—2-
methylisonicotinamide D2 is shown in Scheme 16.
Scheme 16
:>—\ NH
\—/N _2, 1. TFA
HCOH \—/N
0/o NCN’BOC NaBH(0Ac)3 /UO C:,BOC 2. C1CH2CH2CZOH
HN HATU
3 51
DIPEA
W0 2015/143148
Step I: To a solution of compound 3 (510 mg, 0.929 mmol) in 1.2-
dichloroethane (3 mL) at 0 0C was added HCOOH (120 mg, 1.39 mmol) and NaBH(OAc)3
(256 mg). After the reaction mixture was d at room ature for 3 hrs, water (10
mL) was added and the mixture was extracted with CHClg/isoporpanol (3:1, 30 mL x 3). The
organic phase was dried with anhydrous Na2SO4 and concentrated under reduced pressure.
The resulting residue was used directly in the next step without further purification.
Step II: The conversion from compound 51 to compound D1 was performed
according to the ures as described in Example 11. First, compound 51 was d
with TFA to form a free amine. To a solution of the free amine (400 mg, 0.865 mmol) in
anhydrous THF under N2 at -30 0C was added 3-chloropropanyl acid (113 mg), DIPEA (223
mg), and HATU (390 mg). The reaction mixture was d to slowly warm up to room
temperature. After stirred at room ature for 1 hr, the LC-MS showed no starting
material left. Isopropanol/CHC13 (1 :3; 60 mL) and H20 (30 mL) was added. The organic
phase was washed with NaHCOg, dried over anhydrous Na2SO4, concentrated under reduced
pressure, and purified via Combi-Flash (1-10% MeOH in DCM) to give compound D1. MS
observed for C29H37C1N603: 553.1 (M+H+); HPLC retention time: 6.81 min.
[003 87] Step III: To a solution of compound D1 (514 mg) in dioxane (5 mL) was
added NaOH (104 mg) in H20 (2 mL). After the reaction e was stirred at 50 0C for 1
hr, LC-MS showed no ng material left. The reaction mixture was extracted with
isopropanol and CHC13(1 :3) (60 mL). The organic phase was concentrated and purified via
Combi-Flash (1-10% MeOH in DCM) to give compound D2 in 31% yield (149 mg) for the
last three steps. MS ed for C29H36N603: 517.6 (M+H+); HPLC retention time: 6.92
min.
Example 23
Synthesis of (R)-N-(1-(1-acryloylazepan-3 -yl)(( 1 -cyclopropylpiperidinyl)oxy)- 1H-
benzo[d]imidazolyl)(trifluoromethyl)isonicotinamide D3
mmCF3
V10 02
—147—
[003 8 8] (R)-N—(l -( l -Acryloylazepan-3 -yl)((l -cyclopropylpiperidinyl)oxy)- lH-
benzo[d]imidazolyl)(trifluoromethyl)isonicotinamide D3 was synthesized according to
the procedures as described in Example 22. MS observed for C31H35F3N603: 597.5 (M+H+);
HPLC retention time: 2.10 min.
e 24
Synthesis of (R)-N—( l -( l -acryloylazepan-3 -yl)(( l propylpiperidin—4-yl)oxy)- lH-
benzo[d]imidazolyl)methylisonicotinamide D4
[003 89] (R)-N—(l -( l -Acryloylazepan-3 -yl)((l -cyclopropylpiperidinyl)oxy)- lH-
benzo[d]imidazolyl)methylisonicotinamide D4 was synthesized according to the
procedures as described in Example 22. MS observed for C31H38N603: 543.6 (M+H+); HPLC
retention time: 1.99 min.
Example 25
Synthesis of (R)-N—( l -( l -acryloylazepan-3 -yl)(( l -isopropylpiperidinyl)oxy)- lH-
benzo[d]imidazolyl)(trifluoromethyl)isonicotinamide D5
98%N CF3
YO N2
(R)-N—(l -( l -Acryloylazepan-3 -(( l -isopropylpiperidinyl)oxy)- lH-
d]imidazolyl)(trifluoromethyl)isonicotinamide D5 was synthesized according to
the ures as described in Example 22. MS observed for C31H37F3N603: 599.5 (M+H+);
HPLC retention time: 2.11 min.
Example 26
Synthesis of (R)-N—( l -( l -acryloylazepan-3 -yl)(( l -isopropylpiperidinyl)oxy)- 1H-
benzo[d]imidazolyl)methylisonicotinamide D6
YCr Cw
[0039 l] (R)-N—(l -( l -Acryloylazepan-3 -yl)(( l -isopropylpiperidinyl)oxy)- 1H-
benzo[d]imidazolyl)methylisonicotinamide D6 was synthesized ing to the
procedures as described in Example 22. MS observed for N603: 545.5 (M+H+); HPLC
retention time: 1.98 min.
Example 27
Synthesis of (R)-N—( l -(l -acryloylazepan-3 -yl)(( l -(2,2,2-trifluoroethyl)piperidinyl)oxy)-
1H-benzo[d]imidazolyl)methylisonicotinamide D7
The synthesis of (l -( l -acryloylazepan-3 -(( 1 -(2,2,2-
trifluoroethyl)piperidinyl)oxy)-1H-benzo[d]imidazolyl)methylisonicotinamide D7 is
shown in Scheme 17.
Scheme 17
N\>—NH _
\ N CF3CHZSO3CF3 :\>_NH\
o / 30/052 N/Boc
:rifidCVN 1. TFA O\ N
2. C1CH3CH3C30H
HATU CNV
DIPEA
3. NaOH
—149—
Step I: To a solution of compound 3 (120 mg, 0.2 mmol) in DME (2 mL) at 0
0C was added CF3CH20802CF3 (95 mg) and DIPEA (103 mg). After the reaction mixture
was d at room temperature overnight, a second batch of CF3CH20802CF3 (95 mg) and
K2C03 (30 mg) were added. The reaction mixture was stirred at room temperature for 3 days
and then purified with flash column chromatograph with 0-30% EtOAc in hexanes to give
nd 52 in 53% yield (66 mg). MS: 531.7 (M+H+).
Step II: The sion from compound 52 to compound D7 was performed
ing to the procedures as described in Example 22. MS observed for C30H35F3N603:
585.7 (M+H+); HPLC retention time: 7.01 min.
Example 28
sis of (R)-N-(7-(( l -acetylpiperidinyl)oxy)- l -(l -(3 -chloropropanoyl)azepan-3 -yl)-
lH-benzo[d]imidazolyl)—2-(trifluoromethyl)isonicotinamide D8 and (R)-N-(7-(( l -
acetylpiperidinyl)oxy)- l -(l -acryloylazepan-3 -yl)- lH-benzo [d]imidazolyl)
(trifluoromethyl)isonicotinamide D9
The synthesis of (R)-N-(7-((l -acetylpiperidinyl)oxy)-l-(l-(3-
chloropropanoyl)azepan-3 -yl)- lH-benzo [d]imidazolyl)(trifluoromethyl)isonicotinamide
D8 and (R)-N-(7-((l -acetylpiperidinyl)oxy)- l -(l -acryloylazepan-3 -yl)- lH-
benzo[d]imidazolyl)(trifluoromethyl)isonicotinamide D9 is shown in Scheme 18, and
was sized according to the procedures as described in Example 22..
Scheme 18
2Y2zE Ioo
/\Iz zfz02I 20J”
/\l |>
.—] ’Tl
—> O
O/O N/BOC 2.C1CH2CH2CZOH
N’BOC
O N HATU
j“ Y 54 DIPEA
-l50-
(7-((1-Acetylpiperidinyl)oxy)(1-(3-chloropropanoyl)azepan-3 -yl)-
1H—benzo[d]imidazolyl)(trifluoromethyl)isonicotinamide D8. MS observed for
C30H37ClN6O4: 635.1 (M+H+); HPLC retention time: 2.03 min.
(R)-N—(7-((1-Acetylpiperidinyl)oxy)(1-acryloylazepan-3 -yl)- 1H-
benzo[d]imidazolyl)(trifluoromethyl)isonicotinamide D9. MS observed for
C30H36N6O4: 599.1 (M+H+); HPLC retention time: 2.09 min.
Example 29
Synthesis of (R)-N—(1-(1-acryloylazepanyl)((tetrahydro-2H-pyranyl)oxy)- 1H-
benzo[d]imidazolyl)methylisonicotinamide D 10
(R)-N—(1-(1-Acryloylazepanyl)((tetrahydro-2H-pyranyl)oxy)- 1H-
benzo[d]imidazolyl)methylisonicotinamide D10 was sized according to the
procedures as bed in Examples 2, 3, and 18. MS observed for N504: 504.10
(M+H+); HPLC retention time: 2.21 min.
Example 30
Synthesis of (1-(1-acryloylazepan-3 -yl)((1 , 1 -dioxidotetrahydro-2H-thiopyran
yl)oxy)- 1H-benzo[d]imidazolyl)methylisonicotinamide D 1 1
(R)-N—(1-(1-Acryloylazepan-3 -yl)((1 ,1-dioxidotetrahydro-2H—thiopyran
yl)oxy)-1H—benzo[d]imidazolyl)methylisonicotinamide D11 was synthesized according
to the procedures as described in Examples 2, 3, and 18. MS observed for C28H33N505S:
552.5 (M+H+); HPLC ion time: 2. ll min.
*****
The examples set forth above are provided to give those of ordinary skill in the
art with a complete disclosure and description of how to make and use the claimed
embodiments, and are not intended to limit the scope of what is sed herein.
Modifications that are s to persons of skill in the art are intended to be within the
scope of the following claims. All publications, patents, and patent applications cited in this
specification are incorporated herein by reference as if each such publication, patent or patent
application were specifically and individually indicated to be incorporated herein by
reference.
-l52-
Claims (67)
1. A compound of Formula XIa or XIX: (XIa) (XIX) or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt or solvate thereof; n each R1 is independently selected from the group consisting of: , , , , , , , , , , , , , , , O N , , and ; R2 is C6-14 aryl or heteroaryl; each R4, R5, and R7 is independently (a) hydrogen, cyano, halo, or nitro; (b) C1- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 lkyl, C6-14 aryl, C7-15 l, heteroaryl, or heterocyclyl; or (c) 1a, –C(O)OR1a, –C(O)NR1bR1c, –C(NR1a)NR1bR1c, –OR1a, –OC(O)R1a, –OC(O)OR1a, –OC(O)NR1bR1c, –OC(=NR1a)NR1bR1c, –OS(O)R1a, –OS(O)2R1a, –OS(O)NR1bR1c, –OS(O)2NR1bR1c, –NR1bR1c, –NR1aC(O)R1d, –NR1aC(O)OR1d, –NR1aC(O)NR1bR1c, –NR1aC(=NR1d)NR1bR1c, –NR1aS(O)R1d, –NR1aS(O)2R1d, –NR1aS(O)NR1bR1c, –NR1aS(O)2NR1bR1c, –SR1a, –S(O)R1a, –S(O)2R1a, –S(O)NR1bR1c, or –S(O)2NR1bR1c; R6a is C3-7 cycloalkyl, C6-14 aryl, heteroaryl, or heterocyclyl; R7a is C3-7 cycloalkyl, C6-14 aryl, aryl, or heterocyclyl; R2n is C1-6 alkyl or –OR1a; each R1a, R1b, R1c, and R1d is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 l, C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or R1a and R1c together with the C and N atoms to which they are attached form heterocyclyl; or R1b and R1c together with the N atom to which they are attached form heterocyclyl; and wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more tuents Q, where each Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) C1-6 alkyl, C2-6 l, C2-6 alkynyl, C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, and heterocyclyl, each of which is further ally substituted with one or more substituents Qa; and (c) –C(O)Ra, –C(O)ORa, –C(O)NRbRc, –C(NRa)NRbRc, –ORa, –OC(O)Ra, –OC(O)ORa, –OC(O)NRbRc, –OC(=NRa)NRbRc, –OP(O)(ORa)2, –OS(O)Ra, –OS(O)2Ra, –OS(O)NRbRc, –OS(O)2NRbRc, –NRbRc, O)Rd, –NRaC(O)ORd, –NRaC(O)NRbRc, –NRaC(=NRd)NRbRc, –NRaS(O)Rd, –NRaS(O)2Rd, –NRaS(O)NRbRc, –NRaS(O)2NRbRc, –SRa, –S(O)Ra, –S(O)2Ra, –S(O)NRbRc, and –S(O)2NRbRc, wherein each Ra, Rb, Rc, and Rd is independently (i) hydrogen; (ii) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or cyclyl, each of which is optionally substituted with one or more substituents Qa; or (iii) Rb and Rc together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more substituents Qa; wherein each Qa is independently selected from the group consisting of (a) oxo, cyano, halo, and nitro; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, and heterocyclyl; and (c) f, –C(O)ORf, –C(O)NRgRh, –C(NRf)NRgRh, –ORf, –OC(O)Rf, –OC(O)ORf, NRgRh, Rf)NRgRh, –OP(O)(ORf)2, –OS(O)Rf, –OS(O)2Rf, –OS(O)NRgRh, –OS(O)2NRgRh, –NRgRh, –NRfC(O)Rk, –NRfC(O)ORk, –NRfC(O)NRgRh, –NRfC(=NRk)NRgRh, –NRfS(O)Rk, –NRfS(O)2Rk, –NRfS(O)NRgRh, –NRfS(O)2NRgRh, –SRf, –S(O)Rf, –S(O)2Rf, –S(O)NRgRh, and –S(O)2NRgRh; wherein each Rf, Rg, Rh, and Rk is independently (i) en; (ii) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C6-14 aryl, C7-15 l, heteroaryl, or heterocyclyl; or (iii) Rg and Rh together with the N atom to which they are attached form heterocyclyl.
2. The compound of claim 1, having the structure of Formula XIa: (XIa) or a single enantiomer, a c mixture, a mixture of diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt or solvate thereof.
3. The compound of claim 2, wherein R2n is methyl, uoromethyl, difluoromethyl, trifluoromethyl, –OH, or –OCH3.
4. The compound of any one of claims 1 to 3, wherein R7a is C3-10 cycloalkyl or heterocyclyl, each of which is optionally substituted with one or more substituents Q.
5. The compound of claim 4, wherein R7a is heterocyclyl, optionally tuted with one or more substituents Q.
6. The compound of claim 4, wherein R7a is N O O N R1a , R1a , , , O N O N O N , R1a , R1a , , R1a , O N N O N O N R1b O N R1b O R1a , , R1a , R1a , , O O N O O O O N O , O , R1a, R1a , , , , , , , , , , , , or ; p and q are each independently an integer of 0, 1, or 3, with the proviso that the total of p and q is no less than 1; and each r is independently an integer of 0, 1, 2, 3, 4, 5, or 6.
7. The compound of claim 4, wherein R7a is , , , , , , or .
8. The compound of claim 2, wherein the nd is selected from the group consisting of: O O N N N N NH NH N N O O O O N N N O N , , A1 A2 N N O O N , O , D2 , , D3 D4 N CF3 N NH NH N N N N O O O O O O N N N N , , D5 D6 N N O O F3C N N N NH NH N N N N O O O O O N N O O S , and O ; D10 D11 or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt or solvate f.
9. The compound of claim 1, having the structure of Formula XIX: R4 O R5 N R2 O N N R1 (XIX) or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant f; or a pharmaceutically able salt or solvate thereof.
10. The compound of claim 9, having the structure of Formula XXa: (XXa) or a single enantiomer, a racemic mixture, a mixture of reomers, or an isotopic t thereof; or a pharmaceutically acceptable salt or solvate f.
11. The compound of claim 9, wherein R2n is methyl, monofluoromethyl, difluoromethyl, trifluoromethyl, –OH, or –OCH3.
12. The compound of any one of claims 9 to 11, wherein R7 is chloro, methyl, monofluoromethyl, difluoromethyl, trifluoromethyl, or –OR1a.
13. The compound of claim 12, wherein R7 is chloro.
14. The compound of any one of claims 9 to 13, wherein R6a is: N O O N , R1a , R1a , , , O N O N O N , R1a , R1a , , R1a , O N N O N O N R1b O N R1b O R1a , , R1a , R1a , , O O N O O O O N O , O , R1a, R1a , , , , , , , , , , , , , , , , or ; wherein: p and q are each independently an integer of 0, 1, or 3, with the proviso that the total of p and q is no less than 1; and each r is independently an integer of 0, 1, 2, 3, 4, 5, or 6.
15. The compound of any one of claims 9 to 13, n R6a is: , , , , , , or .
16. The compound of any one of claims 1, 9, and 12 to 15, wherein R2 is 6- to 10- membered monocyclic or bicyclic aryl, optionally substituted with one or more substituents Q.
17. The compound of any one of claims 1, 9, and 12 to 15, wherein R2 is 5- to 10- membered monocyclic or bicyclic heteroaryl comprising 1 to 4 atoms selected from N, O, and S, optionally substituted with one or more substituents Q.
18. The nd of any one of claims 1, 9, and 12 to 15, wherein R2 is phenyl, pyridinyl, pyridazinyl, benzo[c][1,2,5]oxodiazolyl, or benzo[c][1,2,5]thiodiazolyl, each of which is optionally substituted with one or more tuents Q.
19. The compound of any one of claims 1, 9, and 12 to 15, wherein R2 is hydroxypyridinyl , methoxy-pyridinyl, methyl-pyridinyl, difluoromethyl-pyridinyl, trifluoromethyl-pyridinyl, methylaminocarbonyl-pyridinyl, or methyl-pyridazinyl.
20. The nd of any one of claims 1, 9, and 12 to 19, wherein R4 is hydrogen.
21. The compound of any one of claims 1, 9, and 12 to 20 wherein R5 is hydrogen.
22. The compound of any one of claims 1, 9, and 12 to 21, wherein R6 is hydrogen.
23. The compound of claim 9, wherein the compound is selected from the group consisting of: O N N Cl O , , C1 C2 , , C3 C4 , , C7 C8 , , C9 C10 , , C11 C12 , , C13 C14 N CHF2 N CHF2 NH NH O N N O N N O O O Cl Cl O N N O O , , and C15 C16 N OCH3 O N N Cl O or a single enantiomer, a racemic mixture, a mixture of reomers, or an ic variant thereof; or a pharmaceutically acceptable salt or solvate thereof.
24. A compound selected from: N N NH NH N N N N O O O O O O N N N O N Cl and Cl , D1 D8 or a single enantiomer, a racemic mixture, a e of diastereomers, or an isotopic variant thereof; or pharmaceutically acceptable salt or solvate thereof.
25. A pharmaceutical composition comprising the compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt or solvate f; and a ceutically acceptable excipient.
26. The pharmaceutical composition of claim 25, wherein the composition is formulated as a single dosage form.
27. The pharmaceutical composition of claim 25 or 26, wherein the composition is formulated as oral, parenteral, nasal, respiratory, pulmonary, or intravenous dosage form.
28. The pharmaceutical ition of claim 27, wherein the pharmaceutical composition is in an oral dosage form.
29. The pharmaceutical composition of claim 28, wherein the oral dosage form is a tablet or capsule.
30. Use of the compound of any one of claims 1 to 24, or the pharmaceutical composition of any one of claims 25 to 29, in the preparation of a medicament for treating, preventing, or ameliorating a proliferative disease in a human subject.
31. The use of claim 30, wherein the proliferative disease is cancer.
32. The use of claim 31, wherein the cancer is drug-resistant.
33. The use of claim 31 or 32, wherein the cancer ns an ERBB variant.
34. The use of claim 33, wherein the ERBB variant is an EGFR variant.
35. The use of claim 34, wherein the EGFR variant contains one or more deletions, insertions, or tutions at the amino acid positions of 689, 700, 709, 715, 719, 720, 746-759, 761-765, 767-775, 783, 784, 790, 796, 826, 839, 846, 858, 861, and 863.
36. The use of claim 35, n the EGFR variant contains one or more deletions, insertions, or substitutions at the amino acid positions of 719, 746-751, 790, and 858.
37. The use of claim 35, wherein the EGFR variant contains one, two, or more deletions, insertions, and/or substitutions, each independently selected from G719C, G719S. G719A, ΔE746-A750, ΔE746-T751, A750 (ins RP), ΔD761-E762 (ins EAFQ), D770 (dup SVD), ΔV769-D770 (ins ASV), ΔD770-N771 (ins SVQ), ΔP772-H773 (ins PR), ΔH773-V774 (ins NPH), ΔH773-V774 (ins H), ΔH773-V774 (ins PH), and ΔH773-V774 (ins GNPH), T790M, and L858R.
38. The use of claim 34, wherein the EGFR variant contains T790M, L858R, or a ation thereof.
39. The use of claim 33, wherein the ERBB variant is a HER2 variant.
40. The use of claim 39, wherein the HER2 is overexpressed in the cancer.
41. The use of any one of claims 31 to 40, wherein the cancer is resistant to an EGFR inhibitor.
42. The use of claim 41, wherein the cancer is resistant to afatinib, canertinib, dacomitinib, nib, gefitinib, icotinib, lapatinib, neratinib, pelitinib, varlitinib, or a combination thereof.
43. The use of any one of claims 31 to 42, wherein the cancer is bladder cancer, brain tumor, breast , cancer of the mouth and throat, colorectal cancer, lung cancer, or pancreatic cancer, prostate cancer, stomach cancer, or uterine cancer.
44. The use of claim 43, wherein the cancer is lung cancer.
45. The use of claim 43, wherein the cancer is non-small cell lung cancer.
46. The use of any one of claims 31 to 45, wherein the cancer is ed or refractory.
47. A method of treating, preventing, or ameliorating a erative disease in a non-human subject, the method comprising administering a compound of any one of claims 1-24, or the composition according to any one of claims 25-29.
48. The method of claim 47, wherein the erative disease is cancer.
49. The method of claim 48, wherein the cancer is drug-resistant.
50. The method of claim 48 or 49, wherein the cancer contains an ERBB variant.
51. The method of claim 50, wherein the ERBB t is an EGFR variant.
52. The method of claim 51, wherein the EGFR variant contains one or more deletions, insertions, or substitutions at the amino acid positions of 689, 700, 709, 715, 719, 720, 746-759, 761-765, 767-775, 783, 784, 790, 796, 826, 839, 846, 858, 861, and 863.
53. The method of claim 51, wherein the EGFR variant contains one or more deletions, insertions, or tutions at the amino acid positions of 719, 746-751, 790, and 858.
54. The method of claim 51, wherein the EGFR variant contains one, two, or more deletions, insertions, and/or substitutions, each independently selected from G719C, G719S. G719A, ΔE746-A750, ΔE746-T751, ΔE746-A750 (ins RP), E762 (ins EAFQ), ΔS768-D770 (dup SVD), ΔV769-D770 (ins ASV), ΔD770-N771 (ins SVQ), ΔP772-H773 (ins PR), ΔH773-V774 (ins NPH), ΔH773-V774 (ins H), V774 (ins PH), and ΔH773-V774 (ins GNPH), T790M, and L858R.
55. The method of claim 51, wherein the EGFR t contains T790M, L858R, or a combination thereof.
56. The method of claim 50, wherein the ERBB variant is a HER2 t.
57. The method of claim 56, n the HER2 is overexpressed in the cancer.
58. The method of any one of claims 48 to 57, wherein the cancer is resistant to an EGFR inhibitor.
59. The method of claim 58, n the cancer is resistant to afatinib, canertinib, dacomitinib, erlotinib, gefitinib, icotinib, lapatinib, neratinib, pelitinib, varlitinib, or a combination thereof.
60. The method of any one of claims 48 to 59, wherein the cancer is bladder cancer, brain tumor, breast cancer, cancer of the mouth and throat, colorectal cancer, lung cancer, or pancreatic cancer, prostate cancer, stomach cancer, or uterine cancer.
61. The method of claim 60, n the cancer is lung cancer.
62. The method of claim 60, wherein the cancer is non-small cell lung cancer.
63. The method of any one of claims 48 to 62, wherein the cancer is relapsed or refractory.
64. A compound according to claim 1 substantially as herein described or exemplified.
65. A pharmaceutical ition according to claim 25 substantially as herein described or exemplified.
66. A use according to claim 30 ntially as herein described or exemplified.
67. A method according to claim 47 substantially as herein described or exemplified.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461968225P | 2014-03-20 | 2014-03-20 | |
US61/968,225 | 2014-03-20 | ||
PCT/US2015/021455 WO2015143148A1 (en) | 2014-03-20 | 2015-03-19 | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ724372A NZ724372A (en) | 2021-06-25 |
NZ724372B2 true NZ724372B2 (en) | 2021-09-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11787788B2 (en) | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | |
US11242352B2 (en) | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | |
US11427565B2 (en) | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | |
US8772287B2 (en) | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | |
NZ724372B2 (en) | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |